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Abstract 
 
Dysregulation of the Renin Angiotensin System (RAS), and its cognate receptor, the 
angiotensin (AngII) type 1 receptor (AT1R), has been implicated in the pathogenesis of 
several cardiovascular disorders including hypertension, fibrosis, congestive heart failure and 
stroke. Despite the development of pharmacological agents that target the RAS, the persistent 
burden of cardiovascular disease remains.  My PhD focuses on the AT1R, specifically its 
ability to ‘crosstalk’ and transactivate signalling pathways downstream of the Epidermal 
Growth Factor Receptors (EGFR).  This paradigm of EGFR transactivation thereby enables 
the AT1R to potentially regulate cell growth, differentiation, apoptosis and promote 
cancerous cell growth.  Part of ongoing work in the Thomas laboratory is to better understand 
the roll of previously identified novel proteins in AT1R-EGFR transactivation, including 
CHKA (Choline Kinase Alpha), BMX (non-receptor tyrosine kinase) and TRIO (Triple 
Functional Domain PTPRF Interacting). It is therefore the focus of my research to use 
molecular and cellular approaches to interrogate the mechanistic basis for EGFR 
transactivation and better define the relative role of these novel proteins in AT1R-EGFR 
signalling. 
 
Although it is of great interest to identify and characterise the molecular, temporal and spatial 
mechanisms of AT1R-EGFR transactivation, demonstrating EGFR transactivation directly, in 
live cells, and in real-time has been challenging.  Typically, end-point assays (e.g., phospho-
ERK1/2) are used as a surrogate readout of EGFR activation, however they are often 
downstream readouts and are not applicable to live cells.  Herein, I report the use of a 
Bioluminescence Resonance Energy Transfer (BRET) based assay to report the recruitment 
of the EGFR adaptor protein, growth factor receptor-bound protein 2 (Grb2), association with 
the EGFR.  In live HEK293 cells, both epidermal growth factor (EGF) and AngII stimulation 
produced sustained ligand-dependent recruitment of Grb2 to the EGFR.  The BRET assay 
was applied to a variety of cell lines and also used to screen a panel of 19 GPCRs, with the 
AT1R and vasopressin receptor showing distinct EGFR transactivation. Additionally, HER2, 
a member of the EGFR family (also known as ErbB2) and preferred dimerisation partner of 
the EGFR, was also transactivated by the AT1R.  Mechanistically, we observed that the 
AT1R-mediated ERK1/2 activation was completely dependent on Gq/11 as well as EGFR 
tyrosine kinase activity, whereas EGFR-Grb2 recruitment was independent of Gq/11 and only 
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partially dependent upon the EGFR tyrosine kinase activity. This Gq/11 independence was 
confirmed using a G protein-uncoupled AT1R mutant that demonstrated transactivation 
comparable to that seen in the AT1R wild type.  Finally, we provide evidence that both 
AngII- and EGF-stimulation promotes a physical association between AT1R-EGFR, however 
the molecular requirements vary for each receptor. 
 
In addition, I report in this thesis the concept of ‘reverse-transactivation’, whereby a 
significant proportion of the total EGF signalling is dependent upon the co-activation of the 
AT1R and its capacity to couple to G proteins.  A BRET-based assay was used, both in 
transfected HEK293 cells and primary isolated vascular smooth muscle cells (VSMC), to 
demonstrate that EGF-stimulation of the EGFR leads to the activation and arrestin-binding of 
the AT1R.  This EGF-mediated recruitment of -arrestin to the AT1R was completely 
dependent upon EGFR tyrosine kinase activation and apparently involves the active, Gq 
coupled state of the AT1R. Moreover, a truncated AT1R, lacking all carboxyl-terminal 
phosphorylation sites, was incapable of recruiting arrestin following EGF-stimulation, 
indicating reverse transactivation requires phosphorylation and binding of arrestin to the 
AT1R.  The rapid internalisation of the AT1R following AngII-stimulation was not observed 
following EGF activation, instead causing increased recruitment of AT1R to the plasma 
membrane.   
 
In summary, I have developed and applied a sensor BRET based-assays to characterise the 
molecular, temporal and spatial aspects of AT1R-EGFR transactivation. We provide evidence 
of bi-directional receptor crosstalk, whereby both the AT1R and EGFR have the capacity to 
transactivate each other, however the molecular mechanisms governing this crosstalk vary for 
each receptor.  Collectively, this powerful new platform, which interrogates the most 
proximal events of AT1R-EGFR transactivation, can be used to better define AngII influences 
on cardiovascular physiology and pathology, and therapeutically lead to the development of 
new drugs against cardiovascular disease.   
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1.0 General Introduction 
 
1.1 Cardiovascular Disease – Cellular Remodelling 
 
Cardiovascular disease (CVD) refers to diseases of the heart and blood vessels, including 
stroke, heart attack and failure, as well as vascular dysfunction.  The prevalence of heart 
disease has increased in Australia over the last decade, with 30% of all deaths contributed to 
CVD (Heart Foundation Australia, 2014). Despite the development of improved 
pharmaceuticals, the disease burden on the community and economy is significant, and 
alternative approaches are required to improve prevention and treatment methodologies.  
Cellular remodelling, through the actions of cellular growth (hypertrophy), fibrosis, cellular 
migration and proliferation, has been shown to contribute to the pathogenesis of CVD, 
making it a potential therapeutic target for intervention (Ferrario, 2016).   
 
The Renin Angiotensin System (RAS) plays a central role in the development and regulation 
of cellular remodelling, mediating a broad range of homeostatic and modulatory processes.  
RAS dysregulation also promotes the development of pathological states through actions in 
cellular growth and remodelling, endothelial dysfunction, angiogenesis, inflammation and 
cancer (Lijnen, Petrov & Fagard, 2000; Mehta & Griendling, 2007; Nakashima, Suzuki, 
Ohtsu et al., 2006; Ruiz-Ortega, Rupérez, Esteban et al., 2005; Wegman-Ostrosky, Soto-
Reyes, Vidal-Millán et al., 2015).  Accordingly, therapeutic agents that target the RAS such 
as Angiotensin (AngII) converting enzyme (ACE) inhibitors and AngII receptor blockers 
(ARBs) modify the process of cardiac remodelling and remain frontline therapeutics 
(Cuspidi, Negri & Zanchetti, 2008).  Thus, the blockade of the RAS regresses cellular 
remodelling and in turn inhibits CVD progression, most likely by attenuating the direct 
effects of AngII on the heart. 
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1.2 Angiotensin II and the AT1 Receptor 
 
1.2.1 The Renin Angiotensin System 
 
The peptide hormone AngII (Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8) plays an integral role 
in cardiovascular and renal pathophysiology and physiology, having been shown to influence 
a large range of cardiovascular homeostatic and modulatory processes. AngII is produced as 
part of the RAS cascade as outlined in Figure 1.01. The synthesis of renin is the initial rate-
limiting step and the initiator of RAS signalling (Skeggs, Kahn, Lentz et al., 1957).  Renin is 
initially produced and stored in the granular cells within the juxtaglomerular apparatus of the 
kidney as its inactive form, prorenin. Once cleaved and secreted into the bloodstream, 
prorenin undergoes processing to form the biologically active form, renin (Bajwa & Kwatra, 
2012). The classical endocrine view of the RAS involves renin cleaving liver-borne 
angiotensinogen to generate the decapeptide, Angiotensin I (AngI).  Circulating AngI is 
cleaved by the angiotensin converting enzyme (ACE) and is converted to the octapeptide, 
AngII (Gul, Ramdas, Mandavia et al., 2012).  AngII then exerts its effects through integrated 
actions on the cardiovascular system, central nervous system and the kidney.  AngII 
stimulates vasopressin release (increasing water retention by the kidney), vasoconstriction 
(thereby increasing total peripheral resistance), thirst (via the central nervous system) and 
aldosterone release from the adrenal cortex (promoting water retention and the reabsorption 
of sodium chloride), ultimately leading to an increase in blood pressure (Atlas, 2007).   
 
Undoubtedly, the actions of AngII on its cognate G protein-coupled receptor (GPCR), the 
Angiotensin type 1 receptor (AT1R), accounts for the majority of the biological functions 
attributed to AngII (Gul, Ramdas, Mandavia et al., 2012).  AngII can also bind to the 
angiotensin type 2 receptor (AT2R), which is thought to have opposing actions in response to 
AngII.  AT2R activation contributes to the cardioprotective effects of ARBs (Brede, 
Hadamek, Meinel et al., 2001; Ferrario, 2010), although this cardioprotective role is lost in 
hearts that excessively overexpress the AT2R (Xu, Sun, Carretero et al., 2014).  More 
recently, the simplistic view that the RAS system is a linear biochemical cascade comprised 
of two proteolytic steps has been replaced by a much more complex system involving various 
mediators, receptors and multifunctional enzymes as shown in Figure 1.01 (Dzau, 1988).   
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Figure 1.01: The Renin Angiotensin System 
A simplified schematic of the major components of the RAS.  The classical RAS pathway was 
initially considered to involve sequential cleavage of angiotensinogen by Renin and ACE to yield 
AngII.  AngII exerts the majority of its physiological actions through binding and activating the 
AT1R, in addition to the AT2R.  However, during the past two decades, there have been additional 
advancements in the RAS biochemical axis, including the discovery of an ACE homologue, ACE2, 
which produces the Ang1-7 fragment that may act via the MAS receptor. Angiotensin converting 
enzyme (ACE), aminopeptidase A (APA), insulin-regulated aminopeptidase (IRAP), MAS 
receptor (MASR), Mas-related GPCR type D (MrgDR)   
 
 
Additional advancements in the RAS regulation include the recently identified ACE 
homologue, ACE2, considered the cardio-protective axis of the RAS (Shi, Mao, Xu et al., 
2010) (Figure 1.01).  ACE2, predominantly expressed in the heart, blood vessels and kidney 
(Oudit, Crackower, Backx et al., 2003), cleaves the carboxyl-terminal amino acid from AngII 
to form Angiotensin1-7 (Ang1-7), also formed by the action of ACE on Angiotensin1-9.  
Ang1-7 reportedly binds to the MAS receptor (MASR, a GPCR), and is believed to counter 
the actions of AngII leading to vasodilation and a decrease in cell proliferation, fibrosis and 
oxidative stress (Zhang, Chen, Zhong et al., 2014), however more recent studies have shown 
that Ang1-7 cardioprotective effects are thought to involve both the MASR and AT1R as well 
as other unknown targets (Teixeira, Parreiras-e-Silva, Bruder-Nascimento et al., 2017). 
Furthermore, almandine, similar structurally to Ang1-7 (a substitution at the first amino acid 
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position) does not bind to the MAS receptor, instead acting through the Mas-related GPCR 
type D (MrgD) receptor to promote vasodilation and antihypertensive effects (Etelvino, 
Peluso & Santos, 2014; Lautner, Villela, Fraga-Silva et al., 2013).  Other advancements 
include the identification of the prorenin receptor, which binds renin and prorenin and 
enhances the catalytic conversion of angiotensinogen to AngI, increasing AngII generation 
(Nguyen, Delarue, Burcklé et al., 2002).  Activation of the prorenin receptor can mediate 
intracellular pathways independent of the generation of AngII, having been shown to be an 
accessory protein of vacuolar H+-ATPase and implemented in Wnt signalling, low-density 
lipoprotein (LPL) clearance, glucose metabolism and profibrotic signalling (Cruciat, 
Ohkawara, Acebron et al., 2010).  
 
It is now well established that local RAS systems exist in many tissues and that these function 
as an independent entity from the blood-borne RAS (Coble, Grobe, Johnson et al., 2015; 
Ferrario, 2010; Leung & Carlsson, 2001; Satou & Gonzalez-Villalobos, 2012; Satou, Shao & 
Navar, 2015; Sparks, Crowley, Gurley et al., 2014; Yang, Smolders & Dupont, 2011).  For 
over 30 years, researchers have known of the existence of renin and renin activity, as well as 
the presence of the mRNA for angiotensinogen, renin and ACE in a variety of tissues (e.g., 
brain, heart, kidney, vasculature etc.). Of particular note is the cardiac RAS, with the 
myocardium capable of synthesising and secreting major components of the RAS 
(Crackower, Sarao, Oudit et al., 2002; Dzau & Re, 1994).  
 
1.2.2 The AT1 Receptor 
 
The AT1R is expressed in a range of organs including the heart, liver, kidney, brain, adrenals, 
vasculature and lung (De Gasparo, Catt, Inagami et al., 2000). The AT1R is an approximately 
40-41kDa seven transmembrane (TM) domain-containing protein composed of 359 amino 
acids.  All GPCRs, including the AT1R, share a common molecular topology with a 
hydrophobic core of seven transmembrane spanning -helices that form an 
extracellular/intra-membrane ligand binding pocket, an extracellular N-terminus and an 
intracellular carboxyl terminal (C-terminus) tail. The AT1R and AT2R were cloned 
simultaneously over two decades ago, and led to the discovery of two distinct AT1R subtypes 
in the rat and mice, the AT1a and AT1b receptor located on chromosome 17 and 2, 
respectively (Koike, Horiuchi, Yamada et al., 1994; Murphy, Alexander, Griendling et al., 
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1991; Sandberg, Ji, Clark et al., 1992).  This contrasts humans, which have a single AT1R 
encoded by the AGTR1 gene on chromosome 3q.  Although the AT1a and AT1b receptor are 
located on two different chromosomes, the two subtypes display over 90% homology in the 
coding region of the cDNA sequence and 95% homology at the amino acid level (Martin, 
White, Li et al., 1995).  In contrast, the coding region of the AT1R and AT2R cDNA exhibit 
only 30% homology.   
 
Both the AT1a and AT1b receptor subtypes share nearly identical ligand binding affinities 
and signalling properties, while expression appears to be tissue dependent, with the AT1b 
receptor abundant in the pituitary gland and adrenal cortex, whereas the AT1a receptor is 
more abundant in the heart, kidney, liver, smooth muscle and lungs (Gasc, Shanmugam, 
Sibony et al., 1994; Guo, Uno, Ishihata et al., 1995).  Genetic ablation of either or both 
subtypes show that the AT1a receptor plays an important role in the regulation of blood 
pressure and is the dominant subtype in cardiovascular physiology (Ito, Oliverio, Mannon et 
al., 1995; Timmermans, Wong, Chiu et al., 1993).  The AT1a receptor is the predominant 
receptor used to characterise AT1R physiology and pharmacology, and for this reason, all 
work in this thesis was performed using the AT1a receptor subtype, heretofore referred to as 
the AT1R for simplicity.   
 
1.3 AT1 Receptor Signalling & Regulation 
  
1.3.1 G protein-coupled receptors 
 
Seven transmembrane spanning GPCRs represent the largest superfamily of cell surface 
receptor proteins and are arguably the most physiologically important class of receptor signal 
transducers (Katritch, Cherezov & Stevens, 2013).  The total number of confirmed human 
GPCRs is in excess of 800 unique full-length members (Fredriksson, Lagerstrom, Lundin et 
al., 2003).  GPCRs are considered the gatekeepers of intracellular communication and can 
subsequently bind a myriad of signalling molecules, including photons, ions, odorants, 
peptides, lipids, proteins and bioamines (Vischer, Watts, Nijmeijer et al., 2011). Generally, 
GPCRs transduce information provided by the extracellular stimuli into appropriate 
downstream effectors via their coupling to heterotrimeric guanine nucleotide binding proteins 
(G proteins) (Johnston & Siderovski, 2007).  The binding of agonist to GPCR selects for a 
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receptor conformation state that allows for the disassociation of the G protein, and the 
activation of a variety of intracellular second messengers.  However, dysregulation and 
mutations of GPCRs, and the resulting signalling pathways, has been implicated in the 
pathogenesis of many diseases, and it is of no surprise that GPCRs represent the largest 
family of drug targets (Insel, Tang, Hahntow et al., 2007). 
 
 1.3.2 AT1 Receptor binding and activation 
 
Despite the critical role of AT1R in cardiovascular pathophysiology and the widespread 
clinical use of AT1R blockers to treat CVD, its structure at the atomic level has remained 
elusive until the recent revelation of the crystal structure for the human AT1R in complex 
with a variety of inverse agonists and antagonists (Zhang, Han, Batyuk et al., 2017; Zhang, 
Unal, Desnoyer et al., 2015; Zhang, Unal, Gati et al., 2015).  As already mentioned, the AT1R 
exhibits the canonical seven transmembrane -helical architecture, comprising of an 
extracellular N-terminus, three extracellular (ECL-3) and intracellular (ICL-3) loops, an 
amphipathic helix 8 and lastly an intracellular carboxyl terminus (Zhang, Unal, Gati et al., 
2015). The four putative extracellular domains each contain a cysteine residue that is capable 
of forming two disulphide bonds, (De Gasparo, Catt, Inagami et al., 2000; Ohyama, Yamano, 
Sano et al., 1995).  One of which is unique to the AT1R and connects the N-terminus with 
ECL3, helping to shape the extracellular side of the AT1R. The other, which is conserved 
among GPCRs, connects helix III with ECL3 and is important for receptor folding expression 
and conformational stability (Zhang, Unal, Gati et al., 2015). 
 
A full discussion of structural and functional characteristics of AngII-AT1R interactions is 
beyond the scope of this thesis, however specific AngII residues and AT1R amino acids are 
critical for ligand binding.  Upon AngII stimulation, the AT1R undergoes conformational 
changes in TM3 and TM6 helices, allowing for TM2 and TM7 interaction (Miura, Zhang, 
Boros et al., 2003). Amino acid residues of TM2, 3, 4, 5, 6 and 7 form the ligand binding 
pocket and force AngII to adopt a vertical binding configuration, with its amino terminus 
interacting with the ECL2 and the carboxyl terminus interacting more deeply within the TM 
core (Fillion, Cabana, Guillemette et al., 2013).  The major contacts of AngII that activate the 
AT1R are the amino acids Phe
8 (Holloway, Qian, Pipolo et al., 2002; Miura, Feng, Husain et 
al., 1999; Nikiforovich, Zhang, Yang et al., 2006; Noda, Feng, Liu et al., 1996; Yamano, 
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Ohyama, Kikyo et al., 1995) and Tyr4 (Miura, Feng, Husain et al., 1999; Nikiforovich, 
Mihalik, Catt et al., 2005).  The phenylalanine at position 8 is critical for agonist activity with 
mutation of Phe8 shown to weaken agonist activity and produce an agonist-to-antagonist 
transition (Wilkes, Masaro, Schiller et al., 2002).  In the absence of receptor activation, the 
receptor is held in an inactive conformation via two intramolecular hydrogen bonds that exist 
between Asn111 and Asn295 (Balmforth, Lee, Warburton et al., 1997), with the recent 
elucidation of AT1R crystal structure confirming this (Zhang, Unal, Gati et al., 2015).  The -
carboxyl group of Phe8 docks with Lys199, enabling Phe8 side chain to interact with His256 
and Phe259 and stabilise an active receptor conformation (Noda, Saad & Karnik, 1995; 
Oliveira, Costa-Neto, Nakaie et al., 2007). Phe8 interaction with His256 facilitates Tyr4 
coordination with Asn111 and destabilises this hydrogen bond network and allows Tyr292 to 
interact with the conserved residue Asp74 (Groblewski, Maigret, Larguier et al., 1997; Inoue, 
Nakamura & Inagami, 1997). It is thought that this set of interactions play a vital role in 
relaying the conformational changes in the ligand binding pocket to the cytoplasmic domain 
and coupling to downstream signalling.   
 
 1.3.3 Classical Gq/11 AT1 Receptor Signalling  
As per most GPCRs, the classical mechanism of AT1R signal transduction involves receptor 
coupling to heterotrimeric G proteins.  The G protein complex is composed of three 
polypeptides: G, which binds and hydrolyses guanine triphosphate (GTP), and a G dimer 
(Milligan & Kostenis, 2006).  Prior to ligand binding, the inactive G subunit is bound to 
guanine diphosphate (GDP) and associates with the G dimer (Gilchrist, 1996). Following 
ligand binding, a conformational change follows, decreasing G affinity for GDP (Oldham & 
Hamm, 2008).  GDP disassociates from the complex, and GTP binds, rendering the G 
subunit active.  G-GTP disassociates from both the receptor and the G dimer, allowing 
both the G-GTP and G to interact with downstream effector enzymes and regulate cell 
signalling.   The cellular response is terminated following the hydrolysis of G-GTP to G-
GDP, thus allowing the reformation of the inactive form of the heterotrimeric G protein 
complex.  
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GPCRs can interact with a variety of G proteins, including Gi, Gs, Gq, G11, G12, and 
G13, subsequently activating a multitude of second messengers and intracellular protein 
kinases (Higuchi, Ohtsu, Suzuki et al., 2007). The ‘classical’ AT1R signalling responsible for 
vasoconstriction, primarily couples to the heterotrimeric G protein Gq/11 (Belmonte & 
Blaxall, 2012).  Gq/11 activation results in PLC- activation and subsequent hydrolysis of 
phosphatidycholine-4,5-biphosphate (PIP2) to form two key second messengers, inositol 
triphosphate (IP3) and diacylglycerol (DAG) (Balakumar & Jagadeesh, 2010).  IP3 binds to 
its receptor located at the sarcoplasmic reticulum, which initiates the release of calcium 
(Ca2+).  Ca2+ release is further enhanced with free Ca2+ additionally binding to Ca2+-release 
channels and/or AngII directly stimulating cell membrane voltage-gated Ca2+ channels.  
Depending on the tissue, Ca2+ then binds to calmodulin or troponin (myocardium), activating 
myosin light chain kinase (MLCK).  This triggers phosphorylation of myosin light chain and 
initiates vascular smooth muscle contraction. The additional second messenger derived from 
PIP2 hydrolysis, DAG, is a lipid second messenger and a potent activator of Protein Kinase C 
(PKC) through binding to a conserved C1 domain, leading to PKC plasma translocation 
(Wang, 2006).  PKC is also a well-known mediator of the mitogen-activated protein (MAPK) 
pathway, a critical mediator of signal transduction in mammalian cells that contributes to the 
vasoconstrictive properties of receptor activation (Lu & Xu, 2006). 
A number of receptor mutations within conserved regions have been show to perturb 
classical, G protein-mediated signalling from the AT1R.   Of the residues introduced 
previously, substitution of Asp74 to asparagine or glycine and Tyr292 to phenylalanine 
uncouples the receptor from G protein activation (Bihoreau, Monnot, Davies et al., 1993).  
Mutation of Asn111 to glycine (N111G), biases the receptor towards the Gq/11 pathway, 
resulting in an approximate ~50% increase in IP3 production compared to wild type AT1R 
(Groblewski, Maigret, Larguier et al., 1997; Noda, Feng, Liu et al., 1996). This constitutively 
active mutant  [N111G]AT1R is not phosphorylated (Cabana, Holleran, Leduc et al., 2015; 
Thomas, Qian, Chang et al., 2000). The highly conserved D(E)RY motif in helix III has also 
been shown to mediate receptor activation/inactivation as well as G protein coupling.  
Mutation of DRY to AAY impairs receptor internalisation and attenuates classical Gq/11-
mediated signalling (Feng, Ding, Ren et al., 2005; Gáborik, Jagadeesh, Zhang et al., 2003).  
Another highly conserved amino acid is Try215 at the base of TM5.  Hunyady et al., 1995 
demonstrated that following agonist stimulation, mutant receptor Y215F has an impaired 
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ability to couple to G proteins as well as a significant (but still demonstrable) reduction in 
receptor internalisation (Hunyady, Bor, Balla et al., 1995).  The same group also revealed that 
the conserved sequence, NPxxY (Asn298, Pro299, Leu300, Phe301, Tyr302), located in the TM7 
helix also participates in receptor coupling (Hunyady, Bor, Baukal et al., 1995).  Alanine 
replacement of Asn298, Pro299 and Tyr302 impaired G protein coupling, however showed 
no substantial changes in receptor internalisation kinetics. Helix VIII has also been shown to 
bind Ca2+-regulated effector protein, calmodulin (Thomas, Pipolo & Qian, 1999), and is 
important for receptor coupling to G protein signalling (Sano, Ohyama, Yamano et al., 1997; 
Thomas, Baker, Motel et al., 1995).  When comparing AT1R structure to that of the AT2R, a 
GPCR that poorly couples to G proteins and arrestins, AT2R helix VIII no longer runs 
parallel to the plasma membrane and forms an interface with the intracellular cavity of the 
7TM bundle, repressing canonical AT2R activity and sterically blocking various receptor 
partners (Zhang, Han, Batyuk et al., 2017).  Most recently solved GPCR structures suggest 
that helix VIII stabilises the active-like receptor state but also works as a gate keeper, 
sterically blocking or recruiting G proteins (Zhang, Han, Batyuk et al., 2017; Zhang, Unal, 
Gati et al., 2015).  These AT1R mutants provide evidence that a number of topologically 
distinct contacts are required for agonist-induced coupling of the AT1R to Gq/11.    
1.3.4 AT1 Receptor Regulation 
The co-ordinated actions of two families of proteins, the GPCR serine/threonine kinases 
(GRKs) and arrestins, are critical for receptor down regulation and desensitisation (Ahn, 
Shenoy, Wei et al., 2004; Balakumar & Jagadeesh, 2014; Patel, Noor & Rockman, 2010). 
Following ligand binding, GRKs phosphorylate serine/threonine sites located on the AT1R C-
tail, resulting in the attenuation of G protein-dependent signalling and targets the receptor for 
internalisation (Magalhaes, Dunn & Ferguson, 2012).  GRK-mediated phosphorylation 
promotes the binding of the cytoplasmic adaptor protein -arrestin, which facilitate the 
aggregation of deactivated receptors into clathrin-coated vesicles and enable the 
internalisation and sorting of receptor into endosomes.    
AT1R phosphorylation can result in homologous or heterologous desensitisation.  
Homologous desensitisation accounts for specific phosphorylation of an activated GPCR and 
the attenuation of further signalling.  GRK2, 3, 5 and 6 are ubiquitously expressed and 
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interact with most GPCRs, however the relative contribution of GRKs to AT1R 
desensitisation is not well resolved. Heterologous desensitisation is mediated by second 
messenger-activated kinases such as protein kinase A (PKA) and PKC, which phosphorylate 
and desensitise the receptor (Cho, Cho, Park et al., 2007; Kelly, Bailey & Henderson, 2008; 
Xiang, Yu, Guo et al., 2001).  AT1R heterologous desensitisation was originally thought to be 
independent of -arrestins, however it has been recently demonstrated that PKC activation 
(whether it be by Adrenergic-1A receptor, phorbol myristate ester (PMA) or EGFR 
activation) mediates AT1R phosphorylation and -arrestin2 binding (Tóth, Prokop, 
Gyombolai et al., 2018). 
Arrestins terminate AT1R signalling and mediate receptor internalisation, serving as key 
regulators of AT1R function.  The -arrestin family comprises four cytoplasmic adaptor 
proteins: -arrestin1 and -arrestin2 (also denoted as -arrestin2 and -arrestin3, 
respectively) as well as two closely related visual -arrestins (Smith & Rajagopal, 2016).  -
arrestins share high sequence homology (89%) and exhibit the same structural features.  
GPCRs tend to either interact with -arrestins transiently, termed “Class A” GPCRs, or form 
tight stable complexes with arrestins, known as “Class B” receptors (Oakley, Laporte, Holt et 
al., 2000).  Class B receptors, which include the AT1R, accumulate in endocytic vesicles and 
form a stable receptor-arrestin complex.  The serine-threonine-rich segment of the carboxyl 
terminus is essential for AT1R phosphorylation and endocytosis (Kule, Karoor, Day et al., 
2004).  Almost complete inhibition of AT1R phosphorylation is observed in truncated AT1R 
in which 34 amino acids are removed from the carboxyl terminus (Thomas, Motel, Kule et 
al., 1998), with studies revealing that the truncated AT1R, [TK325]AT1R mutant, is unable to 
recruit -arrestins. 
Structural studies of arrestin have revealed three conserved motifs that maintain the inactive 
state of arrestin consisting of the C-terminal tail, the polar core and a number of hydrophobic 
inter-domain interactions (Gurevich & Gurevich, 2004).  Arrestin is thought to first engage 
with the phosphorylated C-terminus of the receptor, disrupting the three-element interaction, 
releasing the C-terminus of arrestin and destabilising the polar core (Shukla, Manglik, Kruse 
et al., 2013; Shukla, Westfield, Xiao et al., 2014).  This leads to a major conformational 
change of arrestin; the most prominent conformational change is the movement of the finger 
loop, which inserts into the crevice of the activated receptor, allowing for a fully engaged 
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GPCR-arrestin complex (Kang, Zhou, Gao et al., 2015).  Notably, a transition from inactive 
state, to the C-tail engaged arrestin-GPCR complex, to the fully engaged GPCR-arrestin 
complex has been observed (Sente, Peer, Srivastava et al., 2018).  It has been suggested that 
distinct GRKs imprint specific phosphorylation patterns, so called phosphorylation barcodes 
onto the receptor, which are then differentially ‘read out’ by arrestin, resulting in tail- or fully 
engaged GPCR-arrestin complexes which result in distinct functional outcomes.  More 
recently, an additional mechanism of arrestin activation has been described that does not 
require the GPCR tail (Latorraca, Wang, Bauer et al., 2018).  The receptor transmembrane 
core can bind distinct surfaces of arrestin and can stimulate arrestin activity independent from 
the receptor cytoplasmic tail.  The intracellular loops of the receptor interact with the arrestin 
body rather than the marked finger loops, destabilising charged residues that maintain arrestin 
in its inactive form (Eichel, Jullié, Barsi-Rhyne et al., 2018).  A general consensus is that 
ligand-mediated core conformation can act independently or in concert with phospho-
barcoding of the receptor C-tail to achieve specific arrestin conformations and signalling 
functions (Hilger, Masureel & Kobilka, 2018).  This variability in GPCR-arrestin binding is 
thought to give rise to either the stable GPCR-arrestin complexes commonly seen with “Class 
B” receptors, or the transiently formed “Class A” GPCR-arrestin complexes.   
The prevailing view that arrestins only uncouple and desensitise G protein-mediated 
responses has also been challenged in recent years.  GPCRs have been described that rely on 
-arrestins as genuine signal initiators that facilitate the activation and subcellular localisation 
of signalling cascades (Lefkowitz, Rajagopal & Whalen, 2006; Luttrell, Ferguson, Daaka et 
al., 1999; Rajagopal, Kim, Ahn et al., 2010; Ren, Reiter, Ahn et al., 2005; Shenoy, Drake, 
Nelson et al., 2005; Wei, Ahn, Barnes et al., 2004; Wei, Ahn, Shenoy et al., 2003). It is now 
clear that a number of catalytically active proteins bind arrestins upon ligand-binding, among 
them is the Src family tyrosine kinases (DeFea, Vaughn, O'bryan et al., 2000; Luttrell, 
Ferguson, Daaka et al., 1999), components of the MAPK cascade (DeFea, Zalevsky, Thoma 
et al., 2000; Luttrell, Roudabush, Choy et al., 2001; McDonald, Chow, Miller et al., 2000), 
cyclic adenosine monophosphate (cAMP) phosphodiesterase (Perry, Baillie, Kohout et al., 
2002), diacelglycerol kinase (Nelson, Perry, Regier et al., 2007) and many more.  Of 
particular relevance to this thesis is the discovery that arrestins act as a ‘signalling scaffold’ 
that can recruit extracellular signal-regulated kinase (ERK1/2), a MAPK that appears to be a 
critical component in eliciting mitogenic responses (Whitmarsh, 2007). This arrestin-
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mediated ERK1/2 activation influences the spatial and temporal nature of ERK1/2 signal 
transduction.  
1.3.5 Atypical signalling from the AT1 Receptor 
The full diversity of GPCR-mediated signals cannot be entirely explained by the classical 
heterotrimeric G protein signalling pathway (Maudsley, Martin & Luttrell, 2007). A number 
of papers have demonstrated that in the absence of G protein signalling, the AT1R can still 
signal to downstream ERK1/2 pathways (Kim, Ahn, Rajagopal et al., 2009; Wei, Ahn, 
Shenoy et al., 2003) Studies have revealed the existence of two independent pathways – a G 
protein- (occurs 2minute) and a -arrestin-mediated pathway (>5minutes) (Kim, Ahn, 
Rajagopal et al., 2009; Luttrell, Roudabush, Choy et al., 2001; Wei, Ahn, Shenoy et al., 2003) 
that facilitates ligand-activated scaffolding of multiple proteins that are linked to cardio-
protective downstream signalling molecules.  Within endosomal vesicles, -arrestin is 
thought to act as a scaffold and subsequently lead to the assembly of kinases involved in the 
ERK1/2 cascade - Raf-1, MEK and ERK1/2, thus leading to functionally distinct pools of 
nuclear (G protein-mediated) and cytoplasmic (arrestin-mediated) pools of ERK1/2 (Ahn, 
Shenoy, Wei et al., 2004).   
The identification of G protein-dependent and -independent signalling has lead to the 
development of biased ligands that can selectively block or engage a subset of the AT1R 
signalling repertoire.  Several studies have demonstrated that by selectively engaging 
arrestin-mediated pathways (in the absence of any detectable G protein signalling), biased 
ligands can promote cardio-protective and antiapoptopic signalling pathways, and therefore 
present as a new class of AT1R-targeted therapeutics.  The first, and most widely used biased 
ligand, Sar1, Ile4, Ile8-AngII (SII), stimulates chemotaxis, promotes cellular proliferation, 
growth and protein synthesis, cardiac contractility and reduces apoptosis (Wei, Ahn, Shenoy 
et al., 2003).  This has lead to the development of TRV120027, a -arrestin-biased AT1R 
ligand with increased potency and arrestin efficacy, and is currently in clinical trials for the 
treatment of acute heart failure (Felker, Butler, Collins et al., 2015; Violin, DeWire, 
Yamashita et al., 2010).  However, this arrestin-dependent, G protein-independent ERK1/2 
activation has been recently challenged.  Grundmann et al., 2018 systematically dissected G 
protein- from arrestin-driven ERK1/2 phosphorylation for a broad set of GPCRs 
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(Grundmann, Merten, Malfacini et al., 2018).  The study concluded that arrestins are still 
recruited to GPCRs in the absence of active G protein and that early stage and late phase 
ERK1/2 activity is driven by G proteins and not arrestins.   
Like all GPCRs, the AT1R lacks intrinsic kinase activity, yet following AT1R stimulation it 
has been shown to induce cell growth, proliferation and differentiation, processes that are 
considered to be independent of traditional models of GPCR signalling (Eishingdrelo & 
Kongsamut, 2013).  This has led to the discovery of signal transduction pathways that do not 
entirely involve G proteins; instead employing signalling intermediates to ‘cross-talk’ with 
receptor tyrosine kinases (RTKs) and subsequently lead to the rapid activation of MAPK 
(Liebmann, 2001).  Arguably, the best-characterised AngII-mediated kinase pathway is 
ERK1/2.  Since the discovery of cross-talk between AT1R-RTK, many RTKs have been 
shown to be transactivated by the AT1R, with the EGFR being the most widely studied.  
EGFR-stimulated growth promoting signalling pathways are well characterised in the 
literature, however what is less understood is GPCR-mediated, in particular AT1R-mediated, 
mitogenic signalling pathways (Kim, Abraham, Williams et al., 2012).   
1.4 EGFR Transactivation  
 
1.4.1 Initial discovery of EGFR transactivation 
 
30-40 years ago, it was thought that GPCRs and RTKs represent distinct and separate 
signalling pathways that converged on downstream effectors.  This theory was disputed in the 
early to mid 1990’s following observations that GPCR- and RTK-mediated signalling 
pathways are not mutually independent, with studies showing that GPCRs have the capacity 
to activate RTKs and mitogenic signalling (Faure, Voynoyasenetskaya & Bourne, 1994).  
However, the defining transactivation experiment did not occur until 1996 when Ullrich and 
colleagues first published the phenomenon of transactivation between GPCRs and the EGFR 
(Daub, Weiss, Wallasch et al., 1996). The seminal study (Daub, Weiss, Wallasch et al., 1996) 
showed that a variety of GPCR agonists: endothelin-1 (ET-1), lysophosphatidic acid (LPA) 
and thrombin induced rapid phosphorylation and subsequent activation of EGFR and 
HER2/neu in Rat-1 cells.  GPCR activation induced transactivation and subsequently coupled 
GPCRs to ERK1/2 activation, c-fos gene expression and DNA synthesis.  These effects were 
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blocked using a selective EGFR inhibitor, AG1478, and a dominant-negative EGFR.  For the 
first time, activation of RTKs by GPCRs was revealed as the mechanism of mitogenic 
signalling and proliferation, countering prevailing views of GPCR signal transmission.   
 
The observation of transactivation was subsequently substantiated by numerous independent 
groups; what was initially reported in Rat-1 fibroblasts was shown to extend in other more 
general cell types including the liver (Olivares-Reyes, Shah, Hernandez-Aranda et al., 2005; 
Shah & Catt, 2002; Shah, Yesilkaya, Olivares-Reyes et al., 2004) kidney (Chen, Chen, 
Neilson et al., 2006), cardiac fibroblasts (Murasawa, Mori, Nozawa et al., 1998), vascular 
smooth muscle cells (VSMC) (Eguchi, Numaguchi, Iwasaki et al., 1998), prostate (Lin & 
Freeman, 2003), anterior pituitary (Suarez, Diaz-Torga, Gonzalez-Iglesias et al., 2003), breast 
cancer (Greco, Muscella, Elia et al., 2003) and neuronal cultures (Huang, Richards & 
Sumners, 1996). 
 
1.4.2 EGFR family of receptor tyrosine kinases signal transduction 
 
EGFR, also designated HER1, is a 170-KDa glycoprotein and is one of four members of the 
HER family of ligand-activated RTK (Wieduwilt & Moasser, 2008).  The four receptors 
belonging to the HER family are EGFR (HER1 or ErbB1), HER2 (neu or ErbB2), HER3 
(ErbB3) and HER4 (ErbB4). HER receptor proteins are expressed in cells of mesodermal and 
ectodermal origins, with all four receptors expressed in the heart (Jorissen, Walker, Pouliot et 
al., 2003; Roskoski, 2014; Yarden & Sliwkowski, 2001).  All HER receptors share conserved 
structural features, including an extracellular ligand-binding region, single membrane 
spanning domain and lastly, an intracellular cytoplasmic kinase domain, that contains 
autophosphorylation sites that flank the cytoplasmic kinase domain (Bogdan & Klambt, 
2001).  Of the twenty tyrosine residues capable of phosphorylation within the cytoplasmic 
domain, seven of these are identified as autophosphorylation sites (Bishayee, Beguinot & 
Bishayee, 1999). 
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Figure 1.02: EGFR Activation 
Schematic of EGFR domains, structure and dimerisation.  (A) EGFR consists of an extracellular 
domain containing two leucine-rich ligand-binding domains (L1 and L2) and two cysteine-rich 
regulatory domains (C1 and C2).  The transmembrane (TM) domain connects to a short 
juxtamembrane (JM) sequence followed by the tyrosine kinase domain (Kinase).  The C-terminal 
comprises of the carboxyl terminal region and contains sites of phosphorylation.  (B) EGF binding to 
EGFR monomer allows receptor activation and dimerisation of the EGFR, allowing EGFR 
autophosphorylation at distinct tyrosine residues. This phosphorylation then becomes a platform for 
binding adaptor proteins, Shc and Grb2.  
 
Prevailing models identified that EGFR exists in the monomeric form at the cell surface with 
ligand binding inducing HER homo- or hetero-dimerisation (Purba, Saita & Maruyama, 
2017). Upon ligand activation, the receptor sites become occupied by monomeric growth 
factor providing two stable 1:1 EGF:EGFR intermediate complexes, allowing the 
intracellular kinase domains into close proximity for trans-autophosphorylation (Böni-
Schnetzler & Pilch, 1987; Yarden & Schlessinger, 1987).  However, subsequent studies have 
shown that a subset of RTKs can exist in an inactive dimeric form in the absence of ligand 
(~30-40% of total receptors) (Clayton, Orchard, Nice et al., 2008; Clayton, Walker, Orchard 
et al., 2005; Hofman, Bader, Voortman et al., 2010; Yu, Sharma, Takahashi et al., 2002).  
EGFR, present as preformed dimers, are auto-inhibited and are kept in an inactive state 
through the intracellular domain and the transmembrane domain of the receptor (Hofman, 
Bader, Voortman et al., 2010; Kozer, Barua, Orchard et al., 2013; Purba, Saita & Maruyama, 
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2017). A specific region located in the extracellular module is essential for the 
multimerisation of the EGFR, (but not required for pre-formed receptor dimerisation), 
allowing dimers to self-associate and form higher-order structures (Huang, Bharill, Karandur 
et al., 2016).  The current consensus is that following EGF stimulation, these preformed 
complexes allow for the full activation of receptor to occur more efficiently.   
 
Although there are ten identified possible conformations of HER dimers, HER2 functions as 
a ligand-less receptor and relies on heterodimerisation with other HER members for 
signalling functionality.  It is recognised that HER2 is the preferred co-receptor due to an 
intrinsically extended interaction loop, which renders it constitutively active (Graus-Porta, 
Beerli, Daly et al., 1997; Maruyama, 2014; Wilson, Gilmore, Foley et al., 2009).    
Additionally, while HER3, retains the ability to form an active signalling complex with 
remaining members of the HER family of receptors, it is generally considered to be kinase 
defective as it lacks the ability to phosphorylate exogenous peptides due to the absence of 
several key functional residues, although this has been recently challenged with ErbB3 shown 
to bind ATP and catalyse autophosphorylation (Ma, Lyu, Huang et al., 2014; Shi, Telesco, 
Liu et al., 2010; Steinkamp, Low-Nam, Yang et al., 2014). 
 
Following autophosphorylation of key tyrosine phosphorylation sites, the activated receptor 
functions as a binding site for Src Homology 2 (SH2) and phosphotyrosine binding (PTB) 
domains (Kaneko, Joshi, Feller et al., 2012; Sakaguchi, Okabayashi, Kido et al., 1998).  SH2 
and PTB domains recognise phosphorylated tyrosine residues within the context of a specific 
amino acid sequence, allowing for protein-protein interaction (Pawson & Nash, 2000).  
Accordingly, the activated EGFR becomes a platform for the assembly of signalling 
molecules and adaptor molecules that possess site-specific phosphorylation docking sites 
(Wagner, Stacey, Liu et al., 2013). Adaptor proteins Shc and Grb2 lack enzymatic activity 
and assist signalling by acting as a platform upon which downstream signalling molecules are 
recruited and activated (Burke, Schooler & Wiley, 2001).  Shc is tyrosine phosphorylated by 
the receptor and allows the binding of Grb2 via its SH2 domains.  Grb2 interaction with the 
EGFR recruits the guanine nucleotide exchange factor, Sos, to the plasma membrane, 
allowing it to be in close vicinity to its target protein Ras, a small GTP-binding protein 
(Rojas, Oliva & Santos, 2011). The membrane-anchored Ras exchanges GDP for GTP and 
recruits Raf, a serine-threonine kinase upstream of the MAPK cascade.  What follows, is the 
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sequential activation of the MAPK signalling cascade (Figure 1.03). Raf phosphorylates and 
activates the dual-specificity MEK which in turn is activated and phosphorylates MAPK, also 
denoted as ERK1/2. Phosphorylation of ERK1/2 initiates its translocation to the nucleus, 
where it activates transcription factors and alters gene expression. 
 
MAPKs, a family of protein kinases, have remained functionally conserved throughout 
eukaryotes, and are a key players in a variety of fundamental cellular processes, including 
proliferation, growth, differentiation, migration, transformation and apoptosis (Mordret, 
1993; Osaki & Gama, 2013).  There are three major MAPK families – classical ERK1/2, Jun 
Kinase (JNK) and p38 MAPK, with the ERK1/2 pathway the best characterised mammalian 
MAPK pathway (Zhang & Liu, 2002), and is dysregulated in approximately one-third of all 
cancers (Dhillon, Hagan, Rath et al., 2007).  ERK1/2 activation can be dependent or 
independent of RTK, however growing evidence supports the notion that EGFR is an 
important mediator of ERK1/2 activation.  
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Figure 1.03: GPCR-activated MAP Kinase signalling pathway 
Following GPCR activation, transactivation and dimerisation of the EGFR, the EGFR 
autophosphorylates distinct tyrosine residues. This then becomes a platform for adaptor proteins, Shc 
and Grb2, initiating the recruitment of Sos and allowing it to be in close vicinity to membrane-bound 
Ras. Ras recruits Raf-1, initiating the sequential activation of the MAPK signalling pathway, 
concluding with the phosphorylation of ERK1/2. ERK1/2 translocates to the nucleus, activating 
transcription factors and altering gene expression in favour of growth, mitosis and differentiation. 
 
1.4.3 Triple Membrane Passing Signal  
 
Ullrich’s group proposed a model of GPCR-EGFR transactivation now referred to as the 
‘Triple Membrane Passing Signal’ (TMPS).  A large proportion of HER family receptor 
ligands are expressed as membrane-anchored proteins that require cleavage. In this TMPS 
model, inactive membrane-bound EGF-ligands are released, enabling these ligands to bind 
and activate the EGFR (Figure 1.04) (Prenzel, Zwick, Daub et al., 1999). Matrix 
metalloprotease (MMP) belong to the endopeptidase family of enzymes that are involved in 
ectodomain shedding of inactive membrane-bound precursors and produce the 
complementary active form (Heparin-binding-EGF (HB-EGF), neuregulins & EGF) (Manso, 
Elsherif, Kang et al., 2006; Ohtsu, Dempsey & Eguchi, 2006). The initial study suggested 
that GPCR activation induces the activation of a transmembrane MMP, leading to the 
cleavage of proHB-EGF and the binding of its mature form, HB-EGF, to activate the EGFR.   
 
Chapter One: General Introduction 
 
 21 
The process was designated TMPS as it involves three traversing signalling phases across the 
plasma membrane (Wetzker & Bohmer, 2003).  A plethora of MMPs have since been shown 
to be involved in the transactivation of a variety of RTKs following GPCR activation 
(Cattaneo, Guerra, Parisi et al., 2014).  As studies progressed, agonist bound GPCRs were 
also shown to activate another family of metalloproteases, A Disintegrin and 
Metalloproteases (the ADAMs) (Carpenter, 2000; Izumi, Hirata, Hasuwa et al., 1998).  As 
molecular tools developed, a wide range of MMPs and ADAMs have since been implicated 
in the TMPS model (Asakura, Kitakaze, Takashima et al., 2002; Itabashi, Maesawa, Oikawa 
et al., 2008; Mifune, Ohtsu, Suzuki et al., 2005; Yan, Shirakabe & Werb, 2002; Zhang, Jiang, 
Black et al., 2000). Limitations however still exist, the exact identity of MMP/ADAMs and 
intracellular mechanisms contributing to their activation has not been fully elucidated, and 
reproducibility has been a major limiting factor.    Given the wide range of EGFR ligands, in 
addition to the multiple GPCRs and RTKs shown to transactivate, to this day, no uniform 
mechanism explains transactivation.  In the ensuing 20 years, it has become increasingly 
clear that other key mediators are involved, suggesting a more complex system involving 
non-receptor tyrosine kinases and the activation of additional second messengers. 
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Figure 1.04: Triple membrane passing signal  
Ligand activated GPCRs can signal via their cognate heterotrimeric G protein, leading to the 
activation of various second messengers including Ca2+, PKC, Pyk2, Src and ROS, initiating the 
subsequent phosphorylation and activation of the EGFR. Alternatively, the ‘TMPS’ paradigm has also 
been widely studied, whereby second messengers activate membrane-bound MMPs/ADAMs that 
cleave latent growth factors and promote ligand shedding into the extracellular space. The activated 
EGFR dimerises and activates subsequent MAPK signalling pathways, leading to a cellular response. 
-arrestins have also been shown to promote EGFR transactivation, mediating a G protein-
independent response. 
 
 
1.4.4 Key players in AT1R-EGFR Transactivation  
 
Many candidate proteins that potentially link GPCRs with mitogenic signalling have been 
heavily studied, particularly in the heart, VSMC, kidney and liver systems.  Several 
intermediate signalling molecules including, PKC, Ca2+, Pyk2, Src, reactive oxygen species 
(ROS) and -arrestin have been heavily implicated throughout the literature. The extent to 
which these identified molecules participate in AngII-stimulated mitogenic signalling 
depends on several factors including largely the cell-type, the receptors involved and the 
cellular environment (healthy vs. disease state) (Gschwind, Zwick, Prenzel et al., 2001; 
Sadoshima, 1998; Zou, Komuro, Yamazaki et al., 1998).   
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1.4.4.1 Evidence for EGFR transactivation in VSMC 
 
VSMCs are perhaps the best-studied tissue for AT1R-EGFR transactivation, with EGFR 
transactivation critical in mediating pathophysiological vascular remodelling and subsequent 
end-organ damage and cardiovascular disease.  All members of HER/ErbB family, as well as 
most of their ligands, are expressed by VSMC (Makki, Thiel & Miller, 2013).  Accumulating 
evidence indicates that AngII induces Gq/Ca2+-dependent EGFR activation, allowing the 
EGFR to serve as a ‘scaffold’ for the assembly of Src and Pyk2, which, in turn, leads to the 
activation of downstream kinases (ERK1/2, Akt, p38 MAPK) (Eguchi, Dempsey, Frank et 
al., 2001; Eguchi, Numaguchi, Iwasaki et al., 1998; Ohtsu, Higuchi, Shirai et al., 2008).  
VSMC contraction is regulated via activation of MLCK or inhibition of myosin light chain 
phosphatase (MLCP) (Mehta & Griendling, 2007; Nguyen Dinh Cat & Touyz, 2011).  Src 
family kinases attenuate myosin light chain phosphorylation and contraction in AngII-infused 
mice, regulating vascular contraction via MCLP (Qin & Zhou, 2015).     
 
AT1R agonist stimulation transiently increases intracellular ROS concentration and protein 
synthesis in VSMC, causing hypertrophy, hyperplasia and migration of VSMC (Frank & 
Eguchi, 2003; Frank, Eguchi, Inagami et al., 2001; Seshiah, Weber, Rocic et al., 2002; 
Touyz, Cruzado, Tabet et al., 2003).  Although the mechanism by which ROS activate 
tyrosine kinase can vary (Cattaneo, Guerra, Parisi et al., 2014), the predominant generation of 
ROS is via the membrane-bound NADPH oxidase complex.  Following AT1R stimulation 
and activation of NADPH oxidase, ROS production is thought to occur in a biphasic manner.  
The initial phase occurs quickly (within a minute) and is thought to be dependent on PKC 
activation. What follows is the second phase of ROS generation that is of greater magnitude 
(Seshiah, Weber, Rocic et al., 2002; Shah, Yesilkaya, Olivares-Reyes et al., 2004). ROS 
generation contributes to the metalloprotease-dependent shedding of HB-EGF (Frank & 
Eguchi, 2003). 
 
Studies using adenoviral-mediated RNA interference showed ADAM17 to be the major 
sheddase for HB-EGF generation and further revealed its requirement for ERK1/2 activation 
and hypertrophy induction by AngII in VSMC (Elliott, Bourne, Takayanagi et al., 2013).  
The same group has previously shown that overexpression of a dominant-negative ADAM17 
also completely abolished EGFR phosphorylation and EGFR-mediated protein synthesis 
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(Ohtsu, Dempsey, Frank et al., 2006), an effect not seen with overexpression of a dominant-
negative ADAM10.   
 
Furthermore, Caveolin-1 silencing prevented AngII-induced ADAM17 activation, vascular 
remodelling and abdominal aortic aneurysm (AAA) (Takayanagi, Crawford, Kobayashi et al., 
2014). Caveolin, a structural component of caveolae, has been implicated as a major 
functional microdomain that is essential for AngII-mediated EGFR transactivation.  It is 
thought that localised signalling domains formed in caveolae are essential for the dispersion 
and organisation of the AT1R signalling repertoire in VSMC (Umesalma, Houwen, 
Baumbach et al., 2016). Furthermore, caveolin-1 is essential in AngII-stimulated inward 
remodelling and hypertrophy, with MMP9 involved exclusively in inward remodelling, but 
not hypertrophy (Umesalma, Houwen, Baumbach et al., 2016).  However, infection of VSMC 
with adenovirus encoding caveolin-1 inhibits AngII-mediated HB-EGF shedding, EGFR 
transactivation, ERK1/2 activation, hypertrophy and migration (Takaguri, Shirai, Kimura et 
al., 2011), suggesting that ADAM17 co-localises with caveolin in lipid raft fractions and 
caveolin interferes with AngII-induced ADAM17 activation and EGFR transactivation. 
 
1.4.4.2 Evidence for EGFR transactivation in the heart 
 
EGFR transactivation plays an essential role in the physiology as well as the pathophysiology 
of cardiac myocytes and fibroblasts.  Accumulating evidence suggests EGFR is involved in 
cardiac development, regulation of myocardial function and adaption/remodelling in response 
to physiological and pathological loads (Forrester, Kawai, O'Brien et al., 2016).  Numerous 
GPCRs have been linked to EGFR transactivation in cardiac cells including the AT1R (Smith, 
Chan, Qian et al., 2011; Thomas, Brandenburger, Autelitano et al., 2002), adrenergic (Kim, 
Eckhart, Eguchi et al., 2002; Turner, 2003), muscarinic (Krieg, Qin, McIntosh et al., 2002; 
Miao, Bi, Zhao et al., 2015), adenosine (Williams-Pritchard, Knight, Hoe et al., 2011), 
endothelin (Clerk & Sugden, 1999; Kodama, Fukuda, Takahashi et al., 2002), bradykinin 
(Methner, Donat, Felix et al., 2009), opioid (Cao, Liu & Van Winkle, 2005; Förster, Kuno, 
Solenkova et al., 2007) and the protease activated receptor (Sabri, 2002).   G protein-
dependent signalling in the heart has been studied for decades, revealing significant roles for 
Gq/11 in the increased production of protein synthesis and hypertrophic responses in the 
heart.   
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The use of neonatal cardiomyocyte model, whereby the AT1R is reintroduced by adenoviral 
infection, demonstrated that a dominant negative Gq inhibited AngII-induced hypertrophy 
and ERK1/2 activation, suggesting Gq is involved in EGFR transactivation and 
cardiomyocyte hypertrophy (Thomas, Brandenburger, Autelitano et al., 2002).  Using the 
same neonatal cardiomyocyte model, cardiomyocyte hypertrophy required G protein coupling 
and ADAM-mediated HB-EGF production (Seta & Sadoshima, 2003; Smith, Chan, Qian et 
al., 2011).  More recently, studies have also begun to comprehensively characterise 
transcriptional regulation and the relative contribution of Gq/11 dependent and independent 
signalling following AngII stimulation.  Unlike -arrestin signalling, direct induction of gene 
expression by AT1R is dependent on Gq activation (Christensen, Knudsen, Schneider et al., 
2011).  Seta and Sadoshima subsequently proposed the role of AT1R tyrosine 319 (Y319) as 
the mechanism by which the EGFR is transactivated (Seta & Sadoshima, 2003).  The authors 
showed that overexpression of the Y319F AT1R mutant abrogated AngII-induced EGFR 
transactivation and AngII-induced cell proliferation in cardiac fibroblasts.  It was suggested 
that phosphorylated Y319 acts as a scaffold for the adaptor protein, SHP-2, and mediated 
AT1R-EGFR interaction and transactivation of the EGFR.  However, this G protein 
independent mode of AT1R-mediated transactivation has been challenged, with others 
reporting that Y319 phosphorylation is not required for AngII-mediated EGFR 
transactivation (Smith, Chan, Qian et al., 2011). 
 
Many studies support a role of cardiac EGFR transactivation in pathological cardiac 
hypertrophy; however increasing evidence suggests that selective engagement of G protein-
independent mechanisms, namely -arrestin-mediated pathways, promotes cardioprotective 
signalling (Kim, Abraham, Williams et al., 2012; Rajagopal, Whalen, Violin et al., 2006; 
Tilley, Nguyen & Rockman, 2010; Violin, DeWire, Yamashita et al., 2010).  In response to 
an in vivo cardiac injury, -arrestin biased AT1R ligand promoted cell survival during cardiac 
injury, cardiac contractility and enhanced ERK1/2 and Akt signalling (Kim, Abraham, 
Williams et al., 2012).  Notably, the -arrestin biased agonist of the AT1R, SII, promotes 
positive ionotrophic effects on adult cardiomyocytes and increased cardiomyocyte 
contractility, identifying -arrestin2 and GRK6 as the mediator of this Gq/11-independent 
response (Rajagopal, Whalen, Violin et al., 2006).  This was confirmed in a more recent 
study showing that a -arrestin biased agonist increases cardiomyocyte contractility (Tilley, 
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Nguyen & Rockman, 2010; Violin, DeWire, Yamashita et al., 2010).  Interestingly, 
membrane stretch induces -arrestin biased signalling of AT1R in the absence of ligand or G 
protein activation.  Hearts lacking -arrestin2 fail to induce a response to mechanical stretch, 
as well as impaired EGFR transactivation and an increased myocyte apoptosis, overall 
revealing an inhibition of pro-survival signalling (Rakesh, Yoo, Kim et al., 2010).   
 
1.5 New insights into AT1R-EGFR transactivation 
Since the discovery of GPCR-EGFR transactivation in the mid 1990’s, hypothesis-driven 
candidate approaches have identified a number of proteins involved in receptor ‘cross-talk.’  
Although this approach has been informative, the complete mechanism is still lacking with 
recent progress in the field stalling.  A major requirement of the field is to identify key 
molecules that are critical in linking GPCR activation to EGFR transactivation.  This lead the 
Thomas group to perform an unbiased functional genomics approach to identify potential 
proteins involved (George, Purdue, Gould et al., 2013).  One major advantage of employing a 
functional genomic screen is the unbiased screening approach to identify novel genes 
involved in the transactivation process, which may potentially serve as therapeutic targets for 
the treatment of diseases commonly associated with AT1R-induced mitogenic signalling.  
Since the development of functional genomics in the early 2000’s, technological 
advancements have enabled researchers to perform high-throughput methods to study gene 
and protein expression using large-scale screens. One of the key developments was the 
introduction of RNA interference (RNAi) technology. Although shown to occur 
endogenously (Martineau & Pyrah, 2007; Milhavet, Gary & Mattson, 2003), functional 
genomics has harnessed RNAi technology as a powerful molecular tool to better understand 
the function of specific gene products. RNAi inhibits gene expression through the use of 
RNA molecules: microRNA (miRNA) and small interfering RNA (siRNA), that bind to 
target messenger RNA (mRNA) and consequently initiate its degradation and/or decrease its 
translation (MacFarlane & Murphy, 2010). What has become increasingly popular in the 
scientific community is employing large-scale genome-wide RNAi screens combined with 
target genes ‘knock-down’ (Boutros & Ahringer, 2008; Simpson, Davis & Boag, 2012). This 
provides further insight into a gene’s function, meaning an individual gene can be 
interrogated within a certain biological concept. Assuming that kinases are likely involved in 
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mediating AT1R-EGFR transactivation, the Thomas lab incorporated these recent 
developments and used a cellular model to perform a functional RNAi screen that identified 
novel proteins that are involved in AT1R-EGFR transactivation (George, Purdue, Gould et al., 
2013). 
Firstly, a human cellular model was generated by introducing the AT1R into a human 
mammary epithelial cell (HMEC) line using retroviral delivery.  The HMEC cell line robustly 
activated the EGFR and ERK1/2 in response to AngII, confirming a transactivation process. 
siRNA knockdown of known targets – AT1R, its cognate G protein (Gq/11) and EGFR 
revealed a significant decrease in phosphorylation of both the EGFR and ERK1/2 following 
AngII stimulation, confirming the cell lines appropriateness. Following this, a transactivation 
assay was optimised in a microplate format, which used the AlphaScreen SureFire phospho-
ERK1/2 kit as the readout.  
The functional RNAi screen comprised of two separate screens – a primary and a secondary 
screen (Figure 1.05). The initial primary screen encompassed 720 kinase genes from the 
Dharmacon SMARTpool siRNA kinome library. Each kinase gene was then ranked on their 
ability to modulate AT1R-EGFR transactivation. From this, 50 highly ranked candidates were 
identified as genes that either positively or negatively regulated transactivation and were 
further selected to be verified in the secondary screen, and were ranked as ‘high’, ‘medium’, 
or ‘low’ hits. When considering potential candidate genes, the primary interest was genes that 
have not been previously associated with HER function, although it is reassuring that many 
of the hits had already been identified in the literature (highlighted in grey Figure 1.05 table).  
From the screen, three novel genes were identified, as they have not been previously 
implicated in the literature to participate in GPCR-EGFR transactivation: BMX (Bone 
marrow kinase X-linked kinase), CHKA (Choline kinase alpha) and lastly TRIO (triple 
function domain protein).   
Individual knockdown of BMX, CHKA or TRIO attenuated tyrosine phosphorylation of the 
EGFR by AngII stimulation and appear to function downstream of the activated AT1R and 
upstream of the EGFR.  BMX is a member of the Tec family of non-receptor tyrosine kinases 
(Tamagnone, Lahtinen, Mustonen et al., 1994).  CHKA phosphorylates choline to produce 
phosphocholine, an important intermediate in the generation of the key membrane 
phospholipid, phosphatidylcholine (Aoyama, Liao & Ishidate, 2004),  Lastly, TRIO is a large 
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multidomain protein with two functional guanine nucleotide exchange factor (GEF) domains 
and a serine/threonine kinase domain (Debant, Serra-Pagès, Seipel et al., 1996). None of 
these candidates have been specifically or mechanistically linked to GPCR-EGFR 
transactivation, although, as we will outline in subsequent sections of this thesis, there is 
prevailing literature that provides important clues as to how they might be acting. 
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Figure 1.05: Kinome siRNA screen used to identify three novel genes involved in AT1R-
EGFR transactivation – CHKA, TRIO & BMX  
Using the HMEC-LST cell line, the functional screen identified potential kinase genes (using the 
Dharmacon SMARTpool siRNA kinome library) involved in ERK1/2 activation following AngII 
stimulation. The ERK1/2 readout was performed using the AlphaScreen SureFire phospho-ERK1/2. 
The primary screen ranked all tested kinases on their ability to modulate AT1R-EGFR transactivation. 
The secondary screen validated 50 of the highest ranked candidates. Following this, the functional 
screen identified three novel genes – CHKA, TRIO and BMX.  
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1.6 Where to next?  
In order to improve our understanding of GPCR-EGFR transactivation, adequate technology 
is required to better interrogate the molecular mechanisms governing EGFR transactivation.  
A common growth target of both the AT1R and EGFR is the phosphorylation and activation 
of ERK1/2, which is widely used as a surrogate marker for AT1R-EGFR cross-talk.  EGFR 
transactivation is subsequently defined as the ability of AG1478, a moderately selective 
inhibitor of EGFR, to prevent AT1R-mediated ERK1/2 phosphorylation.  Although the 
activation of ERK1/2 culminates in the activation of growth promoting signals, it represents a 
kinase distally downstream of the EGFR (as shown in Figure 1.03).  Arguably, a more direct 
readout of EGFR transactivation is the phosphorylation and activation of the EGFR, the 
convergence point for many signalling pathways, including that of transactivation. However, 
phospho-EGFR assays, through the use of western blots, are often laborious, finicky, time 
consuming, insensitive and inconsistent.   
Despite the utility of ERK1/2 phosphorylation assays using western blotting, this approach 
has several well-known limitations.  These include the inability to detect the activation and 
recruitment of proteins in live cells and in real-time.  Over the last decade, the development 
of Resonance Energy Transfer (RET) assays has enabled the study of dynamic cellular 
processes in living cells and has been widely used in the field of GPCR and RTK biology 
(Kocan & Pfleger, 2011; Stoddart, Kilpatrick & Hill, 2017).  RET technology measures 
protein-protein interactions in which energy transfer occurs between a luminescent donor 
complex (e.g., Renilla luciferase; Rluc) attached to a protein of interest and a second protein 
labelled with a complementary fluorescent acceptor molecule (e.g., yellow fluorescent 
molecule; Venus) (Figure 1.06).   Light is emitted following the oxidation of an external 
substrate (coelenterazine h) by the donor luciferase.  If the donor- and acceptor-tagged 
proteins are in close proximity (no more than 10nm apart), non-radiative transfer of energy 
occurs between the two molecules, which in turn excites the acceptor fluorescent moiety and 
enables the acceptor molecule to emit light at a longer wavelength (Figure 1.06).  Two main 
types of RET-based methods exist, fluorescent-RET (FRET) and bioluminescent-RET 
(BRET) based assays.   
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Figure 1.06: The principle of BRET1 – studying protein-protein interactions  
BRET allows researchers to study the interactions of GPCR (fused alongside a donor luminescent, 
Rluc8) with a protein of interest (fused alongside a complementary acceptor fluorophore, Venus). 
Following the addition of the Luciferase substrate coelenterazine to the system, if there is no 
interaction between the co-transfected donor- and acceptor-tagged proteins, light energy from the 
oxidation of coelenterazine by the luciferase will be emitted at 480nm. If the GPCR and the protein of 
interest are within 100Å, resonance energy transfer from the luminescent donor to the complementary 
acceptor fluorophore occurs, which in turn emits light energy at a longer wavelength of 520nm. 
 
One of the first such studies to utilise a BRET-based approach, monitored GPCRs interaction 
with its associated G protein, specifically β2-adrenergic receptor (β2AR) interaction with 
Gsβ12 (Galés, Rebois, Hogue et al., 2005).  Following this seminal study, BRET assays 
have been used to identify effector proteins downstream of GPCRs, GPCR conformational 
changes (Hudson, 2016) and GPCR homo- and hetero-dimerisation (Porrello, Pfleger, Seeber 
et al., 2011). Detection of β-arrestin recruitment using BRET has been reported in more than 
50 manuscripts and for a wide range of GPCRs, including time courses, dose responses and 
ligand dependency, all accessed in live cells and in real-time (Ayoub & Pin, 2013; Namkung, 
Radresa, Armando et al., 2016). More recently, FRET and BRET techniques have shown that 
many GPCRs, including the AT1R, exist as homo- or hetero-dimers with other GPCRs 
(Sleno, Devost, Pétrin et al., 2017; Tóth, Gyombolai, Szalai et al., 2017), with receptor-
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receptor complexes shown to alter GPCR pharmacology, coupling as well as receptor 
trafficking. BRET-based approaches have also revealed that RTKs have the capacity to 
homo- and hetero-dimerise, demonstrating that the EGFR and HER3 heteromerise in a 
ligand-dependent manner (Ayoub, See, Seeber et al., 2013).  The main limitation of RET-
based assays is that it requires the exogenous expression of the receptor/protein of interest 
genetically fused with the luminescent donor or acceptor fluorophore.  The recent 
development of the NanoLuc variant results in a significantly stable and smaller luciferase 
molecule (19kDa, compared to Rluc8 38kDa) that produces a significantly brighter and 
sustained luminescent signal (Hall, Unch, Binkowski et al., 2012).  The development of 
NanoLuc enables the expression of tagged-proteins of interest at near physiological 
expression, however more promising is the ability to express NanoLuc-GPCR fusions under 
an endogenous promotion using a CRISPR/Cas9 system (White, Vanyai, See et al., 2017).   
Using a combination of BRET and FRET technologies, the existence of GPCR-RTK 
heteromer complexes have been reported for a number of receptors (Jensen, Godfrey, Niklas 
et al., 2013; Maudsley, Pierce, Zamah et al., 2000).  Most notably, Bhattacharya and 
colleagues showed that through the use of FRET, G protein-coupled receptor 54 (GPCR54) 
interacts directly with EGFR, with this association further enhanced following kisspeptin 
treatment, GPR54 endogenous ligand (Zajac, Law, Cvetkovic et al., 2011).  Similarly, FRET 
studies have shown that isoprenaline treatment induces 1-adrenergic receptor (1AR) 
association with the EGFR, whereas in contrast, EGF stimulation significantly disrupts this 
association (Tilley, Kim, Patel et al., 2009). These higher order receptor complexes create 
new alternatives in term of physiological function, from ligand binding to signal transduction, 
trafficking, desensitisation and downregulation. To date, such approaches have not been used 
to interrogate transactivation, and while BRET/FRET approaches have the potential to report 
on the most proximal events in ligand-mediated receptor activation, they can also provide 
information about where and when these interactions occur in the cell.  
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1.7 Project Rationale 
 
Although a new light was shone on the process of mitogenic signalling via GPCRs when 
Ullrich’s group published their pioneer study in 1996 (Daub, Weiss, Wallasch et al., 1996), a 
gap still exists in the current knowledge. There is an ever present need to digress from 
conventional western-based approaches that study signalling proteins in solution and/or 
isolated membranes, to instead measure dynamic protein-protein interactions in live cells and 
in real-time.  The use of BRET has proven beneficial in monitoring receptor-specific events, 
and can offer tremendous potential in better understanding the most proximal events in 
ligand-mediated RTK activation and its sensitivity to chemical inhibitors of their function.  
Therefore, in this thesis, the aims of my project are split into three different sections with the 
following goals: 
1) To use a BRET-based approach to identify and characterise the molecular basis of 
transactivation, examining the spatio- and temporal-requirements of AT1R-mediated 
EGFR transactivation.    
2) To further interrogate the role of BMX, CHKA and TRIO in AT1R-EGFR 
transactivation. 
3) To investigate the structural and functional characteristics of a phenomenon that I 
have titled ‘reverse transactivation’, a novel concept I have identified during my 
canditure whereby the AT1R is activated by the EGFR.   
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2.0 Methods 
2.1 Materials 
 
This Chapter describes the general methods that have been used throughout this thesis.  These 
methods are described here in detail.  The sources of drugs and plasmids are indicated in 
individual chapters.   
 
 2.2 Bacterial Methods 
2.2.1Transformation of 5-alpha Heat Shock competent cells  
 
Transformation of New England Biolabs (NEB) High Efficiency 5-alpha Competent E.Coli 
cells (NEB Cat# C2987H) were performed according to manufacturers instructions.  Briefly, 
1-100ng of plasmid DNA was mixed with 50L of 5-alpha Competent E.Coli cells and 
incubated on ice for 30 minutes before being heat shocked at 42°C for 30 seconds and placed 
on ice for 5 minutes.  SOC medium was added and incubated at 37°C for 1 hour with shaking 
at ~250 revolutions per minute (rpm).  Approximately 50-100L of SOC media/competent 
cells were spread on agar plates containing the appropriate antibiotics, and left overnight for 
12-16 hours at 37°C.  Surviving colonies were used to inoculate 3-4mL of LB media 
containing the relevant antibiotic and left overnight shaking (250rpm) for 12-16 hours.  This 
was then used as a starter culture for mini- and maxi-prep plasmid DNA preparation.  
 
 2.2.2 Glycerol Stocks 
 
A glycerol stock was created for long-term storage of positive clones. 2mL of bacterial 
culture was centrifuged and pelleted at 12,000 x g for 5minutes at room temperature.  The 
pellet was resuspended in a 1:1 ratio of sterile lysogeny broth (LB) media (Appendix A) and 
glycerol.  All glycerol stocks were stored at -80°C. 
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2.3 DNA Methods 
 2.3.1 Mini-prep plasmid DNA preparation 
 
Small-scale plasmid preparation was carried out using PureLink Quick Plasmid Miniprep Kit 
(Invitrogen, Cat# K210010) as per the manufacturer’s instructions.  Briefly, 2mL of starter 
cultures described as per section 2.2.1 was centrifuged at 12, 000 x g for 5 minutes and 
resuspended, lysed and precipitated. The supernatant was resuspended onto a spin column 
and centrifuged at 12,000 x g for 1 minute.  A variety of wash steps were performed prior to 
DNA elution with TE Buffer (supplied in the kit).  Plasmid DNA was stored at -20°C. 
 
 2.3.2 Maxi-prep plasmid DNA preparation 
 
Large-scale plasmid preparation was carried out using PureLink HiPure Plasmid Filter 
Maxiprep Kit (Invitrogen, Cat# K210016) as per the manufacturer’s instructions.  LB media 
(300mL) was inoculated with 300L of starter culture and transformed overnight shaking 
(250rpm) for 12-16 hours at 37°C.  The overnight culture was pelleted by centrifugation (4, 
000 x g for 10 minutes), resuspended and lysed, and DNA was then transferred to an 
equilibrated HiPure Filter Column.  The column containing the DNA was washed and eluted 
before precipitating the DNA with isopropanol and washed with ethanol.  The pellet was air-
dried and resuspended in 500L of TE Buffer (supplied in the kit). Plasmid DNA was stored 
at -20°C. 
 
 2.3.3 DNA Quantification 
 
DNA concentration was quantified using a NanoDrop ND-1000 Spectrophotometer 
(Nanodrop Technologies).  DNA concentrations were estimated by measuring an OD reading 
of 1 at 260nm absorbance. 
 
2.4 Cell Culture 
 2.4.1 Immortalised Cell Lines 
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Mouse embryo fibroblast (NIH-3T3) cells, monkey fibroblast (COS-7) cells, human 
colorectal adenocarcinoma (HT-29) cells, human embryonic kidney 293 (HEK293), 
HEK293FT cells, HEK-adherent-293 cell line, which is a derivative of HEK293 with 
increased adherence and human cervical cancer (HeLa) cells were cultured in Dulbecco’s 
Modified Eagle Media (DMEM, Life Technologies Cat# 11995065) supplemented with 10% 
Foetal Bovine Serum (FBS, Life Technologies) and antibiotic-antimycotic solution with 
HEK293FT cells containing an additional 0.3mg/mL glutamine.  Stably expressing NHA-
AT1R-HEK293 and HEK293FT cells were maintained as above in DMEM/10%FBS with the 
addition of 200g/mL Geneticin (Gibco, Cat# G-148).  Chinese hamster ovary (CHO-K1) 
cells were cultured in -Modified Eagle Media (-MEM, Life Technologies Cat# 12571063) 
supplemented with 10% FBS and antibiotic-antimycotic solution.  All cells were maintained 
at 37°C at 5% CO2 and passaged when confluent.  HEK293, HeLa and CHO-K1 were 
purchased from American Type Tissue Culture (ATCC).  HEK293FT and COS-7 cells were 
kindly provided by Professor Kevin Pfleger (Harry Perkins Institute, University of Western 
Australia, Perth, AUS) and NIH-3T3, HT-29 cells a kind gift from Dr Daniel Croker 
(University of Queensland, Brisbane, AUS). All cells were grown in 75cm2 or 175cm2 cell 
culture flasks (Corning) under sterile conditions.  Cells were subcultured by washing once in 
sterile phosphate buffer saline (PBS, Life Technologies, Cat# 21600010) before 5 minutes 
incubation with 0.25% trypsin (Gibco, Cat# 25200072).  Cells were counted with a 
haemocytometer prior to plating. 
 
 2.4.2 DNA Transfection – Immortalised cell lines 
 
Lipid phosphate transfection using FuGene (Promega, Cat# E2311) was used to introduce 
exogenous DNA for protein expression.  Cells were seeded onto a 6-well tissue culture plate 
the day prior to transfection to achieve 70-80% confluence.  DNA transfection was performed 
according to manufacturer’s protocol and was scaled up or down in accordance with cell 
culture plate dimensions.  Briefly, for one well of a 6-well plate, 100L of Opti-MEM (Life 
Technologies, Cat# 31985070) was mixed with 3L of FuGene and incubated at room 
temperature for 5 minutes. No more than 1g of DNA total was added and incubated at room 
temperature for 10 minutes to enable lipid:DNA complex to form.  DNA/lipid mixture was 
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then added directly to the cells and left overnight to incubate at 37°C at 5% CO2.  Typically, 
experiments were performed 24 hours following transfection. 
 
2.4.3 Neonatal cardiomyocyte isolation and purification 
 
Approximately 24-hour-old neonatal Sprague Dawley pups (approximately 40-100 per 
preparation) were killed by decapitation before an incision along the thoracic wall and the 
extraction of the intact heart.  The atrium was removed and the remaining ventricles were cut 
into approximately 6-8 pieces to allow for increased surface area for the enzymatic digestion.  
Heart tissue was then transferred to a 50mL Wheaton Celstir water-jacketed double side-arm 
spinner flask pre-warmed to 37°C.  Heart tissue was incubated at slow speed with Enzyme 
Digestion Buffer (Appendix A; 0.3mL buffer per whole heart).  Supernatant, which included 
cell debris, red blood cells and extracellular matrix, was excluded by disposing of the first 20-
minute dispersion.  The remaining 20 minute dispersion was repeated 4-8 times, with each 
supernatant carefully transferred to a sterile 50mL falcon tube containing 5mL newborn calf 
serum (NBCS, Gibco Cat# 16010159) and placed on ice.  After the final dispersion, the cell 
suspension/NBCS mixture was centrifuged at 1000 x g for 6 minutes to pellet cells.  The 
pellet was carefully resuspended in 1 x ADS buffer (Appendix A; 2mL per gradient, 1 
gradient per 8-10 pups).   
 
Cardiomyocytes were purified using a discontinuous Percoll gradient (1.060/1.086 g/mL) 
diluted in 1 x ADS.  Carefully, 2mL of cell suspension/1 x ADS mixture was gently overlaid 
a freshly prepared gradient before centrifugation at 1400 x g for 30 minutes (slowest 
acceleration, no deceleration).  The non-myocyte portion, which included fibroblasts, 
appeared at the top interface between the top Percoll layer and the ADS buffer.  This 
fibroblast portion is either collected and seeded into a 175cm2 cell culture flask with 10% 
FBS and antibiotic (1 gradient/175cm2 cell culture flask) or discarded.  The second interface 
between the top and bottom Percoll densities contained neonatal myocytes and were carefully 
removed and transferred to a new 50mL falcon tube.  The cells were resuspended in 1 x ADS 
buffer to remove any remaining Percoll gradient, and washed twice. Pelleted cardiomyocytes 
were resuspended in a final volume of 20mL plating medium (Minimal Essential Medium 
supplemented with 10% NBCS; Appendix A).  To prevent the proliferation of any remaining 
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fibroblasts, plating media was supplemented with the anti-miotic agent 5-Bromo-
2’deoxyuridine (BrdU; 0.5mM). 
 
Resuspended cells were counted using a haemocytometer and plated on 0.1% gelatine-coated 
tissue culture dishes.  Cells were seeded at a high density (1250 cell/mm2) for Westerns.  If 
cells were to be used for nucleofector transfection, 5.0x106 cells were used/cuvette (refer to 
Nucleofector section 2.4.5).  Following overnight incubation, cells were washed twice with 
PBS and media was replaced with defined myocyte media (DMEM CCTSS2 with 50mM 
KCl; Appendix A).  The Percoll Isolation process usually resulted in a 95-98% pure 
cardiomyocyte population.   
 
 2.4.4 Isolation of vascular smooth muscle cells 
 
Purified VSMC cultures were performed by Dr Tatsuo Kawai (Lewis Katz School of 
Medicine, Temple University, Philadelphia, USA).  Animals were supplied by Charles River 
Breeding Laboratory Inc., Wilmington, MA, USA.  The thoracic aorta of a male Sprague 
Dawley rat removed and placed into DMEM (4.5g/L glucose) supplemented with 10% FBS 
and antibiotic.  Longitudinally, the isolated aorta was cut and then endothelium was removed 
using a dull scissor.  The aorta was then cut into 3mm square sections with each section 
placed intimal side down in a well of a 6-well plate.  Carefully, 100-200L of DMEM 
(4.5g/L glucose) supplemented with 10% FBS and antibiotic was added to the tissue and 
cultured at 37°C in 5% CO2.   24-48 hours post-explant, the tissue was then monitored for cell 
growth and additional media was added to avoid drying of the tissue.     
 
 2.4.5 Nucleofector 
 
For nucleofector delivery of plasmid DNA into isolated primary cells, a 4D-Nucleofector 
(Lonza) was used to transfect cardiomycoytes and cardiac fibroblasts; meanwhile an Amaxa 
Nucleofector (Lonza) was used to transfect VSMC.  
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2.4.5.1 4D-Nuclefector: Cardiac myocytes and fibroblasts 
 
Cardiomyocyte and fibroblasts were transfected using the 4D-Nucleofector system (Lonza) 
using the primary cell 4D nucleofector kit (Cat# VX4P-3012) according to the 
manufacturer’s protocol. In brief, following cardiomyocyte isolation and purification, both 
cardiac myocytes and fibroblasts (5.0x106 cells/cuvette) were resuspended in 100L of room 
temperature Nucleofector Buffer solution™ containing a 3:1 ratio of receptor:protein of 
interest (0.15g receptor and 0.05g protein of interest) and transfected using the 4D-
Nucleofector program CM-150.  400L of RPMI (Life Technologies, Cat# 61870036) 
supplemented with 10% horse serum was added to each cuvette containing transfected cells 
and then plated on 0.1% gelatine-coated white F96 MicroWell plate (Nunc, Cat# 136101).  
Following overnight incubation, cells were washed twice with PBS and media was replaced 
with defined myocyte media (DMEM CCTSS2 with 50mM KCl; Appendix A) or DMEM 
supplemented with 10% FBS and antibiotic for fibroblasts.  Typically, experiments were 
performed 48 hours following transfection.  
 
  2.4.5.2 Amaxa Nucleofector: VSMC 
 
VSMC were transfected using the Amaxa nucleofector kit (Lonza, Cat# V4XP-1024) 
according to the manufacturer’s protocol. In brief, following VSMC isolation, VSMC 
(1.0x106) were transfected using Amaxa program U-25 in 100L room temperature smooth 
muscle cells (SMC) nucleofector solution™ containing 3:1 ratio of receptor:protein of 
interest (0.15g receptor and 0.05g protein of interest).  500L of DMEM supplemented 
with 10% FBS was added to each cuvette containing transfected cells and then plated on 
white F96 MicroWell plate.  Following overnight incubation, cells were washed twice with 
PBS and media was replaced with serum-free DMEM.  Typically, experiments were 
performed 48 hours following transfection. 
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2.5 Plasmid DNA Cloning 
 2.5.1 Restriction Digest 
 
Each restriction enzyme was used to digest DNA as specified by the manufacturer.  In 
general, 1 U of restriction enzyme (NEB) was used to digest 1g of substrate DNA in 
appropriate 1 x NEBuffer, and incubated at 37°C for 1 hour.  Digested DNA was resolved 
(Section 2.5.2), excised (Section 2.5.3) and quantified (Section 2.3.3) before cloning into 
vectors. 
  
2.5.2 Agarose gel electrophoresis 
 
Digested DNA and DNA fragments were separated using a 1% agarose gels in 1 x Tris-
Acetate-EDTA (TAE) buffer (Appendix A) containing 1 x SYBR® Safe DNA gel stain 
(1:10,000 dilution) (Invitrogen, Cat# S33102).  DNA samples were resuspended with 1 x Gel 
purple or blue loading dye (NEB) and loaded alongside a 1kb DNA ladder (NEB, Cat# 161-
0374).  Digested DNA was resolved at 100V for ~40-60 minutes or until the bands had 
sufficiently separated.  DNA fragments were visualised under UV illumination using a UVP 
BioDoc-It™ System UV Transilluminator (UVP).   
 
2.5.3 Recovery of DNA fragments from agarose gels  
 
DNA was extracted from 1% agarose gels using the QIAquick® Gel Extraction Kit (Qiagen 
Pty. Ltd., Cat# 20200531) according to manufacturer’s protocol.  In brief, SYBR® Safe DNA 
gel stained bands of interest were excised from gels using a scalpel blade.  DNA from gel 
fragments was dissolved and extracted using QIAquick spin columns and eluted in 20L of 
TE buffer.  Excised DNA was stored at -20°C. 
 
 2.5.4 DNA ligation 
 
DNA ligation was performed using a Quick Ligation™ Kit (NEB, Cat# M2200) as per 
manufacturer’s protocol.  In general, a 3:1 vecotr:insert (as per online NEBioCalculator™) 
was mixed with Quick Ligase Reaction Buffer and Quick Ligase.  The mixture was incubated 
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at room temperature for 5 minutes and then placed on ice before being transformed using 
competent cells (Section 2.2.1).   
 
 2.5.5 DNA sequencing 
 
Sequencing was performed at the Australian Genome Research Facility (AGRF) (University 
of Queensland, Brisbane, AUS).  All samples submitted contained a total amount of 0.6g-
1.5g of plasmid DNA and 10pmol of desired primer.  All sequencing was performed using a 
high throughput Sanger sequencing using Applied Biosystems 3730 and 3730xl capillary 
sequencers.   
 
  2.6 Assays 
2.6.1 Ligand-induced BRET assays and Receptor-Heteromer Identification 
Technology assay 
 
Briefly, BRET1 quantifies interactions between receptor (fused with a donor luminescent, 
Renilla luciferase (Rluc8)) and a protein of interest (fused with a complementary acceptor 
fluorophore, Venus) (Kocan & Pfleger, 2011; Kocan, See, Seeber et al., 2008). Following the 
addition of the Luciferase substrate coelenterazine, if there is no interaction between the co-
transfected donor- and acceptor-tagged proteins, light energy from the oxidation of 
coelenterazine by the luciferase will be emitted at 480nm. If the receptor and the protein of 
interest are within 100Å, resonance energy transfer from the luminescent donor to the 
complementary acceptor fluorophore occurs, which in turn emits light energy at a longer 
wavelength of 520nm. Therefore, the degree of BRET signal or protein-protein interaction is 
quantified as a ratio of light emitted at 520nm over 480nm.   
 
Cells were transiently transfected with proteins of interest as per FuGene’s protocol (Section 
2.4.2).  24h post transfection, cells were washed with PBS and detached using 0.25% trypsin, 
resuspended in FluoroBrite™ DMEM (Life Technologies, Cat# A1896701) phenol red-free 
media supplemented with 5% FBS + 10% L-Glutatmine or phenol-red free DMEM 
containing 25mM HEPES, 0.3mg/mL glutamine, 100IU/mL penicillin and 100g/mL 
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streptomycin supplemented with 5% FBS and added to poly-D-lysine-coated white F96 
MicroWell plate at 100,000 cells/well.  Early the following day, cells were serum starved 
with FluoroBrite™ DMEM phenol red-free media supplemented with 10% L-Glutatmine or 
25mM HEPES with 0.3mg/mL glutamine, 100IU/mL penicillin and 100g/mL streptomycin 
for at least 6 hours.  48 hours post-transfection, media was replaced with PBS or Hanks’ 
balanced salt solution (HBSS) containing coelenterazine-h (Promega) at a final concentration 
of 5M.  BRET1 measurements were taken at 37°C every 30 seconds using: a M1000 PRO 
Tecan plate reader (Tecan, Life Sciences) with 430-485 nm and 505-590 nm filters; a 
CLARIOstar Microplate Reader (BMG Labtech) with 420-480 nm and 520-620 nm filters; or 
a LUMIstar Omega Microplate Reader (BMG Labtech) with 450-480 nm and 520-550 nm 
filters. All BRET experiments were performed using the Tecan M1000 PRO plate reader 
unless otherwise specified in the figure legend.  Following baseline readings, cells were 
treated with vehicle, 10μM AngII (Auspep, Cat# 2079) or 1μM EGF (R&D Systems, Cat# 
236-EG).  The BRET signal observed between interacting proteins was normalised by 
subtracting the background BRET ratio as follows: the long wavelength emission over the 
short wavelength emission for a cell sample treated with vehicle was subtracted from the 
same ratio for a second aliquot of the same cell sample treated with 10M AngII or 1M 
EGF (Porrello, Pfleger, Seeber et al., 2011). For these BRET kinetic assays, the arrow 
indicates the first BRET reading following treatment of agonist/vehicle (time of 
ligand/vehicle addition).  Ligand and vehicle treated wells were assayed in triplicate wells in 
each independent experiment. 
 
2.6.2 Bimolecular Fluorescence Complementation Assay 
 
CHO-K1 cells were plated on a collagen-coated 35mm glass bottom dishes (MatTek, Cat# 
P35GCol-1.5-14-C) at a density of approximately 400,000 cells/dish.  24h post-seeding, cells 
were transiently transfected with 150ng DNA of Vn-tagged protein and 150ng DNA of Vc-
tagged protein, to a total of 300ng of protein (compensated with empty vector when 
expressing DNA constructs individually) using FuGene.  24 hours post transfection, cells 
were serum starved using FluoroBrite phenol red-free media + 10%L-Glutamine for 24 
hours. Cells were assayed 48 hours after transfection.  Localisation of complemented Venus 
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fluorescence was viewed with an Olympus FV1000 inverted confocal (FV1000, Olympus, 
Tokyo, Japan) 60x oil immersion objective on a heated (37°C) chamber stage.  
 
2.6.3 [125I]- AngII binding assay 
 
HEK-adherent-293 were transfected with wild type and mutant AT1R: [TK325]AT1R or 
[Y215F]AT1R.  Twenty-four hours post-transfection, cells were serum starved for 12-16 
hours.  Cells were washed twice in ice-cold PBS and incubated at 4°C for four hours in 
serum-free DMEM + 0.1% BSA and [125I]-AngII (60L containing 60,000 counts per minute, 
equivalent to approximately 50pM AngII) with or without unlabelled 1M AngII to define 
non-specific binding.  Each condition was tested in triplicate.  Following incubation, to 
remove unbound [125I]-AngII, cells were washed with PBS and lysed in 1mL 0.25M 
NaOH/0.25% SDS lysis buffer for 10 minutes at room temperature.  Radioactivity was 
determined using a Wizard2 Gamma Counter 2470 (Perkin Elmer) 
 
 2.6.4 Conformational Biosensor Assay 
 
HEK293 cells were transfected with 1g with each fluoresceinarsenical hairpin binder 
(FlAsH)-labelled AT1R as per FuGene’s protocol (Section 2.4.2).  24h post transfection, cells 
were washed with PBS and de-attached using 0.25% trypsin, resuspended in FluoroBrite 
DMEM phenol red-free media supplemented with 5% FBS + 10% L-Glutatmine and added to 
poly-D-lysine-coated white F96 MicroWell plate at 100,000 cells/well.  48 hours post-
transfection, 25mM solution of 1,2-ethanedithiol (EDT; Sigma Aldrich, Cat# 02390) was 
prepared in dimethyl sulfoxide (DMSO; Sigma Aldrich, Cat# D4540).  One volume of 2mM 
FlAsH-EDT2 (Invitrogen, Cat# T34561) labelling reagent (1.87L) was added to two 
volumes of EDT (3.73L) to make a 667M FlAsH solution, this was incubated at room 
temperature and protected from light for 10 minutes.  100L of phenol red free HBSS was 
added and incubated for 5 minutes at room temperature, followed by 4.9mL of HBSS.  In 
parallel, cells were washed with 150L of HBSS and then labelled with 50L of FlAsH-
EDT2 solution described above at 37°C for 1 hour, protected from light. Following 
incubation, cells were washed with 100L1M 2,3-Dimercapto-1-propanol (BAL; Invitrogen, 
supplied with FlAsH) diluted in HBSS buffer and incubated at 37°C for 10 minutes.  The 
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cells were washed again with 1M BAL followed by 150L of Krebs buffer, with no 
incubation.  Lastly, 80L of Krebs buffer was added to the cells and incubated at 37°C for 2 
hours protected from light.  10L of coelenterazine-h was added to each well to give a final 
concentration of 5M and incubated for 5 minutes in a pre-warmed plate reader at 37°C.  
BRET1 measurements were taken at 37°C every 10 milliseconds using a M1000 PRO Tecan 
plate reader.  Filtered light emissions were sequentially measured at 430-485 and 505-590.  
Following base line readings, cells were treated with PBS/HBSS, 10M AngII or 1M EGF 
for the remaining assay.  The change in BRET ratio due to the addition of agonist (or the ∆ 
BRET) was calculated by subtracting the average BRET across all reads pre-treatment from 
the average BRET of the last 30 seconds post-treatment.   
 
2.6.5 CHKA Activity Assay 
 
HEK293 cells were seeded in a 6-well plate at a density of approximately 700,000 cells/well.  
24h after seeding, 1 well was left untreated, the remaining wells were transiently transfected 
with 1g of mock vector (pcNDA3), pcDNA3-Venus, Venus-CHKA, CHKA-Venus or 
pcDNA3-CHKA.  24h post-transfection, cells were washed with PBS, and labelled with 
1Ci/mL methyl-(14C)-choline chloride.  Cells were maintained for 14 additional hours in the 
presence of radioactivity.  Cells were washed with ice-cold TB buffer (137mM NaCl, 5mM 
KCl, 20mM Tris, pH 7.4).  Cells were then fixed with 16% ice-cold trichloroacetic acid.  
Trichloroacetic acid-soluble material, containing choline and phosphocholine, were washed 
three times with four volumes of diethylehter, dried under vacuum and resuspended in 50L 
of water.  30L of each sample was resolved on thin layer chromatography plates using 0.9% 
NaCl:methanol:ammonium hydroxide (50:70:5; V:V:V) as liquid phase.   
 
2.7 Protein Methods 
 2.7.1 Signalling inhibition/stimulation and preparation of extracts 
 
Cells were serum starved for a minimum of 8 hours prior to inhibition with antagonists and/or 
stimulation with agonists.  Unless otherwise specified, stimulation of cell was performed at 
37°C and terminated on ice.  Following termination, cells were washed twice with ice-cold 
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PBS before lysis with radioimmunoprecipitation assay (RIPA) buffer containing phosphatase 
inhibitor cocktail table (PhosSTOP™, Roche Cat# 04906837001) and protease inhibitor 
cocktail tablet (Roche, Cat# 11836170001) (Appendix A).  Cells containing RIPA lysis 
buffer (200L/6-well) were rocked for 1 hour at 4°C and then transferred to a fresh 1.5mL 
eppendorf tube and centrifuged at 10, 000 x g at 4°C for 15 minutes.  The supernatant was 
collected and placed in a fresh 1.5mL eppendorf tube and assayed for protein concentration. 
 
2.7.2 Protein Estimation 
 
Protein concentration was determined using the Pierce™ BCA Protein Assay Kit (Thermo 
Scientific, Cat# 23225) as per the manufacturer’s protocol.  Briefly, standards containing 
diluted albumin was prepared as well as the Working Reagent (WR), 50 parts of BCA reagent 
A with 1 part of BCA reagent B.  10L of each unknown sample was loaded in triplicate into 
a 96-well plate followed by 200L of WR reagent and mixed on a plate shaker for 30 
seconds.  The plate was incubated at 37°C for 30 minutes and absorbance was measured at 
562nm using a plate reader.   For the resolution of all proteins, protein samples were mixed 
with Laemmli sample buffer (BioRad, Cat# 161-0747) containing 8% -mercaptoethanol 
(Sigma Aldrich, Cat# M6250) and heated at 95°C for 5 minutes. 
 
 
2.7.3 SDS-PAGE and Western Blotting 
 
Samples were resolved by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). Protein samples and a molecular weight standard (Precision Plus Protein™ 
Dual Color standards, BIO-RAD, Cat# 161-0374) were electrophoresed at 100V for 
approximately 2 hours.  Proteins were transferred electrophoretically onto polyvinylidene 
fluoride (PVDF) membrane (Immobilon-P, Merck Millipore, Cat# IPFL00010). Membranes 
were incubated with blocking buffer (Odyssey, Cat# 927-50000) at room temperature for 1 
hour and then with primary rabbit polyclonal anti-p44/42 ERK1/2 MAPK and primary mouse 
monoclonal anti phospho-p44/42 MAPK P-ERK1/2 (Cell Signaling, Cat #4695 and #9106 
respectively) (1:1000 dilution in blocking buffer) at 4°C overnight. Membranes were washed 
with washing buffer (PBS with 0.1% Tween20) 4 times for 5 minutes each and incubated 
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with a goat anti-mouse IRDye 800CW (LI-COR Biosciences, Cat# 926-32210) and donkey-
anti rabbit IRDye 680RD (LI-COR Biosciences, Cat# 926-32222) for 1 hour at room 
temperature (1:10, 000 dilution in blocking buffer).  After further washing, membranes were 
scanned using an Odyssey Licor Scanner (LI-COR Biosciences).  Densitometry analysis of 
membrane was performed using Image Studio Version 5.2 software. 
 
 2.7.4 Calcium Mobilisation Assay 
 
HEK293 cells were seeded in 6-well plates at a density of approximately 700,000 cells/well.  
24 hours after seeding, cells were transiently transfected with 500ng GCaMP and 500ng of 
receptor using FuGene (Section 2.4.2).  24 hours post-transfection, cells were washed with 
PBS, and detached using 0.25% trypsin, resuspended in FluoroBrite phenol red-free 
Complete media containing 5% FBS and added to poly-D-Lysine-coated clear bottom black 
polystyrene 96-well microplate at 100,000 cells/well (Corning).  Early the following day, 
cells were serum starved with FluoroBrite phenol red-free media + 10% L-Glutamine for at 
least 6 hours.  Prior to assay, cells were loaded with calcium buffer (1xHBSS, 20 mM 
HEPES, 2.5 mM probenecid, pH 7.4).  If using inhibitors, inhibitors were diluted in calcium 
buffer and left to incubate for 30minutes at 37°C and 5% CO2. Prior to stimulation with 
AngII, background fluorescence of cells was imaged for 10 seconds on the FLIPR Tetra 
(Molecular Devices, Sunnyvale, CA, USA).  AngII was added using the FLIPR Tetra and 
fluorescence was measured for a total of 250 seconds/well.  Data was analysed using the 
FLIPR Tetra Software  (Screenworks 3.1.0.3, Molecular Devices) to calculate Max-Min (10– 
250 seconds) values, then data plotted into GraphPad Prism 7.0 (GraphPad Software, La 
Jolla, CA, USA) to fit curves using non-linear regression. AngII was assayed in triplicate 
wells in each independent experiment. 
   
2.8 Statistical Analysis 
 
Data was analysed in GraphPad Prism 7.0 and expressed as mean ± standard error of mean 
(SEM) of at least two independent experiments.  Unless indicated, p values including 
p<0.001 (***), p<0.01 (**), p<0.05 (*) and not significant (ns) between data sets was 
determined by one-way ANOVA and Bonferroni’s Multiple Comparisons Test.   
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3.0 Characterisation of a BRET based model as a readout of 
AT1R-EGFR transactivation  
3.1 Introduction 
Previous studies link the AT1R and its transactivation of the EGFR to remodelling of the 
heart, blood vessels and kidney.  Hence, elucidating the mechanism of AngII-mediated 
transactivation may lead to important therapeutic strategies for treating CVD.  Ullrich and 
colleagues first published the phenomenon of GPCR-mediated transactivation, and proposed 
a model of EGFR transactivation now referred to as the TMPS (Daub, Weiss, Wallasch et al., 
1996). According to this model, activated GPCRs stimulate MMPs, including ADAMs, to 
cleave inactive membrane-bound EGF ligands to activate EGFR (Carpenter, 2000; Cattaneo, 
Guerra, Parisi et al., 2014; Manso, Elsherif, Kang et al., 2006; Prenzel, Zwick, Daub et al., 
1999). This model has been broadly accepted, although others have suggested a more 
complex mechanism (perhaps cell-specific) involving non-receptor tyrosine kinases and the 
activation of additional second messengers. Definitive resolution of the precise mechanism of 
GPCR-EGFR transactivation requires approaches to monitor this process in living cells, in 
real-time, as well as the capacity to identify key proteins and interactions involved.  While 
some progress has been made on the latter problem – a siRNA screen was recently used to 
identify novel mediators of AT1R-EGFR transactivation (George, Purdue, Gould et al., 2013)  
– to date most readouts of EGFR transactivation have been biochemical, end-point assays 
that do not capture live cell dynamics or kinetics. 
Examination of AT1R-mediated EGFR transactivation has generally been defined as the 
activation of ERK1/2 that is inhibited by the small molecular antagonist of the EGFR kinase 
domain (i.e., AG1478).   However, AG1478 can also inhibit the kinase activity of additional 
members of the HER receptors, raising the possibility that HER2, HER3 and HER4 may 
contribute to AT1R transactivation (Chan, Jenkins, Pipolo et al., 2006; Levitzki & Gazit, 
1995). Furthermore, EGFR signal transduction is complex with ERK1/2 phosphorylation 
representing a signal quite distal from the initial step of EGFR activation. Arguably, a more 
direct readout would be to examine upstream events, including the activation and 
autophosphorylation of the EGFR.  Although a direct readout of phosphpo-EGFR may 
mitigate the limitations of the ERK1/2 assay, both phospho-EGFR and phospho-ERK1/2 
Chapter Three: Characterisation of a BRET-based model 
 54 
assays are endpoint approaches and only provide a snapshot of cellular events.  More 
recently, proximity-based assays, such as RET assays and fluorescein arsenical hairpin 
(FlAsH) biosensors have evolved to enable dynamic analysis of protein-protein as well as 
intra-molecular interactions in real-time (Bourque, Pétrin, Sleno et al., 2017; Devost, Sleno, 
Pétrin et al., 2017). The development and validation of proximity-based assays (particularly 
BRET- and FRET-based assays) have been widely used to characterise receptor interactions 
and have become extremely useful tools for studying GPCR biology, specifically the 
interaction of GPCRs with G proteins and arrestins (Adjobo-Hermans, Goedhart, van Weeren 
et al., 2011; Shukla, Violin, Whalen et al., 2008; Tang, Strachan, Lefkowitz et al., 2014; 
Turu, Szidonya, Gaborik et al., 2006).  
 
A major aim of this thesis was to validate a BRET-based assay that can quantitatively 
measure, AT1R-mediated EGFR transactivation, in live cells and in real-time. The present 
chapter describes the initial validation of a BRET based assay as a suitable readout of AT1R-
EGFR transactivation.  
 
  
Chapter Three: Characterisation of a BRET-based model 
 55 
3.2 Materials & Methods 
 
Methods used throughout this chapter are detailed at length in Chapter 2.0, this includes cell 
culture (Section 2.4), isolation of VSMC (Section 2.4.4), nucleofector delivery of plasmid 
DNA (Section 2.4.5.2), ligand-induced BRET assays (Section 2.6.1) and confocal imaging 
(Section 2.6.2) 
 
 3.2.1 Materials 
 
HEK293, CHO-K1, NIH-3T3, HeLa cells were obtained from American Type Culture 
Collection. HEK293FT were obtained by Thermo Fisher Scientific.  HT-29 cell line was a 
generous gift from Dr Daniel Croker, University of Queensland, AUS.  Amaxa nucleofector 
kit (Lonza, Cat# V4XP-1024) was used to transfect isolated VSMC.  AngII was obtained 
from Auspep or Sigma Aldrich and EGF from R&D Systems or Peprotech.  Inhibitors were 
obtained from Wako Pure Chemical Industries (YM-254890), AstraZeneca (Candesartan), 
Merck Millipore (AG1478), Sigma Aldrich (PP2) and Calbiochem (BAPTA).   
 
3.2.2 DNA Constructs 
 
EGFR-Rluc8 and Grb2-Venus were generously provided by Professor Kevin Pfleger, 
University of Western Australia, Australia and have been described previously (Ayoub, See, 
Seeber et al., 2013). AT1R was generated as previously described (Porrello, Pfleger, Seeber et 
al., 2011; Smith, Chan, Qian et al., 2011). HER2-Rluc8 and HER3-Rluc8 were generated by 
inserting EGFR, HER2, and HER3, obtained from Origene (Rockville, MD, USA) into 
pcDNA3-Rluc8. Control green fluorescent protein (GFP) plasmid DNA, used to assess 
transfection efficiency in isolated VSMC, was provided with the Lonza Nucleofector kit (Cat 
#V4XP-3032, Lonza).  HA-V2R was provided from Dr Thierry Durroux (Functional 
Genomics Institute, Montpellier, France). HA-1AR was generated by GeneArt (Thermo 
Fisher Scientific, Regensburg, Germany) and α1bAR, α2aAR, 2AR, HA-B2R and HA-D1R 
cDNAs were obtained from the Missouri S&T cDNA Resource Centre (www.cdna.org). 
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3.3 Results 
3.3.1 Optimising a BRET-based AT1R-EGFR transactivation assay 
3.3.1.1 DNA construct stoichiometry 
 
In this study, we used a BRET-based assay to monitor the most proximal event in EGFR 
activation, namely the recruitment of the EGFR adaptor protein, growth factor receptor-
bound protein 2 (Grb2), which associates with the EGFR in an activation- and 
phosphorylation-dependent manner (Ayoub, See, Seeber et al., 2013). My co-supervisor 
Professor Kevin Pfleger, who is a specialist in the area, kindly provided several control 
constructs, including EGFR-Rluc8 and Grb-2Venus, which have been published previously 
(Ayoub, See, Seeber et al., 2013). Plasmid DNA constructs were confirmed by Sanger 
sequencing and all experiments were designed to promote optimal BRET assay conditions 
(e.g., titration of AT1R, EGFR-Rluc8 and Grb2-Venus plasmid constructs to obtain optimal 
stoichiometry). 
Initially, receptor/adaptor molecule DNA was titrated in order to achieve optimal ligand-
dependent BRET signal in cells expressing EGFR-Rluc8 and Grb2-Venus. Both HEK293 and 
COS cells were transfected with a fixed amount of Grb2-Venus (0.2g) with increasing 
amounts of receptor EGFR-Rluc8 DNA (0.15g, 0.3g, 0,6g & 0.9g).  EGF-stimulation 
produced a robust and sustained ligand-dependent BRET signal in transfected HEK293 cells 
and COS cells respectively, indicating Grb2 translocation and interaction with the activated 
EGFR (Figure 3.01A and 3.01B respectively), validating that both receptor and adaptor 
molecule were functional.  Both cell lines demonstrated that 0.2g of Grb2-Venus and 
0.15g of EGFR-Rluc8 maximally recruited Grb2 to the EGFR.  All remaining experiments 
were transfected with the aforementioned amounts, unless otherwise specified. 
Previously, EGFR activation (and Grb2 interaction) has been shown to be dependent on the 
small tyrosine kinase inhibitor, AG1478 (Ayoub, See, Seeber et al., 2013; Lanzerstorfer, 
Borgmann, Schütz et al., 2014). Consistent with previous literature, EGF-stimulated 
recruitment of Grb2 to the EGFR was completely inhibited with pre-treatment of AG1478 in 
both HEK293 and COS cells (Figure 3.01C & 3.01D, respectively). EGF-treatment also 
resulted in a dose-dependent increase in BRET signal in HEK293 cells (Figure 3.01E).  
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Lastly, in an attempt to refine the BRET response in COS cells, different cell seeding 
densities were compared.  Figure 3.01F shows that a cell density of 40,000 cells/well seeded 
into a 96-well plate gave the maximal BRET response with the smallest error. 
 
 
Figure 3.01: Kinetic analysis of EGF-induced recruitment of Grb2 to EGFR in HEK293 
and COS cells.  
(A) HEK293 cells (100,000 cells/well) and (B) COS cells (70,000 cells/well) were transfected with 
0.2g of Grb2-Venus alongside increasing amounts of EGFR-Rluc8 (0.15g, 0.3g, 0,6g & 0.9g) 
and were stimulated with 1μM EGF or vehicle. Similarly, (C) HEK293 cells and (D) COS cells co-
expressing 0.2g of Grb2-Venus and 0.15g EGFR-Rluc8 were pre-treated with 1M AG1478 
(EGFR inhibitor) for 30 minutes prior to stimulation with 1μM EGF or vehicle.  (E) HEK293 cells 
expressing the aforementioned ratio of EGFR-Rluc8 and Grb2-Venus were treated with increasing 
concentration of EGF and measured 3 minutes following EGF-stimulation. (F) COS cells expressing 
the aforementioned amount of EGFR-Rluc8 and Grb2-Venus were seeded at various cell densities in a 
96-well plate (25,000, 40,000 and 100,000 cells/well).  BRET measurements were taken using the 
CLARIOstar Microplate Reader (BMG LabTech). Agonist stimulation is indicated by arrows.   Data 
represent mean ± SEM of 2-4 independent experiments with triplicates within.   
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3.3.1.2 Establishing AT1R-mediated EGFR transactivation 
 
To investigate AT1R-mediated EGFR transactivation, EGFR-Rluc8 & Grb2-Venus plasmids 
were co-transfected with increasing amounts of AT1R DNA (0.15g, 0.3g, 0,6g & 0.9g).  
In HEK293 cells, Figure 3.02A demonstrates that 0.3g of transfected AT1R produced 
ligand-dependent Grb2 translocation to the activated EGFR following AngII-treatment.  
Comparably, AT1R-mediated transactivation was shown to extend to COS cells, with 0.3g 
of transfected AT1R also shown to mediate a sustained ligand-dependent BRET signal 
(Figure 3.02B).  Consistent with the idea that GPCR-mediated transactivation engages only a 
small percentage of the total EGFR signalling capacity, the AngII-mediated Grb2 recruitment 
and the downstream activation of ERK1/2 represent approximately 20% of that stimulated by 
the EGF ligand.  We next compared cell-seeding density required to achieve optimal AngII-
mediated BRET response, with 100,000 and 40,000 cells/well displaying maximal BRET 
response for HEK293 and COS cells, respectively (Figure 3.02C and 3.02D).   
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Figure 3.02: Development of a BRET assay to study AT1R-mediated EGFR 
transactivation. 
(A) HEK293 cells and (B) COS cells transfected with 0.2g of Grb2-Venus, 0.15g EGFR-Rluc8 and 
increasing amount of AT1R (0.15g, 0.3g, 0.6g & 0.9g) were treated with 10M AngII or 
vehicle.  Similarly, HEK293 cells (C) and COS cells (D) were transfected with 0.2g of Grb2-Venus, 
0.15g EGFR-Rluc8 and 0.3g AT1R were seeded at various cell densities (25,000 – 100,000 
cells/well) and treated with 10M AngII or vehicle. (E) HEK293 cells expressing the aforementioned 
ratio of EGFR-Rluc8, Grb2-Venus and AT1R were treated with increasing concentrations of AngII 
and measured 3 minutes following AngII-stimulation. Agonist stimulation is indicated by arrows.   
BRET measurements were taken using the CLARIOstar Microplate Reader (BMG LabTech). Data 
represent mean ± SEM of 2-4 independent experiments with triplicates within.   
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3.3.1.3 Examination of plate readers 
 
A final optimisation related to the plate reader used to quantitatively measure AngII-mediated 
transactivation, with a total of three plate readers tested: BMG LumiStar, Tecan M1000 Pro 
and a VictorLight.  All plate readers showed a sustained EGF-mediated BRET response 
(Figure 3.03A-C), however only the BMG and Tecan plate readers showed an AngII-
mediated response (Figure 3.03A & 3.03B respectively).  All remaining experiments used 
either a Tecan M1000 Pro or BMG LumiStar plate reader.   
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Figure 3.03: AT1R-EGFR transactivation BRET assay using different plate readers. 
HEK293 cells transfected with 0.2g of Grb2-Venus, 0.15g EGFR-Rluc8 and 0.3g AT1R were 
stimulated with 10M AngII, 1M EGF or vehicle. BRET measurements were taken using (A) BMG 
LumiStar, (B) Tecan M1000 Pro or (C) VICTOR Light.  Agonist stimulation is indicated by arrows.   
Data represent mean ± SEM of 2 independent experiments with triplicates within.   
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3.3.2 Examination of a variety of immortalised cell lines to transactivate 
EGFR following AngII stimulation.   
 
Over the past 18 years, several cell lines have been show to mediate EGFR transactivation 
and ERK1/2 activation following AngII application.  While HEK293 cells and COS cells 
have been extensively used by others to characterise EGFR transactivation, we wanted to 
next determine whether this phenomenon occurs in a variety of immortalised cell lines using 
the BRET-based assay (Shah, Yesilkaya, Olivares-Reyes et al., 2004). Four additional 
immortalised cell lines were tested, these included HT-29 cells (Figure 3.04A, E, L, M), 
NIH-3T3 cells (Figure 3.04D, F, J, N), CHO-K1 cells (Figure 3.04C, G, K, O) and HeLa cells 
(Figure 3.04D, H, L, P).  A total of 12 conditions were tested for each cell line, with each cell 
line transfected with increasing amounts of Grb2-Venus (0.05g, 0.2g and 0.4g) alongside 
increasing amounts of EGFR-Rluc8 DNA (0.15g, 0.3g, 0.6g and 0.9g).  The optimal 
ratio of receptor:adaptor molecule was determined for each cell line (Table 3.01) and then co-
transfected with increasing amount of AT1R to determine if the cell line has the capacity to 
transactivate EGFR following AT1R-activation.  As shown in Figure 3.04, NIH-3T3 and 
CHO-K1 cell lines demonstrated an increase in EGFR-Grb2 BRET ratio following AT1R 
activation, however HT-29 and HeLa cell lines did not.  Thus, in addition to HEK293 cells 
and COS cells, NIH-3T3 and CHO-K1 cells appear to be appropriate models for interrogating 
AT1R-mediated EGFR transactivation. 
 
Cell Line Optimal EGFR-RLuc8:Grb2-Venus ratio AT1R-mediated transactivation 
HT-29 0.3g EGFR-Rluc8:0.4g Grb2-Venus  
NIH-3T3 0.3g EGFR-Rluc8:0.4g Grb2-Venus ✓ 
CHO-K1 0.9g EGFR-Rluc8:0.2g Grb2-Venus ✓
HeLa 0.15g EGFR-Rluc8:0.6g Grb2-Venus  
Table 3.01: Optimal ratio of EGFR-Rluc8 and Grb2-Venus DNA transfected for each 
immortalised cell line. 
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Figure 3.04: Adaptability of a BRET-based approach to measure AT1R-EGFR transactivation in a variety of immortalised cell lines. 
As per the title of each panel, increasing amounts of EGFR-Rluc8 and Grb2-Venus were co-transfected into (A,E,I) HT-29, (B,F,J) NIH-3T3, (C,G,K) CHO-
K1  and (D,H,L) HeLa cells and stimulated with 1M EGF or vehicle.  The optimal EGFR-Rluc8 and Grb2-Venus ratio for each cell line was co-transfected 
with increasing amounts of AT1R in (M-P) and stimulated with 10M AngII or vehicle. Agonist stimulation is indicated by arrows.   Data represent mean ± 
SEM of 2-4 independent experiments with triplicates within.   
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3.3.3 AT1R-EGFR transactivation in primary VSMC   
 
A final optimisation was to examine the effects of AT1R-EGFR BRET sensors in isolated 
VSMCs.  There is strong evidence demonstrating that EGFR transactivation is critical in 
mediating vascular remodelling, hypertrophy and migration, and is therefore considered to be 
important in the development of cardiovascular diseases (Higuchi, Ohtsu, Suzuki et al., 2007; 
Montezano, Cat, Rios et al., 2014; Touyz, Wu, He et al., 2002). Many of these seminal 
studies have used downstream ERK1/2 activation as a readout of EGFR transactivation.  A 
final optimisation was to assess whether the BRET sensors were portable to isolated primary 
cells and also to establish their value in a more physiologically relevant context. 
 
Electroporation based-transfection, using an Amaxa nucleofector, was used to deliver 
plasmid DNA to primary isolated VSMCs.  Firstly, plasmid DNA encoding alkaline 
phosphatase (ALP) was transfected into VSMCs using electroporation, and used as a positive 
control for delivery and expression of exogenous DNA. VSMCs that expressed ALP showed 
increased ALP activity compared to VSMC that were not transfected with ALP (Figure 
3.05A).  Furthermore, cells were transfected with a GFP reporter plasmid to assess 
transfection efficiency.  We were able to detect GFP positive VSMC while maintaining cell 
viability (Figure 3.05B and 3.05C).  We next sought to transfect isolated primary cells with 
the BRET constructs.  Using an already optimised 3:1 ratio of EGFR-Rluc8 and Grb2-Venus 
DNA (data not included), EGF-stimulation mediated a robust and ligand-dependent Grb2 
translocation to the EGFR (Figure 3.05D).  Furthermore, upon transfection of the AT1R, we 
were able to detect Grb2 recruitment following AngII-treatment, indicative of EGFR 
transactivation (Figure 3.05D) 
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Figure 3.05 Adaptability of BRET in isolated VSMC 
(A) Alkaline phosphatase activity measured in isolated VSMC transfected with and without ALP 
plasmid. **** p<0.0001 compared to cells not expressing ALP construct. (B, C) Confocal imaging of 
isolated VSMC expressing GFP.  (D) Rat isolated primary VSMC transfected with Grb2-Venus, 
EGFR-Rluc8 and AT1R were stimulated with 10M AngII, 1M EGF or vehicle. Agonist stimulation 
is indicated by arrows.   Data represent mean ± SEM of 2-4 independent experiment with triplicates 
within.   
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3.3.4 AngII capacity to transactivate additional RTK members 
 
Having demonstrated the universality of the BRET-based approach to measure EGFR 
transactivation, a final consideration was to test if this technology could be used to screen a 
range of GPCRs and interrogate their capacity to transactivate EGFR, as well as assess if 
AngII can transactivate other members of the RTK family.  In addition to the EGFR, other 
members of the RTK family have been shown to transactivate following AngII-stimulation 
(Lin & Freeman, 2003; Negro, Brar, Gu et al., 2006). We investigated whether AngII-
stimulation recruited Grb2 to other members of the EGFR family, specifically HER2 
(preferred dimer partner for EGFR, which is not ligand-activated) and HER3 (which is 
ligand-activated, but is kinase-deficient).  As shown in Figure 3.06, EGFR and HER2, but not 
HER3, strongly complexes with Grb2 following AngII-stimulation. 
 
Figure 3.06: AngII-mediated transactivation of additional members of the EGFR RTK 
family 
HEK293 cells expressing AT1R, Grb2-Venus and either of EGFR-Rluc8, HER2-Rluc8 or HER3-
Rluc8 were stimulated with 10µM AngII or vehicle.  Agonist stimulation is indicated by arrows.   
BRET measurements were taken using the CLARIOstar Microplate Reader (BMG LabTech). Data 
represent mean ± SEM of 4 independent experiments with triplicates within.   
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3.3.5 Screening for EGFR transactivation by multiple GPCRs 
 
A number of prominent GPCRs have been reported to transactivate the EGFR, including the 
adrenergic (Kim, Eckhart, Eguchi et al., 2002; Turner, 2003), dopamine (Yoon & Baik, 
2013), bradykinin (Methner, Donat, Felix et al., 2009), vasopressin (Fuentes, Reyes, 
Sarmiento et al., 2008; Zhang, Wang, Cao et al., 2016) and adenosine receptors (Williams-
Pritchard, Knight, Hoe et al., 2011), although the exact mechanisms remain unresolved. We 
next examined whether the BRET-based Grb2 recruitment assay could be used to screen 
multiple GPCRs and measure their capacity to transactivate the EGFR.  Shown in Figure 3.07 
is a focused screen of 19 separate GPCRs and their capacity to recruit Grb2 to the EGFR.  All 
assays included EGF activation of the EGFR as an internal control. Interestingly, we 
observed consistent increases in the EGFR-Grb2 BRET ratio for the AT1R and the 
Vasopressin 1b receptor (V1bR).  For a number of other GPCRs, their activation led to a 
decrease (or no change) in the EGFR-Grb2 BRET ratio.  A BRET-based arrestin trafficking 
assay was used for these receptors to substantiate their expression and activation following 
ligand stimulation (Figure 3.08). 
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Figure 3.07:  Screen of multiple GPCRs using the BRET-based transactivation assay.  
As per the title of each graph, parts (A-S), 19 different GPCRs expressed in HEK293FT cells and their ability to induce Grb2-Venus interaction with EGFR-
Rluc8 following stimulation with 1μM EGF, 10μM GPCR agonist-stimulation or vehicle. Agonist stimulation is indicated by arrows.  BRET measurements 
were taken using the CLARIOstar Microplate Reader (BMG LabTech). Data represents mean ± SEM of 3-5 independent experiments.  
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Figure 3.08: Validation of GPCR functionality 
As per the title of each graph, parts (A-S), show 19 different GPCRs expressed in HEK293FT cells, and their ability to induce -arrestin2-Rluc8 interaction 
with membrane marker, K-ras-Venus, following 10μM GPCR agonist-stimulation or vehicle. Agonist stimulation is indicated by arrows. BRET 
measurements were taken using the CLARIOstar Microplate Reader (BMG LabTech). Data represents mean ± SEM of 3-5 independent experiments.  
10 20 30 40 50 60 70
-0.02
0.00
0.02
0.04
0.06
0.08
Time (minutes)
L
ig
a
n
d
-i
n
d
u
c
e
d
 
B
R
E
T
 R
a
ti
o
Angiotensin Type 1 Receptor 
AngII Vehicle   
-0.010
-0.005
0.000
0.005
0.010
L
ig
a
n
d
-i
n
d
u
c
e
d
 
B
R
E
T
 R
a
ti
o
Adenosine A1 Receptor
NECA Vehicle   
-0.01
0.00
0.01
0.02
0.03
0.04
L
ig
a
n
d
-i
n
d
u
c
e
d
 
B
R
E
T
 R
a
ti
o
Adrenergic Alpha 1b Receptor
NA Vehicle   
-0.01
0.00
0.01
0.02
0.03
0.04
L
ig
a
n
d
-i
n
d
u
c
e
d
 
B
R
E
T
 R
a
ti
o
Adrenergic Beta 2 Receptor
ISO Vehicle   
10 20 30 40 50 60 70
-0.02
0.00
0.02
0.04
0.06
0.08
0.10
Time (minutes)
Bradykinin B2 Receptor
BK Vehicle   
-0.01
0.00
0.01
Dopamine D2 Receptor 
DA Vehicle   
-0.01
0.00
0.01
0.02
0.03
Adrenergic Alpha 2a Receptor
NA Vehicle   
-0.01
0.00
0.01
0.02
Adrenergic Beta 3 Receptor
ISO Vehicle   
10 20 30 40 50 60 70
-0.02
-0.01
0.00
0.01
0.02
Time (minutes)
Vasopressin V1a Receptor
AVP Vehicle   
-0.010
-0.005
0.000
0.005
0.010
0.015
Adenosine A2b Receptor
NECA Vehicle   
-0.01
0.00
0.01
0.02
0.03
Adrenergic Alpha 2b Receptor
NA Vehicle   
-0.01
0.00
0.01
0.02
0.03
Dopamine D1 Receptor 
DA Vehicle   
10 20 30 40 50 60 70
-0.02
-0.01
0.00
0.01
0.02
Time (minutes)
Vasopressin V1b Receptor
AVP Vehicle   
-0.010
-0.005
0.000
0.005
0.010
0.015
Adenosine A3 Receptor
NECA Vehicle   
-0.01
0.00
0.01
0.02
Adrenergic Alpha 2c Receptor
NA Vehicle   
-0.01
0.00
0.01
Dopamine D2 Receptor 
DA Vehicle   
A B C D E
F G H I J
K L M N O
P Q R S
10 20 30 40 50 60 70
-0.02
0.00
0.02
0.04
0.06
Time (minutes)
Vasopressin V2 Receptor
AVP Vehicle   
-0.01
0.00
0.01
0.02
Adrenergic Alpha 1a Receptor
NA Vehicle   
-0.01
0.00
0.01
0.02
0.03
0.04
Adrenergic Beta 1 Receptor
ISO Vehicle   
 
Chapter Three: Characterisation of a BRET-based model 
 70 
3.4 Discussion 
 
GPCR-mediated EGFR transactivation is commonly defined as the activation of ERK1/2, 
which although informative, is an indirect and distal readout.  Herein, I describe a BRET 
assay, based on the proximal recruitment of Grb2 to the EGFR to quantitatively monitor, in 
living cells and in real-time, the direct activation of EGFR.  The development of novel 
approaches to study GPCR-mediated transactivation in live cells is important, but to our 
knowledge BRET-based quantification of Grb2 recruitment to the EGFR has not been used as 
a direct readout of GPCR-mediated transactivation.  Pfleger and colleagues have previously 
used the recruitment of Grb2 to RTKs (EGFR and HER3) as a measure of EGFR activation 
and heterodimerisation in HEK293 cells following stimulation with EGF and Heregulin 
(Ayoub, See, Seeber et al., 2013). Moreover, others have also identified such BRET 
approaches as bona fide readouts of EGFR activation (Schiffer, Reding, Fuhs et al., 2007; 
Tan, Wang, Littler et al., 2007).  In this chapter, I initially aimed to determine whether 
stimulation of the AT1R could promote Grb2 translocation and interaction with EGFR in a 
ligand-dependent manner in live cells. AT1R-mediated EGFR transactivation was readily 
demonstrable, but was consistently lower in magnitude compared to EGF-stimulation.  The 
selective activation of EGFR by the AT1R is consistent with many observations that the 
degree of signalling elicited by GPCRs appears to be only a subset of that obtained following 
full activation by EGF ligands (Daub, Weiss, Wallasch et al., 1996; Eguchi, Numaguchi, 
Iwasaki et al., 1998; Shah, Yesilkaya, Olivares-Reyes et al., 2004; Tilley, Kim, Patel et al., 
2009).  
 
EGFR transactivation was initially shown to occur in HEK293 and COS cells. There is 
considerable debate as to which immortalised cell lines have the capacity to transactivate, 
with HEK293 previously considered incapable of transactivation due to their lack of MMPs, 
an essential protein in the transactivation process (Shah, Yesilkaya, Olivares-Reyes et al., 
2004). Catt and colleagues showed in contrast to HEK293 cells, following AngII-stimulation 
COS cells activate EGFR and subsequently phosphorylate ERK1/2 through the release of 
HB-EGF.  This led to the theory that there may be alternative cells lines that show a more 
robust transactivation response.  The use of BRET as a readout of AT1R-EGFR 
transactivation was extended to several immortalised cell lines, with CHO-K1 and NIH-3T3 
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cells shown to mediate EGFR activation following AngII stimulation, indicting the versality 
of this approach to measure EGFR transactivation.  In addition, it is possible that by creating 
an artificial environment where EGFR-Rluc8 & Grb2-Venus are co-transfected alongside the 
AT1R, that transactivation is artificially introduced into a cell that does not normally have the 
capability.  Our laboratory has previously demonstrated that HeLa cells do not activate 
ERK1/2 phosphorylation in an AG1478-dependent manner, therefore it was reassuring that I 
was unable to demonstrate AT1R-EGFR transactivation in HeLa cells. 
We next investigated whether AT1R-mediated transactivation extends to isolated primary 
cells.  AngII has been shown to mediate VSMC remodelling through the transactivation of 
the EGFR (Chan, Umesalma & Baumbach, 2015; Eguchi, Dempsey, Frank et al., 2001).  
Previous studies have shown that AngII induces Gq/Ca
2+-dependent and/or Src-dependent 
transactivation of the EGFR, leading to downstream activation of the MAPK pathways 
(ERK1/2, Akt, p38) and subsequent ROS generation, NADPH oxidase activation and protein 
synthesis, resulting in VSMC migration, hypertrophy and hyperplasia.  Using nucleofector 
delivery, I demonstrated EGF-mediated Grb2 recruitment to the activated EGFR.  Upon 
AngII-stimulation we could also report Grb2 recruitment, indicative of EGFR transactivation.   
A final consideration was if the BRET-based assay could be used to screen multiple GPCRs 
and interrogate their capacity to transactivate the EGFR.  Of the panel of 19 GPCRs tested, 
only the AT1R and V1bR showed consistent EGFR transactivation, as measured by increased 
BRET-based Grb2 recruitment.  An apparent lack of EGFR transactivation for a number of 
these receptors was surprising because they have been reported previously to promote EGFR 
transactivation as measured by activation of MAPK signalling pathways (ERK1/2, p38, 
PI3K/Akt), phospho-EGFR, metalloprotease activation, EGF ligand shedding and 
transcriptional responses (Fuentes, Reyes, Sarmiento et al., 2008; Huang, Benaich, Tape et 
al., 2014; Inoue, Ishiguro, Kitamura et al., 2012; Matus, Ehrenfeld, Pavicic et al., 2016; 
Volpi, Liu & Aguilera, 2006).  
 
It is important to note that a negative response in our assay does not necessarily mean that the 
GPCR is not transactivating nor should it call into question the veracity of our assay.  There 
are a number of plausible explanations: firstly, a trivial argument might be that these ‘non-
transactivating’ GPCRs were non-functional – however, we confirmed their activation by 
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using a readout of ligand-dependent -arrestin trafficking.  Secondly, these GPCRs may not 
be recruiting Grb2 as part of their activation process or, alternatively, there is an association 
but it is different in nature to that generated by the AT1R and V1bR.  Indeed, for a number of 
the GPCRs that did not show enhanced EGFR-Grb2 association, we actually observed 
decreased BRET ratios following ligand stimulation. It could be reasonably argued that this 
reflects dynamic changes in an equilibrium between association, dissociation and 
reconfiguration of putative EGFR-Grb2 complexes – where the balance may favour 
dissociation or reconfiguration that leads to an increased distance between the donor and 
acceptor moieties.   
 
Thirdly, as our assay only reports on the Grb2 recruitment to the EGFR, the possibility exists 
that receptors other than the EGFR (HER2, HER3 or HER4) and or combinations of dimers 
between those receptors, are selectively used by these other GPCRs for transactivation. In 
this regard, it is important to acknowledge that most studies of EGFR transactivation 
typically use end-point assays, where specificity is inferred via inhibition by the small 
molecule inhibitor of the EGFR kinase, AG1478. However, high micromolar concentrations 
of AG1478 (as commonly used) inhibit receptors other than the EGFR (Chan, Jenkins, Pipolo 
et al., 2006; Levitzki & Gazit, 1995). Additionally, we report the recruitment of Grb2 to 
HER2, but not HER3, in response to AngII stimulation.  Whether a specific GPCR is able to 
transactivate EGFR, HER2, HER3 or HER4 will require further investigation, using the 
approaches we have developed.  It will be important to consider that HER2 is the preferred 
dimerisation partner for other EGFR family members, and therefore potentially acting in cis 
to modulate other HER receptors. Indeed, following AngII-stimulation, HER2 has been 
shown to be transactivated and/or modulate transactivation (Lin & Freeman, 2003; Negro, 
Brar, Gu et al., 2006). 
 
3.5 Summary  
 
We report an alternative approach to monitoring AT1R-EGFR transactivation in live cells. 
The use of a BRET-based assay to assess recruitment of the EGFR adaptor protein, Grb2, to 
the EGFR, was shown in a variety of variety of immortalised cell lines as well as primary 
isolated VSMCs.  Both EGF and AngII stimulated Grb2 recruitment to EGFR, indicative of 
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EGFR transactivation. The BRET assay was used to screen a panel of 19 GPCRs and further 
developed for other EGFR family members (HER2 and HER3); the AT1R was able to 
transactivate HER2, but not HER3.  The adaptability of the BRET-based approach provides a 
novel platform to better interrogate the molecular mechanisms underpinning AT1R-EGFR 
transactivation. 
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4.0 BRET-based assay to monitor EGFR transactivation by the 
AT1R reveals Gq/11 protein-independent activation and AT1R-
EGFR complexes 
 4.1 Introduction 
 
GPCRs can employ a range of mechanisms to transactivate EGFR and activate downstream 
ERK1/2, leading to spatially and functionally distinct pools.  For example, others have 
reported that the classical second messenger, Ca2+, as well as ROS mediate AT1R 
transactivation in COS-7 cells (Mifune, Ohtsu, Suzuki et al., 2005b).  Our own group has 
previously shown that EGFR transactivation in neonatal cardiomyocytes requires G protein 
coupling, however inhibition of PKC or Ca2+ had no effect on AngII-mediated ERK1/2 
activation (Smith, Chan, Qian et al., 2011).  It is clear that the second messengers required for 
EGFR transactivation is dependent upon cellular background, as is transactivation itself.   
 
Despite the implied role of Gq/11 in AngII-mediated ERK1/2 activation, several studies have 
suggested Gq/11-independent mechanisms for this process (Grisanti, Guo & Tilley, 2017).  -
arrestin scaffolding signalling has been shown to mediate prosurvival pathways in the heart.  
1AR recruits GRK5/6 and -arrestin, leading to EGFR transactivation and the activation of 
prosurvival-antiapoptopic signalling pathways including Akt and ERK1/2 (Noma, Lemaire, 
Prasad et al., 2007).  This ‘secondary signalling’ has lead to the development of drugs that 
antagonise overactive G protein-signalling, while simultaneously activating -arrestin 
mediated cardioprotective pathways.   
 
In this chapter, the major aim of this project was to determine the functional and structural 
requirements of AT1R-EGFR transactivation.  Having established and optimised a BRET-
based approach that measures the most proximal event in EGFR activation, I extended the 
technology to investigate the molecular processes involved.  
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4.2 Materials & Methods 
Methods used throughout this chapter are detailed in length at Chapter 2.0, this includes cell 
culture (Section 2.4), ligand-induced BRET assays & Receptor-HIT assays (Section 2.6.1) 
BiFC (Section 2.6.2), [125I]-AngII binding assays (Section 2.6.3), Western blot (Section 
2.7.1-2.7.3) and calcium mobilisation assay (Section 2.7.4). 
4.2.1 Materials 
 
HEK293 and CHO-K1 cells were obtained from American Type Culture Collection. A 
HEK293 cell line that lacks both -arrestin1 and -arrestin2 was used as previously described 
(Alvarez-Curto, Inoue, Jenkins et al., 2016). [125I]-Labelled AngII was obtained from 
ProSearch.  AngII was obtained from Auspep or Sigma Aldrich and EGF from R&D Systems 
or Peprotech.  Inhibitors were obtained from Wako Pure Chemical Industries (YM-254890), 
AstraZeneca (Candesartan), Merck Millipore (AG1478), Sigma Aldrich (PP2) and 
Calbiochem (BAPTA).   
4.2.2 DNA Constructs 
 
Preparation of the following cDNA constructs has been previously described: Grb2-Venus 
(Ayoub, See, Seeber et al., 2013), -arrestin2-Venus (Kocan, See, Sampaio et al., 2009), 
AT1R-Vn -arrestin2-Rluc8 (Porrello, Pfleger, Seeber et al., 2011), pcDNA3.1 -arrestin1-
Flag and -arrestin2-Flag (Manglik, Kim, Masureel et al., 2015), and AT1R, [TK325]AT1R 
and [Y215F]AT1R (Smith, Chan, Qian et al., 2011). EGFR-Vc was supplied from Ichi N. 
Maruyama (Okinawa Institute of Science and Technology, Okinawa, Japan) (Tao & 
Maruyama, 2008). The following cDNA constructs were gifts from collaborators: Venus-K-
ras from Prof Nevin Lambert (Georgia Regents University). AT1R-Rluc8 was generated by 
inserting AT1R from AT1R-Venus into pcDNA3-Rluc8, prepared previously from cDNA 
kindly provided by Andreas Loening and Sanjiv Gambhir (Stanford University, California, 
USA. EGFR-Rluc8, was generated by inserting EGFR obtained from Origene (Rockville, 
MD, USA) into pcDNA3-Rluc8. EGFR-Venus was subsequently generated from EGFR-
Rluc8 by replacing the Rluc8 coding region with Venus cDNA from pcDNA3-Venus 
prepared previously from pcC2-Venus kindly provided by Atsushi Miyawaki (RIKEN Brain 
Science Institute, Wako-city, Japan). Internally EE-tagged Gq and G12 and untagged DN 
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Gq Q209L/D277N mutant, G11 and G13 were from UMR cDNA resource centre 
(University of Missouri-Rolla (www.cdna.org)).  
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4.3 Results 
4.3.1 Pharmacological Characterisation of GPCR-EGFR transactivation  
 
In order to examine the molecular mechanisms underlying AT1R-EGFR transactivation, we 
first examined ERK1/2 activation as an indirect readout. HEK293 cells expressing the AT1R 
were stimulated with AngII, leading to the robust and reproducible activation of ERK1/2 
(Figure 4.01A).  To confirm previous observations by us that ERK1/2 activation by AngII 
was due to EGFR transactivation (Smith, Chan, Qian et al., 2011; Thomas, 2001), cells were 
pre-treated with the EGFR kinase inhibitor AG1478 (Figure 4.01A-B), and also the Gq/11 
inhibitor YM-254890, the AT1R inverse agonist candesartan, the Src inhibitor PP2 or the 
Ca2+ chelator BAPTA (Figure 4.01C and 4.01D).  Consistent with previous studies (George, 
Purdue, Gould et al., 2013; Ohtsu, Higuchi, Shirai et al., 2008), AngII-induced ERK1/2 
activation was attenuated by antagonism of the AT1R, inhibition of the EGFR kinase as well 
as the inhibition of Gq/11 (Figure 4.01C and 4.01D).  Furthermore, AT1R-EGFR 
transactivation was blunted by pharmacological inhibition of Ca2+ signalling and Src activity, 
however to a lesser extent (Figure 4.01C and Figure 4.01D). Taken together, EGFR 
transactivation (as measured by ERK1/2 activation) by the AT1R appears to be a Gq/11-
mediated pathway and dependent on EGFR kinase activity. 
 
We next examined whether this pharmacological profile was recapitulated when the BRET 
based Grb2 recruitment assay was used as a readout for EGFR transactivation.  Similar to 
AngII-mediated ERK1/2 activation, candesartan completely inhibited AngII-stimulated Grb2 
recruitment to the EGFR, indicating that transactivation of the EGFR is due to ligand 
activation of the AT1R (Figure 4.01E).  However, remarkably AngII-mediated recruitment of 
Grb2 to the EGFR was not inhibited by pre-treatment with the Gq/11 inhibitor, YM-254890, 
which is in stark contrast to the outcome of the ERK1/2-based readout mentioned above. 
Indeed, YM-254890 treatment led to a sustained BRET signal (Figure 4.01E).  Additionally, 
Grb2 recruitment to the EGFR in response to AngII was only partially dependent upon the 
EGFR kinase activity, as well as Src and Ca2+ (Figure 4.01E and 4.01F).   
  
Chapter Four: Evidence of AT1R-EGFR complexes 
 85 
 
Figure 4.01 Analysis of AT1R-EGFR transactivation when comparing ERK1/2 
phosphorylation and Grb2 recruitment to the EGFR.   
(A-B) HEK293 cells stably expressing AT1R were treated with 500nM AG1478 (EGFR inhibitor) for 
30 minutes prior to stimulation with 100nM AngII, 10nM EGF or vehicle for 5 minutes before 
processing for phospho-ERK1/2:total-ERK1/2 (p-ERK:T-ERK) western blots. Blots are 
representative of 3 independent experiments (B) Quantification of western blot data using 
densitometry analysis (ImageJ) illustrates p-ERK1/2 changes. **** p<0.001 vs. vehicle treated 
control; # p<0.001 vs. AngII treated cells.  (C-D) HEK293 stably expressing AT1R were treated with 
1μM YM-254890 (Gq/11 inhibitor), 1μM Candesartan (AT1R inverse agonist), 10μM BAPTA (Ca2+ 
chelator) and 5μM PP2 (Src inhibitor) for 30 minutes prior to stimulation with 100nM AngII, 10nM 
EGF or vehicle for 5 minutes before processing for ERK/p-ERK1/2 western blots.  Blots are 
representative of 3 independent experiments. (D) Quantification of western blot data using 
densitometry analysis (ImageJ) illustrates phospho-ERK1/2 changes.  **** p<0.001, *** p<0.005, ** 
p<0.01 vs. AngII treated cells. (E-F) HEK293 cells transiently expressing AT1R, EGFR-Rluc8 and 
Grb2-Venus were treated with 1μM AG1478, 1μM YM-254890, 1μM Candesartan, 10μM BAPTA 
and 5μM PP2 for 30 minutes prior to stimulation with 10μM AngII, 1μM EGF or vehicle.  (F) 
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Quantification of ligand-induced BRET ratio (maximum-minimum) between EGFR-Rluc8 and Grb2-
Venus following AngII-treatment and in the presence of inhibitors. Agonist stimulation is indicated 
by arrows.  Data represents mean ± SEM of 3 independent experiments. Statistical analysis by a one-
way ANOVA with a Dunnett’s post-test for multiple comparisons; ** p<0.01; *** p<0.005; **** 
p<0.001 vs. AngII treated cells. 
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4.3.2 The role of Gq/11 and -arrestin in AT1R-EGFR transactivation 
 
Given, the disparity in the apparent contribution of Gq/11 to EGFR transactivation, we next 
sought to interrogate a single point mutant of the AT1R, [Y215F]AT1R, previously reported 
to retain high affinity for AngII, but an inability to couple to Gq/11 mediated signalling 
(Hunyady, Bor, Balla et al., 1995). [Y215F]AT1R had equivalent AngII affinity compared to 
wild type (Figure 4.02C), however it possessed a significant decrease in AngII-stimulated 
Ca2+ production (Figure 4.02A), confirming that [Y215F]AT1R is G protein-uncoupled.  
Comparably, [TK325]AT1R, a truncated AT1R lacking 34 carboxyl terminal amino acids and 
deficient in ligand-mediated phosphorylation and recruitment of β-arrestins (Qian, Pipolo & 
Thomas, 2001; Thomas, Motel, Kule et al., 1998) demonstrated a significant reduction in -
arrestin2 recruitment (Figure 4.02B) while still maintaining wild type AngII affinity (Figure 
4.02C). 
 
Stimulation of the [Y215F]AT1R promoted Grb2 recruitment to the EGFR approximately 
equivalent to the wild type AT1R (Figure 4.03B).  Similarly, the truncated mutant of the 
AT1R, [TK325]AT1R, also showed similar levels of Grb2 recruitment as the wild type 
receptor.    To extend our observations that AT1R-EGFR transactivation may be independent 
of Gq/11 and -arrestin, I also performed EGFR-Grb2 BRET assays in CRISPR-mediated 
Gq/11 and -arrestin knockout HEK293 cell lines (Devost, Sleno, Pétrin et al., 2017).  The 
BRET-based sensors were transfected with the wild type AT1R into a HEK293 parental (PL) 
cell line, a Gq/11 knockout (∆Gq/11) cell line or a -arrestin1/2 knockout (∆-arr1/2) cell line.  
Although comparable AngII-induced EGFR-Grb2 BRET ratios were observed in all three cell 
lines (Figure 4.03C), the use of the G protein-uncoupled mutant [Y215F] AT1R and the Gq/11 
knockout cell line show a sustained, yet sub-maximal, EGFR-Grb2 recruitment following 
AngII-stimulation, suggesting that Gq/11 coupling may influence EGFR downstream 
signalling transmission.   
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Figure 4.02 Validation of mutant AT1Rs. 
(A) HEK293 cells transiently expressed wild type AT1R, [Y215F]AT1R or [TK325]AT1R, were 
treated with 10μM AngII and their receptor-dependent Ca2+ responses were measured.  (B) HEK293 
cells expressing -arrestin2-Venus alongside Rluc8-tagged wild type AT1R, [Y215F]AT1R or 
[TK325]AT1R, were treated with 10μM AngII and BRET ratios determined.  Agonist stimulation is 
indicated by an arrow.  (C) Wild type AT1R, [Y215F]AT1R or [TK325]AT1R were transfected into a 
HEK-adherent-293 cells, with receptor binding assessed by [125I]-AngII radioligand binding assay.  
Data expressed as a percentage of maximal [125I]-AngII binding (i.e., in the absence of competing 
ligand).  Curves were fitted to one-site binding equations.  Data represent mean ± SEM of 3 
independent experiments. 
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Figure 4.03 Grb2 recruitment to the EGFR is independent of Gq/11 and -arrestin. 
(A) Schematic of wild type AT1R and mutant AT1Rs - [TK325]AT1R (truncated AT1R deficient in 
recruiting β-arrestins) and [Y215F]AT1R (inability to couple to Gq/11 signalling pathways).  (B) 
HEK293 cells expressing EGFR-Rluc8 and Grb2-Venus, alongside wild type AT1R, [Y215F]AT1R or 
[TK325]AT1R, were treated with 10M AngII or vehicle.  (C) EGFR-Rluc8, Grb2-Venus and AT1R 
were transfected into the HEK293 parental cell line, as well as Gq/11- and β-arrestin1/2-knockout 
CRISPR cell lines.  BRET measurements were taken using the Victor-X-light (Perkin Elmer). All cell 
lines were treated with 10μM AngII. Agonist stimulation is indicated by arrows. Data represent mean 
± SEM of 3 independent experiments.   
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Rescue experiments (i.e., transfection separately of either Gq, G11 or a dominant negative Gq 
back into the ∆Gq/11 cells); or -arrestin1/2 (transfected separately or together) into the ∆-
arr1/2 cell line were also performed (Figure 4.04A-F).  When comparing ligand-induced 
BRET ratio (AUC), restoration of Gq/11 proteins inhibited AngII-mediated transactivation 
(Figure 4.04C), however had no significant effect on ligand-induced BRET ration (max-min) 
(Figure 4.04E) suggesting, if anything, that Gq/11 coupling increases the rate of EGFR 
signalling termination and desensitisation (Figure 4.04A, 4.04C, 4.04E).  Reintroduction of 
-arrestin1 or -arrestin2 into the ∆-arr HEK293 cells did not affect AngII-mediated EGFR 
transactivation (Figure 4.04B, 4.04D and 4.04F). Together, these data confirm the 
independence from Gq/11 and -arrestin for AT1R-EGFR transactivation.   
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Figure 4.04: Effects of Gq/11 and -arrestin1/2 deletion on Grb2 interaction with the 
EGFR.   
EGFR-Rluc8, Grb2-Venus and AT1R were transiently expressed in the Gq/11 knockout CRISPR cell 
line (A-B) or -arrestin1/2 knockout CRISPR cell line (C-D).  (A) BRET constructs were expressed 
in the absence (pcDNA3.1) or presence of either G11, Gq or Gq dominant-negative (DN) and were 
treated with 10μM AngII, (B) with the ligand-induced BRET ratio quantified using area under the 
curve (AUC). (C) BRET constructs were expressed in the absence (pcDNA3.1) or presence of either 
-arrestin1, -arrestin2 or -arrestin1/2 and were treated with 10μM AngII, (D) with the ligand-
induced BRET ratio quantified using area under the curve (AUC).  BRET measurements were taken 
using the Victor-X-light (Perkin Elmer). Data represent mean ± SEM of 3 independent experiments. 
Statistical analysis by a one-way ANOVA with a Dunnett’s post-test for multiple comparisons; * 
p<0.05  
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4.3.3 AT1R and EGFR exist as complexes 
 
We speculated as to whether the mechanism of GPCR-EGFR transactivation may involve 
heteromerisation of the receptors.  In order to study this, we initially used a bimolecular 
fluorescence complementation (BiFC) assay, whereby complexing between AT1R and EGFR 
would result in the complementation of yellow fluorescent protein (YFP) fragments attached 
separately to the AT1R (AT1R-Vn) and the EGFR (EGFR-Vc) (Figure 4.05A).  AT1R-Vn and 
EGFR-Vc were not fluorescent when expressed separately in cells (Figure 4.05B and 4.05C, 
respectively).  Co-expression of AT1R and EGFR lead to complemented fluorescence with 
clear membrane localisation (Figure 4.05D-F).    
  
 
 
 
Figure 4.05: BiFC for studying AT1R-EGFR heteromerisation.   
(A) The Venus fluorophore is split into N-terminal (Vn) and C-terminal (Vc) fragments and 
genetically fused to AT1R and EGFR, respectively.  Therefore, if AT1R and EGFR that bear C-
terminal Vn and Vc tags form heteromers, fluorescence will be generated via the reconstitution of the 
Venus fluorophore.  (B, C) CHO-K1 cells expressing AT1R-Vn or EGFR-Vc constructs separately 
displayed very low levels of autofluorescence.  (D-F) Co-expression of AT1R-Vn and EGFR-Vc in 
CHO-K1 cells.  Scale bar, 30m. 
  
 
Chapter Four: Evidence of AT1R-EGFR complexes 
 
 93 
To examine whether these complexes are ligand-dependent, we utilised Receptor-Heteromer 
Investigation Technology (Receptor-HIT). Receptor-HIT is a BRET technology that offers 
insights into specific ligand-dependent recruitment of proteins to heteromers (Johnstone & 
Pfleger, 2012; See, Seeber, Kocan et al., 2011). AngII-induced recruitment of β-arrestin2-
Venus to unlabelled AT1R, resulting in BRET with EGFR-Rluc8, is indicative of 
heteromerisation (Figure 4.06A).  Upon AngII stimulation, an increase in BRET ratio 
between β-arrestin2-Venus and EGFR-Rluc8 was observed only when the AT1R was co-
expressed (Figure 4.06B).   We also used a complementary variation of the Receptor-HIT 
assay, whereby AT1R-Rluc8, unlabelled EGFR, and Grb2-Venus were co-expressed in living 
cells, as shown in Figure 4.06C.  In contrast to the EGFR, the AT1R does not interact with 
Grb2 in a ligand-dependent manner. However, if AT1R and EGFR exist as a heteromer, 
AngII stimulation will transactivate the EGFR and initiate translocation of Grb2 to the 
activated EGFR, facilitating BRET between AT1R-Rluc8 and Grb2-Venus.  Even in the 
absence of exogenous EGFR transfection, some AngII-mediated BRET was observed, 
indicating the engagement of endogenous EGFR to recruit Grb2-Venus to AT1R-Rluc8 
(Figure 4.06D).  This effect was enhanced by the ectopic expression of additional unlabelled 
EGFR (Figure 4.06D).   As a final confirmation of ligand-dependent complexing between the 
AT1R and the EGFR, we co-transfected cells with AT1R-Rluc8 and EGFR-Venus, and 
stimulated with AngII or EGF. Both AngII and EGF appeared to modulate the proximity of 
the receptors, as shown in Figure 4.06E and 4.06F.  Together, these experiments indicate that 
AT1R and EGFR not only exist in preformed complexes, but that agonist stimulation can 
modulate their association and/or relative conformations. 
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Fig. 4.06: Detection of ligand-driven AT1R and EGFR receptor complexes using 
Receptor-HIT.   
(A) If the AT1R and EGFR exist as a heteromers, AngII-stimulation will activate -arrestin2 
translocation to the AT1R, enabling BRET to occur between EGFR-Rluc8 and -arrestin2-Venus.  (B) 
HEK293 cells expressing -arrestin2-Venus and EGFR-Rluc8 in the presence or absence of AT1R 
were stimulated with 10μM AngII and the BRET ratio determined.  (C) In contrast to EGFR, the 
AT1R does not interact with Grb2 in a ligand-dependent manner. However, if the AT1R and EGFR 
exist as a heteromers, AngII stimulation resulting in transactivation of the EGFR and initiation of 
Grb2 translocation to the activated EGFR should enable BRET to occur between AT1R-Rluc8 and 
Grb2-Venus.   (D) HEK293 cells expressing AT1R-Rluc8 and Grb2-Venus in the presence or absence 
of transfected EGFR, was stimulated with 10μM AngII. (E) A direct readout of ligand-induced 
changes in AT1R-Rluc8 proximity to EGFR-Venus.  (F) Co-expression of AT1R-Rluc8 and EGFR-
Venus in HEK293 cells stimulated with 10μM of AngII or 1μM EGF.  HEK293 cells expressing 
AT1R-Rluc8 and EGFR-Venus were treated with 1μM YM-254890, 1μM Candesartan or 1μM 
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AG1478 for 30 minutes prior to stimulation with (G) 10μM AngII only or (H) 1μM EGF only. 
Agonist stimulation is indicated by arrows. Data represent mean ± SEM of 3-4 independent 
experiments.  
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4.3.4 Pharmacological characterisation of AT1R-EGFR complexes 
 
Ligand-induced changes in proximity between AT1R-Rluc8 and EGFR-Venus, following 
AngII- and EGF-stimulation, are shown in Figure 4.06G and 4.06H. AngII-mediated 
increases in BRET between AT1R and EGFR were inhibited by candesartan, but not AG1478 
or YM-254890, indicating that ligand-dependent modulation does not require Gq/11 coupling 
or EGFR kinase activity (Figure 4.06G).  In contrast, EGF modulation of AT1R-EGFR 
complexes was abrogated by pre-treatment with AG1478 (Figure 4.06H).  Interestingly, pre-
treatment with candesartan or YM-254890 further increased the EGF-mediated BRET 
between AT1R-Rluc8 and EGFR-Venus (Figure 4.06H).  These data provide evidence for 
distinct mechanisms controlling AngII- and EGF-induced modulation of the heteromer.  
 
AT1R-EGFR heteromers are unlikely to merely reflect agonist-induced clustering of these 
proteins in the membrane and/or their concentration and co-trafficking in endosomes, 
because the association of the EGFR with a membrane marker, K-ras, was decreased 
following EGF stimulation, but not AngII-treatment (Figure 4.07A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.07: EGFR localisation and trafficking  
(A) HEK293 cells expressing AT1R, EGFR-Rluc8 and K-ras-Venus were treated with 10M AngII, 
1M EGF and vehicle.  BRET measurements were taken using the CLARIOstar Microplate Reader 
(BMG LabTech). Agonist stimulation is indicated by arrows. Data represents mean ± SEM of 5 
independent experiments. 
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4.4 Discussion: 
 
GPCR-mediated EGFR transactivation is commonly defined as the activation of ERK1/2, 
which although informative, is an indirect and distal readout.  Herein, I utilise a BRET assay, 
based on the recruitment of Grb2 to the EGFR to quantitatively monitor, in living cells and in 
real-time, the proximal activation of EGFR.  Importantly, I observed that the molecular 
requirements for EGFR transactivation differed depending on the readout used.  For the 
Grb2-EGFR assay, I showed that EGFR transactivation is independent of Gq/11 coupling and 
does not apparently involve the AT1R carboxyl-terminal tail or interaction with arrestin.  
Using a series of additional BRET-based assays, I provide evidence for preformed complexes 
between the AT1R and EGFR that show different attributes, depending on which receptor is 
activated.  In summary, the capacity to interrogate proximal EGFR transactivation provides a 
platform to better define the complex molecular processes involved.  
 
Another major observation of our study was the apparent disconnect between 
pharmacological inhibitors and their relative effect on the readout of transactivation vis-à-vis 
ERK1/2 versus BRET-based Grb2 recruitment assays.  We clearly showed that candesartan 
completely inhibited AngII-induced ERK1/2 phosphorylation and recruitment of Grb2 to the 
EGFR, indicating that EGFR transactivation is due to ligand activation of the AT1R in both 
systems.  Interestingly, cells treated with AG1478 showed a complete inhibition of ERK1/2 
activation in response to AngII, however only a partial reduction of AngII-mediated 
transactivation as measured by BRET-based Grb2 recruitment assay, indicating a possible 
disconnect between proximal recruitment of Grb2 and the eventual activation of ERK1/2.  I 
would argue that Grb2 recruitment is necessary, but not in itself sufficient, to drive ERK1/2 
activation following AT1R activation. Importantly, EGF-mediated recruitment of Grb2 to the 
EGFR was completely inhibited with pre-treatment of AG1478, confirming the efficacy of 
AG1478.  
 
Even more unambiguous was the relative contribution of Gq/11 signalling in AngII-
mediated transactivation as measured by the ERK1/2 and the BRET-based readout.  
Although Gq/11 was absolutely required for ERK1/2 phosphorylation following AngII-
stimulation, in contrast, we observed a sustained EGFR-Grb2 interaction when cells were 
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pre-treated with YM-254890. One potential confounding issue was that different 
concentrations of ligands were used to achieve maximal activation of ERK1/2 and BRET 
assays (refer to the legend of Figure 4.01 for detail) and this may have influenced the 
pharmacological inhibitory profile.  However, we observed similar patterns of inhibition 
of the ERK1/2 readout when cells were stimulated with higher concentration (i.e., 10M 
AngII and 1M EGF, data not shown), indicating the differential contribution of Gq/11 is 
unlikely to be a mere artefact of ligand concentration.  Previously, it was assumed that 
transactivation was a consequence of Gq/11 activation (Smith, Chan, Qian et al., 2011), but 
our data using the proximal assay suggests a re-evaluation of this paradigm might be 
required.  We further adapted the BRET experiments to incorporate mutant versions of 
the AT1R, specifically a G protein-uncoupled AT1R, [Y215F]AT1R, that does not couple 
efficiently to Gq/11 (Hunyady, Bor, Balla et al., 1995; Smith, Chan, Qian et al., 2011). 
Consistent with previous results, activation of [Y215F]AT1R resulted in wild type-like 
Grb2 recruitment to the EGFR. Interestingly, others have reported -arrestin-mediated 
ERK1/2 signalling, with an involvement in cardiomyocyte survival and hypertrophy 
(Aplin, Christensen, Schneider et al., 2007; Esposito, Perrino, Cannavo et al., 2011; Kim, 
Ahn, Rajagopal et al., 2009). Here, we used a carboxyl-terminal truncated AT1R, 
[TK325]AT1R, to demonstrate that AT1R C-tail phosphorylation and -arrestin 
interaction is not crucial for Grb2 recruitment. Furthermore, using CRISPR knockout 
HEK293 cell lines we were also able to show that transactivation (indicated by Grb2 
recruitment to the EGFR) appears to be Gq/11- as well as β-arrestin1/2-independent. This 
disparity warrants further study and clearly emphasises the importance of interrogating 
EGFR transactivation directly at the most proximal point in the process.  It is possible that 
other G proteins might be involved or that the cell background is critical, and this requires 
further study. 
 
Based on the above observations, a final consideration for the current study was the 
possibility that GPCR-mediated EGFR transactivation involved receptor heteromerisation 
(Olivares-Reyes, Shah, Hernandez-Aranda et al., 2005). We initially used a BiFC assay to 
provide preliminary evidence for heteromers between the AT1R and EGFR.  Although 
positive, the limitations of this technique in defining ligand-driven heteromer formation 
meant that we then progressed to Receptor-HIT assays and a BRET-based assay measuring 
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direct association of AT1R-EGFR.  Using all three approaches, we provide evidence that 
AT1R and EGFR can exist as preformed complexes that occur constitutively (i.e. in the 
absence of ligand) and are predominantly localised to the plasma membrane.  In addition to 
preformed complexes, AT1R-EGFR heteromers appear to be responsive to agonist 
stimulation and receptor activation.  Ligand-induced modulation of the AT1R-EGFR 
heteromer was validated using two complementary Receptor-HIT approaches, with both 
demonstrating that AngII leads to a rapid and robust increase in BRET that required both the 
AT1R and EGFR.  Lastly, we demonstrate a more ‘direct’ readout, tagging both receptors and 
monitoring ligand-induced changes in BRET due to modulation of donor-acceptor proximity.  
Together, these data strongly indicate that both AngII- and EGF-stimulation can induce the 
formation of multi-receptor complexes and/or alter the relative conformations of AT1R and 
EGFR in pre-existing complexes. An alternative explanation (that these data merely reflect a 
bystander effect or the co-accumulation of the receptors in endosomes) is not supported by 
our observation (see Fig. 4.07) that the trafficking of the EGFR from the membrane occurs 
with EGF stimulation, but not with AngII.  
 
The concept of GPCRs and EGFRs existing as heteromers is consistent with previous studies.  
Co-immunoprecipitation studies have shown that agonist stimulation (both AngII and EGF) 
promotes a multi-protein complex containing the AT1R and EGFR, however these endpoint 
assays were not in live cells or in real-time (Olivares-Reyes, Shah, Hernandez-Aranda et al., 
2005). The 1- and 2-adrenergic receptors associate with the EGFR (Maudsley, Pierce, 
Zamah et al., 2000; Tilley, Kim, Patel et al., 2009), and while isoprenaline enhances 1-
adrenergic receptor association with EGFR, this is disrupted by EGF-stimulation. Others 
have also used BRET to provide evidence for the bile acid receptor, TGR5, forming 
preassembled heterodimers with the EGFR in lipid rafts, however agonist stimulation showed 
no further enhancement in receptor association (Jensen, Godfrey, Niklas et al., 2013). 
Complementary to our studies, Bhattacharya and colleagues showed G protein-coupled 
receptor 54 interacts with EGFR at the plasma membrane in the absence of agonist.  
However, only stimulation with its endogenous ligand, kisspeptin, significantly increased 
their association, while EGF-treatment did not affect the receptor complex (Zajac, Law, 
Cvetkovic et al., 2011). Although it appears that many GPCRs can transactivate EGFRs, 
heteromerisation has only been indicated for a subset.  It is still unknown how this interaction 
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affects signalling of either receptor, with the mechanism and/or binding domains that 
facilitate heteromer formation largely unknown.   
Whether the complex subserves actual transactivation is difficult to reconcile because 
specific inhibitors that prevent complex formation are not available.  Remarkably, we 
observed that the modulation of BRET signals associated with AT1R-EGFR heteromerisation 
differed depending on whether the complex was modulated by activation of the AT1R or the 
EGFR.  The AngII-induced complex modulation is apparently independent of both Gq/11 and 
EGFR kinase activity. G protein-independent transactivation has been reported for 1-
adrenergic receptor and EGFR continued association (Tilley, Kim, Patel et al., 2009). In 
contrast, in our hands, EGF-mediated modulation of the AT1R-EGFR complex was 
absolutely dependent on the EGFR kinase domain.  Moreover, antagonism of the AT1R or 
inhibition of Gq/11 did not inhibit complex modulation, but rather enhanced the EGF-mediated 
increase in BRET signal between AT1R-Rluc8 and EGFR-Venus.  Whether this enhancement 
plays any role in receptor activation is unclear, but it is interesting to note that traditional 
models of monomeric EGFR dimer formation as the active component have been superseded 
by models that suggest that up to 40% of EGFRs are present as inactive dimers that form 
higher order active receptor signalling complexes (Clayton, Orchard, Nice et al., 2008; 
Clayton, Walker, Orchard et al., 2005; Hofman, Bader, Voortman et al., 2010; Yu, Sharma, 
Takahashi et al., 2002).  This negative modulation of EGFR may be mirrored by the AT1R, 
whereby the AT1R and its associated G protein negatively modulate 
monomeric/dimeric/oligomeric EGFR.   
4.5 Summary 
 
In summary, the combination of different BRET approaches emphasises the importance of 
monitoring EGFR activation proximally and in real-time.  Using this approach, we propose a 
G protein-independent mechanism of EGFR transactivation, instead providing evidence of 
ligand-modulated AT1R-EGFR complexes. The results of our studies need to be considered 
in terms of the broader literature regarding EGFR activation.  The classical view that EGFR 
monomers form activated dimers following EGF ligand binding has been replaced by more 
sophisticated models suggesting preformed dimers and activated tetramers.  In fact there is 
evidence that only a fraction of monomers and dimers recruit Grb2, with Grb2 associating 
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predominantly with EGFR tetramers (Kozer, Barua, Henderson et al., 2014). This begs the 
question whether GPCR-mediated transactivation, and its clear proclivity to activate a subset 
of the total EGFR, may reflect a selective and as yet unexplained transactivation of 
monomers vs. dimers vs. higher order structures. 
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5.0 EGFR signalling involves contemporaneous activation of the 
type 1 Angiotensin receptor.  
5.1 Introduction 
 
RTKs and GPCRs are two major families of plasma membrane receptors, and drugs that 
target them are frontline therapies in cancer and cardiovascular disease (Li, Croce, Steensma 
et al., 2015; Wheeler-Jones, 2005).  RTKs and GPCRs, and their signalling pathways, are 
closely integrated to control cellular physiology.  One example is the capacity of GPCRs, 
including the AT1R, to transactivate the EGFR, as a mechanism to usurp the EGFR growth 
promoting pathways.  The capacity of GPCRs, like the AT1R, to transactivate EGFR may 
explain the capacity of inhibitors of AngII production and/or actions at the AT1R to mitigate 
to aberrant cell growth.  It may also explain that some current cancer treatments e.g., 
Herceptin (an antibody that targets HER2), have apparently off target effects on tissues, such 
as the heart (Huszno, Leś, Sarzyczny-Słota et al., 2013; Keefe, 2002; Onitilo, Engel & 
Stankowski, 2014; Riccio, Coppola, Piscopo et al., 2016). Much of our current understanding 
of transactivation classically refers to the activation of RTK by GPCRs, however very little is 
known about the reciprocal process, whereby GPCR function is modulated by RTKs.   
 
The EGFR (HER1/ErbB1) is a RTK that elicits potent mitogenic responses and plays a 
critical role in the pathogenesis of many cancers (Nicholson, Gee & Harper, 2001; 
Normanno, De Luca, Bianco et al., 2006; Yarden, 2001).  As per the introduction, the four 
EGFR family members – HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) – possess an 
extracellular ligand-binding domain, a transmembrane domain and a cytoplasmic protein 
tyrosine kinase domain.  Members of the EGF ligand family bind directly to the EGFR, 
leading to the homo- and/or hetero-dimerisation, with HER2 being the preferred dimer 
partner.  What then follows is the auto- or trans-phosphorylation of several tyrosine residues 
and the activation of EGFR intrinsic tyrosine kinase activity.  The activated EGFR is known 
to bind a number of secondary signalling proteins that subsequently leads to downstream 
signalling.  The activated EGFR recruits and activates PLC, and leads to the cleavage of 
PIP2 generating IP3, which causes the release of Ca2+ from intracellular stores.   
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In addition to GPCRs transactivation of growth factor receptors, evidence exists that 
activation of growth factor receptors may also influence GPCR activity.  The insulin receptor 
was the first RTK shown to engage G protein signalling (Luttrell, Kilgour, Larner et al., 
1990; Luttrell, van Biesen, Hawes et al., 1995), with insulin-like growth factor 1 (IGF1)-
mediated MAPK signalling shown to be sensitive to both pertussis toxin (Gi inhibitor) 
treatment or sequestration of G-protein βγ subunits (Luttrell, van Biesen, Hawes et al., 1995). 
Subsequently, other RTKs have also been shown to engage GPCR signalling molecules, 
including heterotrimeric G proteins (Poppleton, Sun, Fulgham et al., 1996; Shan, Chen, 
Wang et al., 2006) and -arrestin (Lin, Daaka & Lefkowitz, 1998; Povsic, Kohout & 
Lefkowitz, 2003). Alternatively, others and I (see Chapter 4.0) have provided evidence that 
GPCR transactivation involves the formation of GPCR-RTK complexes, coinciding with the 
phosphorylation and activation of the transactivated GPCR (Akekawatchai, Holland, 
Kochetkova et al., 2005; Alderton, Rakhit, Kong et al., 2001; Delcourt, Thouvenot, Chanrion 
et al., 2007).   
 
As part of my ongoing studies into AT1R-EGFR transactivation, I observed (as controls for 
an experiment) that the EGF-mediated stimulation of the EGFR Ca2+ signalling was 
unexpectedly inhibited by the selective non-peptide AT1R antagonist (candesartan) as well as 
a selective Gq/11 inhibitor (YM-254890).  Based on this, we hypothesis that a proportion of 
EGF-stimulated activity may require the coincident activation of the AT1R and its 
downstream signalling.  Here I use a BRET-based arrestin trafficking to the AT1R and 
conformation-sensitive AT1R biosensors to confirm that EGFR stimulation is capable of 
activating the AT1R, but in a mechanism distinct from the cognate AT1R ligand, AngII.    
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5.2 Materials & Methods 
Methods used throughout this chapter are detailed at length in Chapter 2.0, this includes cell 
culture (Section 2.4), isolation of VSMC (Section 2.4.4), nucleofector delivery of plasmid 
DNA (Section 2.4.5.2), ligand-induced BRET assays (Section 2.6.1) Conformational FlAsH 
Biosensor AT1R assay (Section 2.6.4) and calcium mobilisation assay (Section 2.7.4). 
 
5.2.1 Materials 
 
HEK293 cells were obtained from American Type Culture Collection.  HEK-adherent-293 
cell line was a generous gift from Dr Dominic Ng, University of Queensland, Australia. 
Amaxa nucleofector kit (Lonza, Cat# V4XP-1024) was used to transfect isolated VSMC.  
AngII was obtained from Auspep or Sigma Aldrich and EGF from R&D Systems or 
Peprotech.  Inhibitors were obtained from Wako Pure Chemical Industries (YM-254890), 
AstraZeneca (Candesartan), Merck Millipore (AG1478), Sigma Aldrich (PP2) and 
Calbiochem (BAPTA).   
5.2.2 DNA Constructs 
 
Preparation of the following cDNA constructs has been previously described: -arrestin2-
Venus (Kocan, See, Sampaio et al., 2009), AT1R, [TK325]AT1R and [Y215F]AT1R (Smith, 
Chan, Qian et al., 2011), ICL2, ICL3 and C-tail intramolecular sensors (Devost, Sleno, Pétrin 
et al., 2017) .  The following cDNA constructs were gifts from collaborators: The plasma 
membrane marker Venus/K-ras, as well as the subcellular compartment marker Rab GTPases 
(Rabs) Venus/Rab5a (early endosomes), Venus/Rab7a (late endosomes/lysosomes), and 
Venus/Rab11 (recycling endosomes), were kindly provided by Professor Nevin Lambert 
(Georgia Regents University). Rab1 (endoplasmic reticulum trafficking to the cis-Golgi), 
Rab4 (early endosome recycling), Rab6 (Golgi and trans-Golgi network), Rab8 (trans-Golgi 
network to the plasma membrane), and Rab9 (late endosome trafficking to the trans-Golgi 
network) (Sherwood & Roy, 2013; Wandinger-Ness & Zerial, 2014) were synthesised and 
subcloned by GeneArt into a pcDNA3 expression vector containing Venus without a stop 
codon and with a 20 residue linker of GGGAGGGAGGGAGGGAGGGA, to generate the 
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resulting fusion proteins with the Venus tag on the N terminus of the Rab protein.  The Rab 
proteins have been described previously (Tiulpakov, White, Abhayawardana et al., 2016).  
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5.3 Results 
5.3.1 EGFR activates pathways downstream of the AT1R  
 
Activated EGFR phosphorylates PLC-1 (Sekiya, Poulin, Kim et al., 2004), which 
translocates to the plasma membrane, allowing the hydrolysis of PIP2 to IP3, and the release 
of intracellular Ca2+ (Falasca, Logan, Lehto et al., 1998; Nishibe, Wahl, Hernandez-
Sotomayor et al., 1990).  As shown in Figure 5.01, EGF-stimulation leads to a rapid and 
robust increase in intracellular Ca2+ as determined by a GCaMP biosensor (a genetically 
encoded Ca2+ sensor). This Ca2+ transient is completely inhibited by the EGFR kinase 
antagonist AG1478 (Figure 5.01A). Pre-treatment of cells with candesartan or YM-254890, 
lead to an approximate 50% decrease in maximal EGF-stimulated Ca2+ (Figure 5.01B and 
5.01C).  This data indicates that, in part, EGFR signalling relies on AT1R activation and its 
capacity to couple to Gq/11.  
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Figure 5.01: The effects of AT1R and Gq/11 inhibition on EGFR-mediated Ca2+ response. 
(A-C) HEK293 cells stably expressing AT1R were co-transfected with EGFR and GCaMP and treated 
with 1M EGF or vehicle. EGFR-dependent Ca2+ response (corrected for vehicle response) were 
treated with (A) 500nM AG1478 (EGFR inhibitor), (B) 1μM YM-254890 (Gq/11 inhibitor) or 1μM 
Candesartan (AT1R inverse agonist) for 30 minutes prior to stimulation.  (C) Ligand-induced Ca2+ 
responses were quantified using area under the curve (AUC).  Data represent mean ± SEM of 3 
independent experiments. Statistical analysis by a one-way ANOVA with a Dunnett’s post-test for 
multiple comparisons; ** p<0.01, * p<0.05, vs. EGF treated cells.   
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5.3.2 EGFR activation initiates -arrestin recruitment to the AT1R  
 
Having observed that EGF-stimulation can potentially couple to AT1R/Gq/11 activation, we 
next sought to demonstrate this activation directly using a BRET-based arrestin recruitment 
assay.  This assay utilises an Rluc8-tagged AT1R and a Venus-tagged -arrestin2, whereby 
stimulation of AT1R results in the recruitment of arrestin to the activated, phosphorylated 
AT1R (Pfleger, Dromey, Dalrymple et al., 2006) (Figure 5.02A).  In HEK293 cells, AngII-
stimulation produced a robust and sustained ligand-dependent BRET signal, indicative of -
arrestin2 translocation and binding to the AT1R (Figure 5.02B). Consistent with our 
hypothesis that EGF-stimulation leads to the activation of the AT1R, we observed an EGF-
mediated recruitment of -arrestin2 to the AT1R.  This EGF-mediated activation of the AT1R 
was slower and lower in magnitude compare to AngII (Figure 5.02B).  The capacity of EGF 
to activate the AT1R was also observed in VSMC (Figure 5.02C). 
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Figure 5.02: The development of a BRET-based assay to monitor EGFR-mediated 
AT1R ‘reverse transactivation’ 
(A) Schematic of EGFR-AT1R BRET-based transactivation. AT1R fused to a BRET donor (Rluc8), is 
co-transfected with -arrestin2 adaptor protein tagged with a BRET acceptor (Venus) and the EGFR.  
Stimulation of the EGFR promotes activation of the AT1R and recruitment of -arrestin2. (B) 
HEK293 cells and (C) primary VSMC expressing EGFR, AT1R-Rluc8, and -arrestin2-Venus were 
treated with 10µM AngII, 1µM EGF or vehicle.  Agonist stimulation is indicated by arrow. Data 
represent mean ± SEM of 3 independent experiments. 
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5.3.3 Mechanisms underlying reverse transactivation 
 
I next used pharmacological inhibitors to examine the molecular mechanisms underlying 
EGFR-stimulated AT1R activation.  EGF-mediated recruitment of arrestin to the AT1R, was 
completely inhibited by the EGFR kinase inhibitor, AG1478.  This activation of the AT1R 
was also completely inhibited by pre-treatment with candesartan and YM-254890, indicating 
that arrestin recruitment was dependent on the active state of the receptor and Gq/11 (Figure 
5.03A).  We next adapted the BRET experiments to incorporate mutant versions of the AT1R.  
Similarly, a truncated mutant of the AT1R, [TK325]AT1R, lacking 34 carboxyl terminal 
amino acids and deficient in ligand-mediated phosphorylation and recruitment of β-arrestins, 
was unable to recruit -arrestin following EGF stimulation (Figure 5.04B).  In contrast to 
previous results using YM-254890, a mutated AT1R with a single point mutation, 
[Y215F]AT1R, which can no longer couple to Gq/11, showed wild type levels -arrestin2 
recruitment (Figure 5.04B) in response to EGF-stimulation.   
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Figure 5.03: The use of pharmacological inhibitors in EGF-mediated -arrestin2 
recruitment to the AT1R. 
(A) Schematic of various pharmacological inhibitors and their bio-chemical targets.  AG1478 inhibits 
the EGFR tyrosine kinase domain, candesartan is an inverse agonist of the AT1R and YM-254890 
blocks Gq/11 signalling. (B) HEK293 cells expressing EGFR, AT1R-Rluc8, and -arrestin2-Venus 
were treated with 500nM AG1478, 1μM YM-254890 and 1μM Candesartan for 30 minutes prior to 
stimulation with 10μM AngII, 1μM EGF or vehicle.  Agonist stimulation is indicated by arrows. Data 
represent mean ± SEM of 3 independent experiments. 
 
Chapter Five: Reverse Transactivation 
 
 115 
 
Figure 5.04:  Dependence on β-arrestin and Gq/11 in EGF-mediated -arrestin2 
recruitment to the AT1R.  
(A) Schematic of wild type AT1R and mutant AT1R s - [TK325]AT1R (truncated AT1R deficient in 
recruiting β-arrestins) and [Y215F]AT1R (inability to couple to Gq/11 signalling pathways).  (B) 
HEK293 cells expressing AT1R-Rluc8 and -arrestin2-Venus, alongside wild type AT1R, 
[Y215F]AT1R or [TK325]AT1R, were treated with 10M AngII, 1M EGF or vehicle.  Agonist 
stimulation is indicated by arrows. Data represent mean ± SEM of 3 independent experiments. 
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5.3.4 AT1R Biosensors to monitor receptor conformational changes 
 
To determine whether EGF-stimulation can mediate AT1R conformational changes similar to 
AngII, we used AT1R-based biosensors (Figure 5.05).  The AT1R biosensors report on 
ligand-induced conformational changes and have been reported to discriminate between 
biased and canonical ligands (Devost, Sleno, Pétrin et al., 2017). The biosensor harnesses 
BRET technology with a small fluorescent FlAsH molecule inserted at different positions 
(intracellular loop 2, ICL2; intracellular loop 3, ICL3; and the intracellular C-tail loop, C-tail) 
throughout the AT1R and a donor Rluc8 located at the distal end of the carboxyl-tail (Figure 
5.05A) (Devost, Sleno, Pétrin et al., 2017).  
 
As shown in Figure 5.05B, there was a minimal response of the ICL2 AT1R biosensor to 
AngII, as reported previously (Devost, Sleno, Pétrin et al., 2017), and to EGF .  Relative to 
vehicle control, AngII-stimulation of the ICL3 AT1R biosensor lead to a robust decrease in 
BRET ratio, consistent with an agonist response as previously described (Figure 5.05C).  
Interestingly, stimulation with EGF caused a decrease ICL3 BRET response relative to 
vehicle, which was significantly less than that promoted by AngII.  Finally, using the C-tail 
AT1R biosensor, AngII (but not EGF) led to a significant decrease in the BRET ratio (Figure 
5.05D).  Overall, these data support the idea that both AngII and EGF can both promote 
conformational changes, but these appear to be distinct.   
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Figure 5.05: AT1R FlAsH Biosensors to monitor AngII- and EGF-mediated receptor 
conformational changes.   
(A) The small FlAsH sequence was incorporated to the 2nd and 3rd intracellular loop as well as the 
carboxyl terminal domain of the AT1R.  (B) ICL2 (C) ICL3 and (D) C-tail were transiently 
transfected into HEK293 cells and treated with 10M AngII, 1M EGF or vehicle.  FlAsH-labelled 
and agonist-induced BRET was calculated as described in Chapter 2.6.4 Conformational Biosensor 
Assay.  Data represent mean ± SEM of 4-5 independent experiments. 
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5.3.5 AT1R trafficking and distribution 
 
As a measure of AT1R activation, we next examined the localisation of the AT1R relative to a 
panel of cellular markers (K-ras for the plasma membrane; Rab4 for early endosome) using a 
BRET-based assays previously described (Figure 5.06) (Tiulpakov, White, Abhayawardana 
et al., 2016; White, Vanyai, See et al., 2017).  Stimulation with AngII lead to a rapid 
internalisation of the receptor from the plasma membrane (Figure 5.06B) to intracellular 
vesicles (Figure 5.06C).  In contrast, EGF-stimulation resulted in a slight increase in BRET 
signal with the plasma membrane marker K-ras, indicating that EGF activation of the AT1R 
leads to retention/accumulation of the receptor at the plasma membrane (Figure 5.06B).  In 
contrast to AngII treatment, following EGF-stimulation the AT1R did not traffick to other 
subcellular markers (Figure 5.07). 
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Figure 5.06: The use of membrane and subcellular markers to monitor AT1R 
localisation and trafficking 
(A) A simplified schematic representation of the plasma membrane marker, K-ras, and the early 
endosome marker, Rab4.  Ligand-induced trafficking was monitored using Rluc8-tagged AT1R by 
measuring proximity with Venus-tagged K-ras or Rab4.  (B) HEK293 cells were transfected with 
AT1R-Ruc8 and K-ras-Venus or (C) Rab4-Venus and treated with 10M AngII, 1M EGF or vehicle.  
Agonist stimulation is indicated by arrows. BRET measurements were taken using the CLARIOstar 
Microplate Reader (BMG LabTech). Data represent mean ± SEM of 3 independent experiments.
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Figure 5.07: The use of subcellular markers to monitor AT1R localisation and 
trafficking 
HEK293 cells were transfected with AT1R-Rluc8 and one of the subcellular markers (A) Rab1a, 
endoplasmic reticulum trafficking to the cis-Golgi (B) Rab5, early endosome, (C) Rab6, Golgi and 
trans-Golgi network, (D) Rab7, late endosome/lysosome, (E) Rab8, trans-Golgi network to the plasma 
membrane, (F) Rab9, late endosome trafficking to the trans-Golgi network, (G) Rab11, recycling 
endosomes, and treated with 10M AngII, 1M EGF or vehicle.  Agonist stimulation is indicated by 
arrows. BRET measurements were taken using the CLARIOstar Microplate Reader (BMG LabTech). 
Data represent mean ± SEM of 5-6 independent experiments. 
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5.4 Discussion 
 
The work described in this chapter work came from a serendipitous observation that AT1R 
and Gq/11 inhibitors reduced an EGF-induced PLC- mediated Ca2+ signal.  Our results 
indicate that EGF-stimulation can activate the AT1R as measured by -arrestin2 recruitment 
to the activated AT1R.  The capacity of EGF to recruit arrestin to the AT1R is apparently 
dependent on the EGFR kinase domain as well as AT1R active, Gq/11 coupled state, and AT1R 
C-tail phosphorylation.  Using AT1R-based biosensors, we provide additional, direct 
evidence that EGF-activation promotes an AT1R conformational change that may be distinct 
from the AngII-bound AT1R.  Functionally this may be important, because it predicts that 
treatment with non-peptide AT1R antagonists (such as candesartan) may prevent a significant 
proportion of EGF-mediated signalling.   This may have fundamental implications in the 
understanding of GPCR and RTK signalling. 
 
To confirm AT1R reverse transactivation, we used a BRET-based assay that quantitatively 
measures -arrestin2 recruitment to the AT1R.  As an internal control, arrestin recruitment 
was readily demonstrable upon AT1R activation, indicative of arrestin binding to the 
activated AT1R and its subsequent desensitisation and internalisation.  We initially tested 
whether EGFR stimulation could also promote -arrestin2 translocation and interaction with 
AT1R. Although EGF-mediated arrestin translocation was also apparent, it was consistently 
lower in magnitude and delayed, suggestive that arrestin binds at a much slower rate.  
Furthermore, we show that AG1478 completely inhibited EGF-induced arrestin, indicating 
that the EGFR kinase domain is absolutely required for EGF-induced arrestin recruitment to 
the AT1R.  Interestingly, cells pre-treated with YM-254890 and candesartan completely 
attenuated arrestin recruitment, indicating that EGF-mediated transactivation of the AT1R is 
dependent upon the co-activation of the AT1R and its capacity to couple to Gq/11.  
 
To extend our observations that AT1R transactivation is dependent on receptor 
phosphorylation, we further adapted the arrestin-BRET-based assay to include mutant 
versions of the AT1R.   A carboxyl-terminal truncated AT1R that lacks receptor 
phosphorylation sites, [TK325]AT1R, was incapable of recruiting -arrestin2 following EGF-
treatment.  This data confirms that EGF-induced -arrestin2 binding does not reflect 
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bystander (non-specific) BRET, as AT1R--arrestin2 association was attenuated when the 
truncated form of the AT1R was used. Furthermore, the use of a single point AT1R mutant, 
[Y215F]AT1R, that can no longer couple to Gq/11 mediated pathways, revealed -arrestin2 
recruitment approximately equivalent to the wild type AT1R.  This suggests that the EGFR 
can still activate [Y215F]AT1R, as measured by arrestin recruitment.  
 
At the time of making this observation, I became aware of a study (Tóth, Prokop, Gyombolai 
et al., 2018) into AT1R heterologous phosphorylation and arrestin recruitment, where a 
similar ‘reverse transactivation’ was observed.  Although they didn’t directly focus on this 
observation, they did show the ability of EGF to activate arrestin trafficking to the AT1R.  
They provide evidence that activation of PKC (whether it is by the EGFR or other GPCRs) 
recruits -arrestin2 to the AT1R even in the absence of AT1R ligand. Contrary to our data, 
they suggest a mechanism whereby -arrestin2 recruitment does not require the activate state 
of the AT1R.  Given that the significant proportion of the EGF signalling is blocked by the 
inverse agonist candesartan, we would argue the possibility exists that the EGFR can directly 
activate the AT1R and its downstream Gq/11-mediated events.  
 
Although bidirectional cross-communication between RTKs and GPCRs have been 
previously reported, the evaluation of reverse transactivation is not an exhaustively studied 
phenomenon.  Various studies have suggested that RTK-induced GPCR transactivation is 
mediated exclusively through intracellular signalling, while other have proposed that growth 
factor receptors trigger the extracellular release of GPCR ligands.  Both transcriptional 
upregulation and enzymatic activation can contribute to the synthesis and secretion of GPCRs 
cognate ligand.  It is important to note that transcriptional dependent mechanism has only 
been noted for the chemokine receptor, CCR5, whereby IGF1 stimulation upregulates 
transcription and synthesis of RANTES, CCR5 natural ligand (Mira, Lacalle, González et al., 
2001).  In the case of platelet-derived growth factor (PDGF) and IGF1, RTK activation 
mediates the production of a GPCR ligand that binds to and activates the GPCR in an 
autocrine and/or paracrine manner, however this has only been exhibited for selective GPCRs 
(El-Shewy, Johnson, Lee et al., 2006; Hobson, Rosenfeldt, Barak et al., 2001).   
 
Chapter Five: Reverse Transactivation 
 
 123 
Alternatively, others have suggested that GPCR transactivation involves the formation of 
GPCR-RTK complexes and the phosphorylation of transactivated GPCRs (Akekawatchai, 
Holland, Kochetkova et al., 2005).  This complex formation provides a platform by which 
RTK and GPCRs signals can integrate and activate downstream MAPK signalling pathways 
more efficiently by way of a mechanism independent of ligand production.  It has been 
proposed that the formation of GPCR-RTK signalling platforms not only facilitate the cross-
communication between both receptor systems, but RTK form constitutive complexes with 
the GPCR partner.  Interestingly, association of Sphingosine-1-phosphate receptor (SIP1) 
with PDGFR facilitates tyrosine phosphorylation of Gi  by PDGFR kinase activity, a process 
that prevents G re-association with G subunits, prolonging the duration of G protein 
activation.  Scaffolding proteins are thought to be a major driver of GPCR-RTK complexes 
(Ango, Prézeau, Muller et al., 2001), however as already mentioned in Chapter 4.0, how 
these functional GPCR-RTK complexes occur is still an open question.  
 
One major question that remains unresolved is whether EGF-treatment promotes distinct 
patterns of AT1R conformational changes compared to the AT1R canonical ligand, AngII. We 
interrogated the conformational changes of the receptor using a conformational biosensor as 
reported previously (Devost, Sleno, Pétrin et al., 2017). While we were able to reproduce the 
AngII-mediated conformational changes in these biosensors, similar conformational changes 
were not observed in response to EGF.  There are two possible explanations.  Firstly, EGF-
stimulated AT1R activation is modest, and therefore, the conformational changes may reflect 
this.  Indeed, the changes relative to vehicle ICL3 are of the same direction of AngII, but 
weaker.  Similar logic cannot be applied to the C-tail sensor, which shows robust changes to 
AngII, but not EGF.  Secondly, an alternative possibility is that EGF-stimulation is putting 
the AT1R in a different conformation and this conformation can provide some signalling and 
lead to phosphorylation of the receptor, arrestin trafficking, but importantly does not 
sustain/initiate internalisation of the AT1R. On balance, these data can be interpreted to 
suggest that there is a different conformational state mediated by EGF-stimulation relative to 
AngII-stimulation. 
 
Although there is a clear link between EGFR and cancer, there remains significant 
controversy as to the potential role of the RAS (AngII/AT1R) in cancer (George, Thomas & 
Chapter Five: Reverse Transactivation 
 
 124 
Hannan, 2010; Herr, Rodewald, Fraser et al., 2008; Miyajima, Kosaka, Kikuchi et al., 2015; 
Xu, Fan, Wu et al., 2017).  Some may argue that the capacity of the AT1R to transactivate the 
EGFR may play some role in such a possibility (Greco, Muscella, Elia et al., 2003).  Many 
studies have been able to show AngII-mediated growth and proliferation in variety of models; 
the epidemiological data of large cohort population studies of people treated with ACE 
inhibitors and ARB are ambiguous (Chae, Valsecchi, Kim et al., 2011; Christian, Lapane, 
Hume et al., 2008; Fryzek, Poulsen, Lipworth et al., 2006; Li, Malone, Weiss et al., 2003; 
Wang, Liu, Chao et al., 2013).  One of the avenues opened by the current study is the 
possibility that some of the actions of the EGFR, be it in normal physiology or disease, may 
necessitate the concomitant activation of other receptors e.g. GPCRs, including the AT1R.  
As far as we know, this is not been widely studied but my data provide the platform for 
considering this possibility.   
 
5.5 Summary 
The results of this study demonstrate that by blocking AT1R signalling (whether it be direct 
inhibition of the AT1R or downstream Gq/11 signalling), in part, also blocks a significant 
proportion of EGF-mediated signalling.  Such an observation could have enormous 
implications clinically.  While therapeutics that target EGFR activity are mainstream 
treatments for a variety of cancers, resistance to cancer treatments limit the efficacy of these 
reagents and remains the major challenge for targeted cancer therapy.  This study gives rise to 
the notion that EGFR may necessitate the concomitant activation of the AT1R and may 
provide an alternative avenue by which cancer cells can signal and be modulated.   
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6.0 The contribution of BMX, CHKA and TRIO to AT1R-EGFR 
transactivation 
6.1 Introduction 
 
The exact mechanism of EGFR transactivation remains contentious.  In addition to the TMPS 
paradigm described previously, a number of second messengers have been reported to 
facilitate AT1R-EGFR transactivation, including PKC, Src, Ca
2+, and ROS.  Many research 
groups, including our own, have focused on defining the mechanism of GPCR-EGFR 
transactivation in various cells/tissues, but despite a tremendous amount of hard work and a 
lot of publications, the field has stalled in a mechanistic sense. This prompted the Thomas 
laboratory, in collaboration with Dr Ross Hannan (George, Purdue, Gould et al., 2013), to 
instead employ a functional genomics-approach to identify novel genes modulating AngII-
mediated EGFR transactivation. Based on the assumption that kinases are likely involved in 
mediating AT1R-EGFR transactivation, the developed RNAi screen focused on identifying 
kinases involved in EGFR-mediated ERK1/2 activation following AngII stimulation.  This 
screen identified known genes previously involved in EGFR function (EGFR, HER2, Akt, 
MAPK1) as well as identifying other genes that have not been previously associated with 
EGFR transactivation.  The three most interesting were the choline kinase alpha (CHKA), the 
triple function domain protein (TRIO) and the bone marrow kinase X-linked (BMX) kinase.  
BMX (also termed epithelial tyrosine kinase, ETK) is a non-receptor tyrosine kinase that 
belongs to the Tec family kinases.  Although BMX has not been directly implicated in EGFR 
transactivation, it has been recently suggested to play a role in ischemic preconditioning, and 
cardiac functional phenotype, particularly pressure overload (Mitchell-Jordan, Holopainen, 
Ren et al., 2008; Zhang, Franklin, Li et al., 2010). BMX has a typical array of regulatory 
domains and a highly conserved carboxyterminal kinase domain (Figure 6.01) (Qiu, Wang, 
Liu et al., 2014; Qiu, Robinson, Pretlow et al., 1998).  The amino-terminus contains a 
pleckstrin homology (PH) domain that mediates membrane localisation (Chen, Jiang, 
Gewinner et al., 2013).  The PH domain is followed by an array of zinc-binding Bruton’s 
tyrosine kinase (BTK) homology (BH) domains as well as a SH3 and SH2 domain.  These 
domains are thought to mediate inter- and intra-molecular protein interactions (Chen, Jiang, 
Gewinner et al., 2013; Joseph & Andreotti, 2009; Pursglove, Mulhern, Mackay et al., 2002; 
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Qiu, Wang, Liu et al., 2014).   
CHKA is responsible for the generation of membrane phospholipids (Lacal, 2015) and has 
been demonstrated to play an important role in cell transformation and tumorgenesis 
(Hernando, Sarmentero-Estrada, Koppie et al., 2009). CHKA is a cytosolic enzyme that 
catalyses the phosphorylation of free intracellular choline to phosphocholine, the first step of 
the Kennedy pathway. The Kennedy pathway is the major contributor to the biosynthesis of 
phosphatidylcholine (PtdCho) in mammalian cells (Gruber, Too, Wong et al., 2012). 
Together, PtdCho and phosphoethanolamine (the other major product from the Kennedy 
pathway) is the major constituent of cell membranes, contributing to approximately 50% of 
the total phospholipid species in eukaryotic membranes (Gruber, Too, Wong et al., 2012).  
At least three isoforms of choline kinase exist in mammalian cells and are encoded by two 
genes: CHK (CHKA) and CHK (CHKB), which display 60% similarity and are 
ubiquitously expressed in different tissues (Gallego-Ortega, Ramirez de Molina, Angeles 
Ramos et al., 2009). CHKA has been largely implicated in the development of carcinogenic 
processes and is over expressed in a variety of human cancers and late stage malignant 
tumours (Gallego-Ortega, Gomez del Pulgar, Valdes-Mora et al., 2011; Lin, Hu, Gu et al., 
2017), having recently been suggested as an appropriate marker for poor clinical outcome 
and tumour progression in breast carcinomas (de Molina, Gutierrez, Ramos et al., 2002; 
Miyake & Parsons, 2012), bladder carcinomas (Hernando, Sarmentero-Estrada, Koppie et al., 
2009), lung cancer (Glunde & Bhujwalla, 2007; Ramirez de Molina, Sormentero-Estrada, 
Beldo-Iniesta et al., 2007) and prostate cancer (Challapalli, Trousil, Hazell et al., 2015). A 
consistent metabolic hallmark is the overexpression of both CHKA and altered choline 
phospholipid metabolism, leading to an increase in total choline containing metabolites, as 
well as an increased pool of phosphocholine available for breakdown and synthesis of 
PtdCho (Glunde, Bhujwalla & Ronen, 2011). The synthesis of PtdCho is vital, and plays an 
essential role in the structural maintenance of the plasma membrane as well as a key 
precursor for the generation of various lipid second messengers (Falcon, Hudson, Huang et 
al., 2013) and the propagation of mitogenic signalling events (Rodriguez-Gonzalez, Ramirez 
de Molina, Benitez-Rajal et al., 2003; Yalcin, Clem, Makoni et al., 2010).  Phospholipase D 
(PLD) hydrolyses PtdCho, forming the negatively charged phospholipid, phosphatidic acid 
(PA) (Jenkins & Frohman, 2005).  Generation of PA is known to interact with positively 
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charged effector proteins, including the well-characterised lipid interacting domain, PH-
domain, of SOS (Zhao, Du, Skowronek et al., 2007).  This initiates the translocation of 
various signalling proteins and mediates downstream mitogenic signalling.   
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Figure 6.01: Schematic representation of BMX and CHKA structure and functional domains 
The top figure shows that BMX N-terminus contains the PH domain is immediately followed by the conserved Btk motif.  The C-terminus contains the kinase 
domain preceding the SH3 and SH2 binding motifs.  Below, CHKA consists of 457 amino acids and is classified an ‘atypical’ kinase – a protein with 
confirmed protein kinase activity however has little sequence similarity to any known eukaryotic protein kinases.  The N-terminal domain is composed of a 
single -helix sheet and five-stranded antiparallel -sheets, which is thought to stabilise the protein as a dimer (Dimer interface).  Prior to this is an 18 amino 
acid insertion that is evident in CHKA2 and not CHKA1, its function is not clear.    The C-terminal domain is primarily helical and contains many of the 
conserved regions - the Brenner’s motif and the choline kinase motif.  These regions are highly conserved among other atypical kinases, namely choline 
kinases, eukaryotic protein kinases and aminoglycoside phosphotransferases kinases. 
Chapter Six: The role of BMX, CHKA & TRIO in AT1R-EGFR Transactivation 
 131 
 
Lastly, TRIO is a large multifunctional protein (3097 amino acid protein) that displays 3 
enzymatic domains - a serine/threonine kinase domain, as well as two functional GEF 
domains (specific for GDP/GTP exchange on Rac1 and RhoA) (Bellanger, Lazaro, Diriong et 
al., 1998; Medley, Serra-Pagès, Iannotti et al., 2000). At present, no publications link AngII 
activation to TRIO activity, however AngII does engage other RhoA GEFs, such as Arhgef1 
(Carbone, Brégeon, Devos et al., 2015; Guilluy, Bregeon, Toumaniantz et al., 2010). 
Intriguingly, a forward genetic screen revealed that the TRIO homologue in C.Elegans, 
UNC-73, is a major mediator of Gq/11 signalling (Williams, Lutz, Charlie et al., 2007).  
Furthermore, Gq/11 can activate the C-terminal Rho-specific DH-PH domain of TRIO (Rojas, 
Yohe, Gershburg et al., 2007).  Most relevant to my studies is a recent genome-wide RNAi 
screen performed in Drosophila, which found that TRIO activation is required for Gq 
mediated mitogenic signalling, as well as sustained cellular growth (Vaque, Dorsam, Feng et 
al., 2013). 
 
Given the accumulating literature linking GPCR-EGFR transactivation to tissue remodelling 
and disease state, a broader mechanistic picture of the underlying biology is required.  
Having already optimised a sophisticated BRET-based approach that interrogates AT1R-
EGFR transactivation, it is of great interest to confirm the involvement of these three novel 
proteins in the ‘crosstalk’ between the AT1R and the EGFR. 
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6.2 Materials & Methods 
 
Methods used throughout this chapter are detailed at length in Chapter 2.0, this 
includes cell culture (Section 2.4), ligand-induced BRET assays (Section 2.6.1) and 
confocal imaging (Section 2.6.2). 
6.2.1 Materials 
 
HEK293 cells were obtained from American Type Culture Collection.  HEK293FT were 
obtained by Thermo Fisher Scientific.  AngII was obtained from Auspep or Sigma Aldrich 
and EGF from R&D Systems or Peprotech.  [Methyl-14C]-Choline Chloride was supplied by 
Perkin Elmer.  Thin layer chromatography (TLC) plates were supplied by Sigma Aldrich. 
6.2.2 DNA Constructs 
 
CHKA was generated by GeneArt (Thermo Fisher Scientific, Regensburg, Germany).  
pDONR223-BMX cDNA was a gift from William Hahn & David Root (Addgene plasmid # 
23936).  TRIO-GFP was kindly provided by Dr Anne DeBant (Cell Biology Research 
Institute of Montpellier, France).  c-Src was kindly provided by Sarah Parsons (University of 
Virginia, VA, USA).  mCherry-CHKA was kindly provided by Dr Aria Baniahmad 
(University of Jena, Germany). Venus-BMX, CHKA-Venus and Venus-CHKA were 
generated by inserting BMX and CHKA into pcDNA3-Venus, kindly provided by Dr Kevin 
Pfleger. Rluc8-BMX was generated by inserting BMX from Venus-BMX into pcDNA3-
Rluc8, kindly provided by Dr Kevin Pfleger.  CHKA with no additional tags was generated 
by inserting CHKA into pcDNA3.  Preparation of the following cDNA constructs has been 
previously described: AT1R, [TK325]AT1R and [Y215F]AT1R (Smith, Chan, Qian et al., 
2011), EGFR-Rluc8 and Grb2-Venus (Ayoub, See, Seeber et al., 2013), K-ras-Venus and all 
subcellular compartment markers (Rabs-Venus) (Tiulpakov, White, Abhayawardana et al., 
2016), -arrestin2-GFP (Dinh, Qian, Seeber et al., 2004). AT1R-Rluc8 was generated by 
inserting AT1R from AT1R-Venus into pcDNA3-Rluc8, prepared previously from cDNA 
kindly provided by Andreas Loening and Sanjiv Gambhir (Stanford University, California, 
USA. 
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6.3 Results 
 
6.3.1 BMXs involvement in AT1R-EGFR transactivation 
 
No previous data has linked BMX to EGFR transactivation, except the RNAi screen 
performed prior to this work (George, Purdue, Gould et al., 2013).  We hypothesis that BMX 
interacts with both the AT1R and EGFR, as has been reported for the PAR1 and other 
members of the RTK family (Cohen, Maoz, Turm et al., 2010).  We directly examined BMX 
potential interactions using a BRET-based approach.  A suitable vector containing an in 
frame Venus molecule was genetically fused to the N-terminus of BMX was generated 
(Venus-BMX). Firstly, to investigate the role of BMX in AT1R-EGFR transactivation, we 
monitored the recruitment of Venus-BMX with EGFR-Rluc8 (Figure 6.02A).  As shown in 
Figure 6.02B, following EGF-stimulation, a ligand-dependent BRET signal was observed in 
cells co-transfected with Venus-BMX and EGFR-Rluc8, indicative of BMX translocation and 
interaction with the EGFR.  This association was further enhanced with the addition of AT1R 
DNA (Figure 6.02B). 
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Figure 6.02: Kinetic analysis of EGF-mediated recruitment of BMX to the EGFR.   
(A) Schematic illustration of BMX-EGFR BRET-based assay.  EGFR fused to a BRET donor 
(Rluc8), is co-transfected with BMX tagged with a BRET acceptor (Venus) in the presence or absence 
of the AT1R.  (B) HEK293 cells expressing EGFR-Rluc8 and BMX-Venus in the presence or 
absence of AT1R were treated with 1M EGF or vehicle (indicated by arrow).  Data represent mean 
± SEM of 3 independent experiments with triplicate measurements.    
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We next sought to interrogate if this enhanced association between EGFR-BMX in the 
presence of additional AT1R, is dependent upon Gq/11 coupling.  In order to understand the 
molecular mechanisms underlying BMX-EGFR association, we used a single point mutant of 
the AT1R, [Y215F]AT1R, previously reported to retain high affinity for AngII, but an 
inability to couple to Gq/11 mediated signalling (Hunyady, Bor, Balla et al., 1995).  
Stimulation of the EGFR, in the presence of [Y215F]AT1R, promoted BMX recruitment to 
the EGFR which was less than that promoted by the wild type AT1R (Figure 6.03B).  
Similarly, we repeated the same experiment with a truncated mutant of the AT1R, 
[TK325]AT1R, lacking 34 carboxyl terminal amino acids and deficient in ligand-mediated 
phosphorylation and recruitment of β-arrestins (Qian, Pipolo & Thomas, 2001; Thomas, 
Motel, Kule et al., 1998).  Likewise, [TK325]AT1R also showed a decreased BMX 
recruitment compared to the wild type AT1R (Figure 6.03B).  It is important to note, although 
there is a change in kinetics, there is no decrease in the maximal EGFR-BMX recruitment, 
suggesting that AT1R may influence EGFR-BMX kinetic profile but not the overall 
association.   
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Figure 6.03: Kinetic analysis of EGF-mediated recruitment of BMX to the EGFR in the 
presence of mutant AT1R.   
(A) Schematic illustration of BMX-EGFR BRET-based assay.  EGFR fused to a BRET donor 
(Rluc8), is co-transfected with BMX tagged with a BRET acceptor (Venus) in the presence of wild 
type AT1R, [Y215F]AT1R or [TK325]AT1R. (B) HEK293 cells expressing EGFR-Rluc8 and BMX-
Venus, alongside wild type AT1R, [Y215F]AT1R or [TK325]AT1R, were treated with 1M EGF or 
vehicle (indicated by arrow).  Data represent mean ± SEM of 3 independent experiments with 
triplicate measurements.    
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Lastly, we examined whether AngII-stimulation could also recruit BMX to the EGFR as seen 
following EGF-stimulation (Figure 6.04A).  Contrary to EGF-treatment, AngII-stimulation 
promoted a decrease in BRET ratio, suggesting AngII-stimulation promotes dissociation 
between EGFR and BMX (Figure 6.04B). This AngII-mediated BMX-EGFR dissociation 
was shown to be independent of Gq/11- and arrestin-coupling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.04: Kinetic analysis of AngII-driven recruitment of BMX to the EGFR.   
(A) Schematic illustration of BMX-EGFR BRET-based assay.  EGFR fused to a BRET donor 
(Rluc8), is co-transfected with BMX tagged with a BRET acceptor (Venus). (B) HEK293 cells 
expressing EGFR-Rluc8 and BMX-Venus, alongside wild type AT1R, [Y215F]AT1R or 
[TK325]AT1R, were treated with 10M AngII or vehicle (indicated by arrow).  Data represent mean 
± SEM of 3 independent experiments with triplicate measurements.   
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As shown in Figure 6.05A, we next investigated BMX association with the AT1R, by co-
transfecting cells with Venus-BMX and AT1R-Rluc8.  Similarly, AngII-treatment resulted in 
a decreased BRET response, indicative of BMX dissociation from the AT1R, or a complex 
containing the AT1R.  In response to EGF-stimulation, we observed a partial increase in 
BRET ratio between AT1R and BMX (Figure 6.05B).  Together this data suggests that EGF-
stimulation promotes BMX association with the EGFR, meanwhile AngII-treatment 
promotes BMX dissociation with both the AT1R and EGFR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.05: Kinetic analysis of ligand-driven recruitment of BMX to the AT1R  
(A) Schematic illustration of BMX-AT1R BRET-based assay.  AT1R fused to a BRET donor 
(Rluc8), is co-transfected with BMX tagged with a BRET acceptor (Venus). (B) HEK293 cells were 
co-transfected with Venus-BMX and AT1R-Rluc8 and stimulated with 10M AngII, 1M EGF or 
vehicle (indicated by arrow).   Data represent mean ± SEM of 3 independent experiments with 
triplicate measurements.   
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To examine the distribution and trafficking of BMX, we used a novel BRET localisation 
assay approach.  The use of validated Venus-tagged subcellular localisation markers enable 
us to monitor ligand-induced BMX trafficking in real-time and in live cells (as shown in 
Figure 6.06).  As predicted, AngII-stimulation led to a decreased BRET response between 
BMX and K-ras, a marker localised to the plasma membrane, indicative of BMX 
internalising away from the membrane.  Meanwhile EGF-treatment resulted in BMX 
trafficking to the plasma membrane (Figure 6.07).  Interestingly, relative to vehicle treated 
cells, AngII- or EGF-treated cells did not observe any significant BRET responses between 
BMX and the remaining subcellular compartments (Figure 6.07). 
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Figure 6.06: A simplified schematic representation of subcellular marker localisation 
and protein trafficking. 
Ligand-induced trafficking was monitored using an Rluc8-tagged protein of interest (BMX-Rluc8) 
and measuring its proximity to Venus-tagged cellular markers.  Extended BRET (eBRET) measures 
BMX interaction with plasma membrane marker, Venus-K-ras, or the subcellular compartment 
marker Rabs: early endosome (Venus-Rab5), early endosome recycling  (Venus-Rab4), recycling 
endosome (Venus-Rab11), late endosome/lysosomes (Venus-Rab7), late endosome trafficking to the 
trans-Golgi network (Venus-Rab9), endoplasmic reticulum trafficking to the cis-Golgi (Venus-Rab1), 
Golgi apparatus and trans-Golgi network (Venus-Rab6), trans-Golgi network to plasma membrane 
(Venus-Rab8).  
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Figure 6.07: Kinetic profiling of the trafficking properties of BMX 
(A-L) HEK293 cells were transiently transfected with Rluc8-BMX and Venus-tagged cellular markers (as per the title of each graph).  Cells were stimulated 
with 10M AngII, 1M EGF or vehicle.  Agonist stimulation is indicated by the arrow.   BRET measurements were taken using the CLARIOstar Microplate 
Reader (BMG LabTech). Data represents mean ± SEM of 4 independent experiments with triplicates within.  
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6.3.2 CHKAs involvement in AT1R-EGFR transactivation 
 
To determine if AT1R activation leads to CHKA relocation, I generated and transfected 
vectors containing an in-frame Venus molecule fused to the N- and C-terminus of CHKA: 
Venus-CHKA and CHKA-Venus, respectively.  Correct localisation of the Venus-tagged 
CHKA constructs were initially confirmed using confocal microscopy (Figure 6.08).  As a 
positive control, we observed rapid and sustained -arrestin2-GFP translocation to the plasma 
membrane following AngII-stimulation (Figure 6.08A-C). We next examined whether AngII-
stimulation also resulted in CHKA translocation.  In contrast, HEK293 cells expressing 
Venus-CHKA (Figure 6.08D,E) and CHKA-Venus (Figure 6.08F-H) and treated with AngII 
and did not display CHKA trafficking at 1 minute or 10 minute post agonist treatment. 
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Figure 6.08: CHKA Trafficking in response to AngII-stimulation 
(A-C) As a positive control, AT1R was transiently co-expressed with -arrestin2-GFP in HEK293 
cells.  (D, E) Venus-CHKA and (F-H) CHKA-Venus were transiently co-expressed with AT1R in 
HEK293 cells. All cells were stimulated with 100nM AngII at 37°C.  The distribution of -arrestin2-
GFP and Venus-tagged CHKA was visualised under confocal microscopy (A) prior to AngII-
stimulation, (B) 1 minute post AngII-stimulation and (C) 10 minutes post AngII-stimulation.  
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Through the use of co-immunoprecipitation assays, CHKA has previously been shown to 
form a complex with the EGFR kinase domain in a Src-dependent manner. To determine 
whether CHKA physically associates with EGFR, we tested if EGF-stimulation could 
mediate CHKA interaction with the EGFR, comparing both CHKA-Venus & Venus-CHKA 
interaction with EGFR-Rluc8 in HEK293 and COS cells. Various combinations of EGFR-
Rluc8 and tagged-CHKA were tested, however, no association between EGFR and CHKA 
was evident in HEK293 (Figure 6.09) and COS cells (Figure 6.10). 
Figure 6.09: Kinetic analysis of EGF-mediated recruitment of CHKA to the EGFR in 
HEK293 cells 
An increasing amount of EGFR-Rluc8, (A, E) 0.05g, (B, F) 0.15g, (C, G) 0.3g and (D, H) 0.6g 
were co-transfected with various amounts (0.15g, 0.3g, 0.6g and 0.9g) of (A-D) Venus-CHKA 
and (E-H) CHKA-Venus in HEK293 cells.  Cells were treated with 1M EGF or vehicle (indicated 
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by arrows).   BRET measurements were taken using the CLARIOstar Microplate Reader (BMG 
LabTech). Data represent mean ± SEM of 3 independent experiments with triplicate measurements.   
 
Figure 6.10: Kinetic analysis of EGF-mediated recruitment of CHKA to the EGFR in 
COS cells 
An increasing amount of EGFR-Rluc8, (A, E) 0.05g, (B, F) 0.15g, (C, G) 0.3g and (D, H) 0.6g 
were co-transfected with various amounts (0.15g, 0.3g, 0.6g and 0.9g) of (A-D) Venus-CHKA 
and (E-H) CHKA-Venus in COS cells.  Cells were treated with 1M EGF or vehicle (indicated by 
arrows).   BRET measurements were taken using the CLARIOstar Microplate Reader (BMG 
LabTech). Data represent mean ± SEM of 3 independent experiments with triplicate measurements.   
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Others have shown that either mutation or truncation of CHKA N-terminus has no significant 
impact on CHKA kinase activity; therefore all follow-up experiments were conducted with 
Venus-CHKA (Clem, Clem, Yalcin et al., 2011; Malito, Sekulic, Too et al., 2006).   Miyake 
& Parsons proposed that EGFR forms a complex with the cytosolic kinase c-Src, which 
recruits CHKA to the cell membrane (Miyake & Parsons, 2012). I recapitulated the above 
experiments with the addition of c-Src in a hope that c-Src is crucial for mediating the 
interaction of CHKA with the EGFR; this also showed no association (Figure 6.11).  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6.11: Kinetic analysis of EGF-mediated recruitment of CHKA to the EGFR with 
the addition of c-Src 
Increasing amounts of Venus-CHKA and c-Src were co-transfected with EGFR-Rluc8 in HEK293 
cells.  HEK293 cells were transfected with 0.15g of EGFR-Rluc8, alongside (A) 0.15g, (B) 0.3g, 
(C) 0.6g and (D) 0.9g of Venus-CHKA and increasing amounts of c-Src (as per the title of the top 
graph).  Cells were treated with 1M EGF or vehicle (indicated by arrows).   BRET measurements 
were taken using the CLARIOstar Microplate Reader (BMG LabTech). Data represent mean ± SEM 
of 2 independent experiments with triplicate measurements.  
1 2 3 4 5 6 7 8 9 10 11
-0.06
-0.04
-0.02
0.00
0.02
0.04
0.06
Time (minutes)L
ig
a
n
d
-i
n
d
u
c
e
d
 
B
R
E
T
 R
a
ti
o
100ng c-src
200ng c-src
400ng c-src
700ng c-src
1 2 3 4 5 6 7 8 9 10 11
-0.06
-0.04
-0.02
0.00
0.02
0.04
0.06
Time (minutes)L
ig
a
n
d
-i
n
d
u
c
e
d
 
B
R
E
T
 R
a
ti
o
1 2 3 4 5 6 7 8 9 10 11
-0.06
-0.04
-0.02
0.00
0.02
0.04
0.06
Time (minutes)L
ig
a
n
d
-i
n
d
u
c
e
d
 
B
R
E
T
 R
a
ti
o
1 2 3 4 5 6 7 8 9 10 11
-0.06
-0.04
-0.02
0.00
0.02
0.04
0.06
Time (minutes)L
ig
a
n
d
-i
n
d
u
c
e
d
 
B
R
E
T
 R
a
ti
o
A
B
C
D
0
.1
5
m
g
 V
e
n
u
s-
C
H
K
A
0
.3
0
m
g
 V
e
n
u
s-
C
H
K
A
0
.6
0
m
g
 V
e
n
u
s-
C
H
K
A
0
.9
0
m
g
 V
e
n
u
s-
C
H
K
A
 
Chapter Six: The role of BMX, CHKA & TRIO in AT1R-EGFR Transactivation 
 
 147 
CHKAs active enzyme consists of dimers or tetramers, and one confounder may be that the 
presence of a Venus-tag may interfere with activity. One final consideration was to transfect 
Venus-CHKA alongside CHKA with no additional tags (pcDNA3-CHKA). The addition of 
pcDNA3-CHKA was presumed to allow for CHKA-Venus to dimerise and form active 
dimers.  This experiment also showed no increase in BRET ratio between Venus-CHKA and 
EGFR-Rluc8 following EGF-stimulation (Figure 6.12).  As a final test, CHKA activity was 
confirmed directly using an in vitro CHKA activity assay.  
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Figure 6.12: Kinetic analysis of fluorescently tagged CHKA and its interaction with 
EGFR with the addition of untagged-CHKA 
EGFR-Rluc8 was transiently transfected into HEK293 cells alongside increasing amounts of Venus-
CHKA and untagged-CHKA.  HEK293 cells expressing 0.15g EGFR-Rluc8, (A) 0.05g Venus-
CHKA, (B) 0.2g Venus-CHKA, (C) 0.4g Venus-CHKA and (D) 0.6g Venus-CHKA alongside 
increasing amounts of untagged-CHKA (as per the title of the top graph). Cells were treated with 
1M EGF or vehicle (indicated by arrows).   BRET measurements were taken using the CLARIOstar 
Microplate Reader (BMG LabTech). Data represent mean ± SEM of 2 independent experiments with 
triplicate measurements.   
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As shown in Figure 6.13, I tested whether the CHKA fusion constructs were enzymatically 
active.  Current methods for studying CHKA enzymatic activity involve labelling cells with 
radiolabelled choline and separating choline and phosphocholine (P-Choline) metabolites 
using thin layer chromatography (Figure 6.13).  As a positive control, cells were transfected 
with CHKA plasmid with no additional tags (pcDNA3-CHKA), and was able to produce P-
Choline (Figure 6.13).  I was unable to detect a P-Choline band for both Venus-tagged 
CHKA plasmids, suggestive that both CHKA-Venus and Venus-CHKA are kinase defective.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13: In vitro CHKA Activity Assay.  
(A) HEK293 cell were transfected with 1μg of CHKA, CHKA/Venus, Venus/CHKA, empty Venus 
plasmid and mock plasmid. 24hours following transfection, cells were labelled with methyl choline-
chloride carbon14 for 1hour. HEK293 cells were fixed, washed and resolved on thin layer 
chromatography plates. Choline & phosphocholine levels were imaged using a phosphorimager. A 
representative image of choline and phosphocholine levels showing CHKA plasmid with no 
additional tags was able to produce phosphocholine. (B) A representative image illustrating choline 
and phosphocholine bands. 
 A 
B 
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During my canditure, Asim et al., 2016 generated the first fluorescently labelled CHKA 
construct, mCherry-CHKA (Asim, Massie, Orafidiya et al., 2016). The authors kindly 
donated this construct, and I recapitulated previously performed experiments using 
NanoBRET.  Unfortunately, this also showed no EGFR-CHKA association following EGF-
stimulation (Figure 6.14).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14: Kinetic analysis of CHKA interaction with EGFR using a Nano-BRET 
approach 
Increasing amounts of EGFR-Nluc and mCherry-CHKA were co-transfected into HEK293 cells.  (A) 
0.05g, (B) 0.2g and (C) 0.4g of mCherry-CHKA were transiently transfected with increasing 
amounts of EGFR-Nluc (as per the title of the top graph). Cells were treated with 1M EGF or 
vehicle (indicated by arrows).   Data represent mean ± SEM of 2 independent experiments with 
triplicate measurements.   
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To better understand CHKA’s involvement in AT1R-EGFR cross-talk, increasing amounts of 
CHKA were transfected alongside EGFR/Rluc8, Grb2/Venus & AT1R. My hypothesis was 
that, if CHKA does play a role in transactivation, increasing the amount of the protein may be 
expected to enhance transactivation. The over-expression of CHKA increased the BRET ratio 
between EGFR/Rluc8 & Grb2/Venus following EGF-stimulation (Figure 6.15A and 6.15B) 
and AngII-stimulation (Figure 6.15C and 6.15D). Additionally, using endogenous levels of 
CHKA expressed in HEK293 cells, inhibition of CHKA with CK37 enhanced EGFR and 
Grb2 association following AngII-stimulation (Figure 6.15E and 6.15F).   
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Figure 6.15: CHKAs involvement in EGF- and AngII-induced Grb2 recruitment to the 
EGFR  
(A) HEK293 cells co-transfected with AT1R, EGFR/Rluc8 and Grb2/Venus in the presence of  
overexpressed CHKA or endogenous levels of CHKA (co-transfected with equal parts of mock 
plasmid) and treated with (A, B) 1M EGF, (C, D) 10M AngII or vehicle. Quantification of ligand-
induced BRET ratio (AUC) between EGFR-Rluc8 and Grb2-Venus with and without the addition of 
CHKA following (B) EGF-stimulation or (D) AngII-stimulation. (*p<0.05 vs. cells transfected with 
0ng CHKA)  (E) HEK293 cells co-transfected with AT1R, EGFR/Rluc8 and Grb2/Venus were 
treated with CK37 (CHKA inhibitor) for 30 minutes prior to stimulation with AngII or vehicle.  (F) 
Quantification of ligand-induced BRET ratio (AUC) between EGFR-Rluc8 and Grb2-Venus 
following AngII-treatment and in the presence CK37. *p<0.05 vs. AngII treated cells.  Agonist 
stimulation is indicated by arrows.  Data represents mean ± SEM of 3 independent experiments. 
Statistical analysis by a one-way ANOVA with a Dunnett’s post-test for multiple comparisons;   
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6.4 Discussion 
 
Using a cellular model of human AT1R-EGFR transactivation, the Thomas laboratory has 
previously performed a functional siRNA screen of the human kinome in an attempt to 
interrogate AT1R transactivation of the EGFR.  The screen identified a suite of genes that 
have been previously established to regulate AT1R-EGFR transactivation, in addition to 
others that have not been previously implicated (including BMX, CHKA and TRIO).  In 
summary, individual knockdown of each molecule attenuated tyrosine phosphorylation of the 
EGFR following AngII-stimulation, and was shown to function downstream of the AT1R.  
Although they have not been previously linked with AT1R-EGFR cross-talk, previous 
literature has provided clues as to how they might be associated.  Therefore, it was of great 
interest to further interrogate the molecular basis for the requirement for BMX, CHKA and 
TRIO in AT1R-EGFR transactivation.   
Although BMX has not been directly implicated in AT1R-EGFR transactivation, BMX can be 
activated by a number of cell surface receptors, namely the IGF receptor and the vascular 
endothelial growth factor receptor (VEGFR) (Chen, Jiang, Gewinner et al., 2013; Zhang, Xu, 
Ekman et al., 2003).  To confirm whether BMX directly binds with the EGFR, we used a 
BRET-based assay that quantitatively measures BMX recruitment to the EGFR.  Following 
EGF-treatment, BMX translocation and direct association with the EGFR was readily 
demonstrable.  This is consistent with previous studies, with co-immunoprecipitation studies 
showing that EGF-treatment results in BMX tyrosine phosphorylation and a marked increase 
in BMX-EGFR association (Jiang, Borgesi, McKnight et al., 2007). Complementary to our 
studies, others have shown that following EGF-treatment, BMX translocates to the 
membrane, where its kinase activity is activated by Src kinase (Chen, Huang, Kung et al., 
2004). In fact, the activation of Btk family kinases by direct phosphorylation by Src family 
kinases has been well documented (Chen, Kim, Li et al., 2001; Rawlings, Scharenberg, Park 
et al., 1996; Tsai, Su, Fang et al., 2000). Signalling molecules that bear phosphotyrosine- and 
proline-rich domains disrupt the intramolecular interaction of the BMX protein, leading to 
unfolding of the kinase domain and exposing BMX potential phosphotyrosine sites (Qiu, 
Robinson, Pretlow et al., 1998; Semaan, Alsaleh, Gottenberg et al., 2008). Future 
experiments include the use of pharmacological inhibitors that target Src, EGFR tyrosine 
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domain and Ca2+ to better understand the molecular requirements that drive BMX-EGFR 
association. Additionally, it is still unknown the exact EGFR residues and/or receptor 
domains that recruit BMX following EGF-stimulation.  Part of ongoing studies is to better 
define BMX mechanism through the use of a kinase defective BMX (K455M) in combination 
with mutant forms of the EGFR whereby key receptor tyrosine residues are individually 
mutated.   
 
BMX-EGFR association was further enhanced in cells co-expressing AT1R.  We were able to 
show that this enhanced BMX-EGFR association, was partially dependent on Gq coupling as 
well as AT1R phosphorylation and arrestin recruitment.  Based on the above observations, we 
next tested BMX-EGFR association following AngII-treatment.  Interestingly, we observed a 
decreased EGFR-BMX BRET response following AngII-treatment.  A final consideration 
was to profile BMX distribution and trafficking through multiple subcellular compartments.  
Following EGF-treatment, we noted a robust recruitment of BMX to the plasma membrane, 
and as predicted, a dissociation following AngII-treatment.  Interestingly, we did not detect 
ligand-induced changes in proximity for the remaining cellular markers.     
 
Given that BMX-EGFR disassociated following AngII stimulation, it was compelling to test 
BMX association with AT1R. Similarly to BMX disassociation with the membrane marker K-
ras, a dramatic decrease in BMX-AT1R association was observed following AngII-
stimulation.  BMX, via its PH domain, has been found to bind to the thrombin activated 
GPCR, PAR1, and this association drives Shc recruitment and oncogenic activity (Cohen, 
Maoz, Turm et al., 2010).  Given that BMX is predominantly a cytosolic protein, this 
suggests that BMX would first have to translocate to the plasma membrane, maybe a small 
percentage is only required at the cellular membrane. Others have also reported that G 
proteins directly bind to BMX, and this interaction is important for BMX activation (Bence, 
Ma, Kozasa et al., 1997; Ma & Huang, 1998; Mao, Xie, Yuan et al., 1998; Tsukada, Simon, 
Witte et al., 1994).  Our data suggests that the AT1R and BMX exist as a preformed complex 
at the membrane. Part of ongoing studies is the use of BiFC (as outlined in Chapter 4.0), a 
fluorescence-based approach that enables direct visualisation of protein interactions in living 
cells.  Tagging BMX and AT1R with two complementary non-fluorescent YFP fragments 
will allow for YFP to reform its native three-dimensional structure and emit fluorescent 
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signal if BMX and AT1R exist as a complex.  We predict this association will occur at the 
plasma membrane and may involve AT1R coupling to Gq/11. 
It remains undetermined why BMX dissociates from the EGFR following AngII-treatment.  
Mechanistically, it would seem logical for BMX to associate with EGFR following AngII 
stimulation.  The PH-domain of BMX has been shown to interact with various protein 
partners and it is thought to spatially regulate BMX interactions. It could be speculated that 
BMX can modulate both GPCR and RTK function by acting as a signalling scaffold that 
allows for the recruitment of other binding partners and effector proteins, or as a second 
messenger that modulates downstream signalling activities. As part of their signalling 
repertoire, AT1R and EGFR regulates BMX activation and trafficking contrarily, however 
how this influences AT1R-EGFR transactivation remains unknown. 
A number of papers have highlighted BMX relevance and role in the cardiovascular system.  
BMX is highly expressed in the endothelium and endocardium of mouse embryo’s large 
arteries (Rajantie, Ekman, Iljin et al., 2001).  Genetic ablation of BMX does not result in any 
obvious developmental phenotype in mice, however has been implicated a variety of 
pathological states, including inflammatory angiogenesis, pressure overload-induced 
hypertrophic growth and arteriogensis (Holopainen, Rasanen, Anisimov et al., 2015; 
Mitchell-Jordan, Holopainen, Ren et al., 2008; Paavonen, Ekman, Wirzenius et al., 2004; 
Zhang, Xu, Ekman et al., 2003).  During my canditure, Holopainen et al., 2015 showed that 
BMX inactivation, and/or mice deficient of BMX, attenuates the development of AngII-
induced cardiac hypertrophy (Holopainen, Rasanen, Anisimov et al., 2015).  All preliminary 
data has been conducted in HEK293 cells, and we are aware that interpolation to other cell 
types must be performed with caution.  Having already demonstrated BRET-based assays in 
VSMC, we hope to recapitulate any major findings in primary cells.   
Having focused on BMX, I next interrogated CHKAs potential role in EGFR transactivation.  
Due to recent findings, much effort is being invested into the molecular mechanisms by 
which CHKA and associated metabolites contribute to the cholinic phenotype in cancer state.  
The overexpression of CHKA and increased activity in cancer state renders it a very 
attractive therapeutic, with CHKA inhibitors showing antitumoral and antiproliferative 
activity (Al-Saffar, Troy, Ramirez de Molina et al., 2006; Granata, Nicoletti, Tinaglia et al., 
2014; Lacal, 1999; Rodriguez-Gonzalez, de Molina, Fernandez et al., 2004).  A variety of 
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novel cancer drugs have been generated showing promising results in pre-clinical trials 
(Lacal & Campos, 2015) with a CHKA inhibitor, TCD-717, approved to enter first stage 
clinical trials (de la Cueva, Ramirez de Molina, Alvarez-Ayerza et al., 2013).  Although 
CHKA has not been directly implicated in the transactivation process, the Thomas Lab has 
proposed a mechanistic model that incorporates recent key findings from the literature 
(Figure 6.16).  It has been shown that CHKA forms a complex with the EGFR kinase domain 
in a Src dependent manner (Miyake & Parsons, 2012). More recently, confocal-based 
immunofluorescence imaging has revealed evidence of membrane co-localisation between 
EGFR and CHKA (Lin, Hu, Gu et al., 2017), with CHKA-EGFR association shown to 
enhance following EGF-stimulation (Miyake & Parsons, 2012).  It is proposed that CHKA 
subsequently converts choline to phosphocholine, contributing to a local increase of PtdCho 
immediately surrounding the complex. PLD is recruited to the EGFR and hydrolyses PtdCho, 
generating PA and choline. The negatively charged PA has been show to be a critical 
upstream regulator of Ras signalling through its interaction with the PH domain of Sos and 
initiating Ras-triggered mitogenic signalling pathway (Zhang & Du, 2009; Zhao, Du, 
Skowronek et al., 2007).  
Figure 6.16: CHKAs proposed involvement in AT1R-EGFR transactivation. 
Following AngII-stimulation, through the aid of second messengers, EGFR is activated and initiates 
the formation of the Src/EGFR/CHKA complex. CHKA subsequently produces a local phosphatidic 
acid pool surrounding the EGFR, triggering the mitogenic signalling pathway. 
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To validate the proposed model of CHKA action, a BRET-based assay was employed to 
determine if CHKA interacts with the EGFR, or alternatively, with the AT1R.  In accordance 
with previous studies, we initially aimed to determine whether stimulation of the EGFR could 
promote CHKA translocation and interaction with the EGFR in a ligand-dependent manner.  
In our hands, we were unable to observe an increased association between CHKA and EGFR 
in both HEK293 and COS cells. However, a major caveat of BRET is that it cannot readily 
distinguish between conformational rearrangements within a protein complex or proteins 
association/dissociation. The use of a BRET-based approach may not be able to capture a 
pre-formed EGFR-CHKA complex, or able to report an increased association/rearrangement 
between EGFR and CHKA following EGF-stimulation.  
Furthermore, it cannot be decisively said whether the addition of the Venus tag rendered 
CHKA inactive. A limitation of BRET is the addition of the Venus-tag can interfere with 
proteins functionality. CHKAs active enzyme consists of dimers (homo- or hetero-dimers) or 
as tetramers.  Both the N-terminal region, as well as the N-terminus proximity to the C-
terminal region, is necessary for the formation of homo- or hetero-dimer complexes 
(Aoyama, Liao & Ishidate, 2004; Malito, Sekulic, Too et al., 2006). Due to the steric 
involvement of sequences close to the C- and N-terminal sites in formation of catalytic 
cavities, the addition of the Venus tag may prevent accurate protein folding and/or the 
formation of active CHKA.  To date, two separate groups have published a fluorescently 
tagged CHKA, one of which I tested.  Unfortunately, both studies did not report if the 
addition of a fluorescent tag interfered with CHKA kinase activity (Lin, Hu, Gu et al., 2017; 
Miyake & Parsons, 2012).    Although the use of BRET1 appears to be an insufficient 
approach to monitor CHKA’s potential interactions, the development of techniques that use 
much smaller tags, namely nanoBRET and FlAsH, may overcome this issue and should be 
considered for future experiments.  Although other groups have reported the existence of 
CHKA-EGFR complexes (Lin, Hu, Gu et al., 2017; Miyake & Parsons, 2012), it must be 
considered that transactivation may not involve CHKA’s direct association with EGFR. 
 
We were able to demonstrate that the addition of CHKA does enhance both AngII- and EGF-
mediated Grb2 recruitment to the EGFR.  Although this ‘over-expression experiment’ does 
not give any further insight into CHKA’s involvement mechanistically, it is reassuring that 
CHKA does influence AngII-mediated transactivation.  Interestingly, we report that pre-
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treatment with a small molecule inhibitor of CHKA, CK37 produced a sustained Grb2 
association with the EGFR following AngII-stimulation.  Interestingly, siRNA knockdown of 
CHKA blunted ERK1/2 phosphorylation following AngII-treatment, an observation that 
needs reconciling.     
CHKA catalytic properties are critical for cell growth and survival, with a variety of studies 
showing that a depletion of CHKA protein (i.e., siRNA and shRNA techniques) reduce 
intracellular phosphocholine levels and a decrease in cell viability (Bañez-Coronel, de 
Molina, Rodríguez-González et al., 2008; Clem, Clem, Yalcin et al., 2011; Mori, Glunde, 
Takagi et al., 2007).  However, CHKA has also been shown to associate with other oncogenic 
proteins and can act as a molecular chaperone, raising the possibility that CHKAs protein 
itself, rather than it catalytic function, may be crucial for cell survival and growth (Asim, 
Massie, Orafidiya et al., 2016; Rauch, Volinsky, Romano et al., 2011).  In an attempt to 
differentiate CHKAs catalytic and non-catalytic role in cancer cell survival, Falcon and 
colleagues compared siRNA-targeted deletion of CHKA to selective inhibition of CHKA 
(Falcon, Hudson, Huang et al., 2013).  They observed marked difference in cell phenotype 
using siRNA-induced knockdown of CHKA compared to selective inhibition of CHKA 
catalytic activity.  This non-catalytic ‘scaffolding-role’ of CHKA may explain this 
discrepancy in CHKAs relative role in EGFR transactivation, and warrants further study.   
6.5 Summary 
 
Given the accumulating literature linking GPCR-EGFR transactivation to tissue remodelling 
and disease state, a broader mechanistic picture of the underlying biology is required. The 
development of an unbiased functional siRNA screen identified three novel proteins that had 
not been previously implicated in EGFR transactivation. The next generation of RAS/AT1R 
/AngII modifying agents will provide increased fidelity by targeting unique and specific 
molecules and pathways (in contrast to merely blocking the receptor in toto). Interrogating 
the mechanism by which these novel proteins are involved will provide new insights into this 
process and may represent a superior target for future drug development.   
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7.0 General Discussion 
 
The capacity of GPCRs to “transactivate” growth factor receptors has been an exemplar of 
receptor crosstalk since the initial observation by Axel Ullrich over 20 years ago (Daub, 
Weiss, Wallasch et al., 1996). This paradigm of crosstalk has been confirmed for a range of 
GPCRs, including the AT1R, where transactivation of the EGFR has been associated with 
cellular growth, remodelling, and apoptosis in the heart, kidney, and blood vessels as well as 
cancerous cell growth (Chan, Jenkins, Pipolo et al., 2006; Chen, Chen, Neilson et al., 2006; 
Greco, Muscella, Elia et al., 2003; Itabashi, Maesawa, Oikawa et al., 2008; Lin & Freeman, 
2003; Ohtsu, Higuchi, Shirai et al., 2008; Thomas, 2001).  Various models have been evoked 
to explain GPCR-EGFR transactivation – Ullrich and colleagues proposed the TMPS model, 
whereby activated GPCRs stimulate MMPs and ADAMs to cleave inactive membrane-bound 
EGF ligands to stimulate the EGFR. While there has been general acceptance of the TMPS 
model, the exact MMP/ADAM/EGF ligand/EGFR engaged by a given GPCR in a specific 
tissue/cell, in a particular context, has been challenging to ascertain unambiguously. 
Moreover, alternative mechanism for EGFR transactivation exists, which may involve non-
receptor tyrosine kinases (Pyk2 and Src, as well as BMX, CHKA and TRIO), additional 
second messengers (Ca2+, PKC, ROS) and arrestins. Many research groups, including our 
own, have focused on defining the mechanism of GPCR-EGFR transactivation in various 
cells/tissues, but despite a tremendous amount of work and publications, it would be fair to 
conclude that the field has stalled in a mechanistic sense.   
 
To address this knowledge gap, we rationalised that there was a need to develop new 
approaches/technologies that could better define the molecular, temporal and spatial aspects 
of AT1R-EGFR transactivation, while also interrogating the relative contribution of gene(s) 
modulating this process. One major factor was that endpoint readouts of EGFR 
transactivation signalling are often downstream of highly amplified and integrated signal 
transduction pathways (i.e. ERK1/2).  Although the activation of ERK1/2 appears to be a 
critical component in eliciting mitogenic responses, a single readout of ERK1/2 almost 
certainly does not always reflect only EGFR transactivation.  We reasoned that a more robust 
and direct readout would be the activation and autophosphorylation of the EGFR, the 
convergence point for many growth regulatory signals, including that of transactivation.  A 
Chapter Seven: General Discussion 
162 
number of groups have measured EGFR phosphorylation (particularly phosphotyrosine 
residues Tyr1068 and Tyr1173) as readouts of EGFR transactivation (Ohtsu, Higuchi, Shirai 
et al., 2008; Shah, Farshori & Catt, 2004; Shah, Farshori, Jambusaria et al., 2003), however 
this end-point assay can be laborious, insensitive and challenging. 
 
In recent years, a number of new technologies have been developed that overcome the 
inadequacies associated with current readouts of EGFR transactivation.  Advancements in 
biophysical methods (these include BRET and FRET techniques) have allowed for live cell 
proximity detection and have been instrumental in determining the functional organisation 
and compartmentalisation of receptors and proteins of interest (Johnstone & Pfleger, 2012; 
Kocan, See, Seeber et al., 2008; White, Vanyai, See et al., 2017).   My current study is the 
first to explore the application of BRET technology, specifically the recruitment of Grb2 to 
the EGFR, to quantitatively monitor, in living cells and real-time, the proximal activation of 
EGFR. Grb2 binds directly to phosphotyrosine residues (Tyr1068 and Tyr1086) or forms a 
multiprotein complex at phosphotyrosine residues Tyr1045, Tyr1148 and Tyr1173 (Capuani, 
Conte, Argenzio et al., 2015; Schlessinger, 2000; Wu, Wee, Jiang et al., 2012) (Figure 7.01).  
Given that Grb2 recruitment links directly EGFR tyrosine kinase to the downstream 
activation of the Ras/Raf/ERK1/2 cascade, it seemed sensible to monitor EGFR-Grb2 
recruitment as the most primal readout of EGFR transactivation.   I was able to demonstrate 
that both EGF- and AngII-stimulation resulted in the recruitment of Grb2 to the EGFR and 
this could be recapitulated in a variety of immortalised and primary cell lines, validating the 
versatility of this BRET-based approach.   
 
The BRET assay was then used to screen a panel of 19 GPCRs and their capacity to recruit 
Grb2 to the EGFR.  Of the 19 GPCRs tested, the V1bR and AT1R showed consistent EGFR 
transactivation.  Initially, this observation was concerning, as a number of these ‘non-
transactivating’ GPCRs have been shown to mediate AG1478-preventable ERK1/2 
phosphorylation.  As highlighted in the discussion of Chapter 4.0, these ‘non-transactivating’ 
GPCRs were tested to be functional.  As part of their biology, these ‘non-transactivating’ 
GPCR may not be recruiting Grb2 as part of their activation process, instead activating 
alternative effector molecules (as shown in Figure 7.01). 
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As illustrated in Figure 7.01, upon EGFR activation, the EGFR can bind directly to a number 
of adaptor molecules and effector proteins, regulating the activation of specific downstream 
pathway.  These ‘non-transactivating’ GPCRs may not engage EGFR-Grb2 association and 
instead promote EGFR activation with alternative effector molecules.  Understanding the 
details of this biased signalling requires a multifaceted approach that can simultaneously 
monitor the direct binding of a wide range of effector proteins to the EGFR.  In a recent 
study, Schiffer and colleagues applied BRET technology to study the interaction of the EGFR 
with a number of effector proteins, namely Grb2, Shc42 (known activators of the MAPK 
proliferation pathway), p85 (activates PI3k-Akt survival pathway), PLC1 (activates 
PKC/Ca2+ signalling pathway) and STAT5a (activator of transcription pathways) (Tan, 
Wang, Littler et al., 2007). Such an approach not only measures the most proximal events in 
receptor activation, but also has the potential to compare a wide range of GPCRs and their 
effects on multiple EGFR effector-specific signalling pathways (Siddiqui, Cong, Daimon et 
al., 2013; Tan, Wang, Littler et al., 2007).   
 
Tan et al., 2007 also applied this technology to screen nine additional RTK members, 
including HER4, highlighting that this technology can be further adapted for additional RTKs.   
Similarly, I compared the recruitment of Grb2 to additional members of the EGFR family of 
growth factor receptors.  Our data demonstrates that the AT1R is able to transactivate HER2 
(the preferred dimerisation partner for other EGFR family members), and raises the possibility 
that the other receptor homologs (HER2, HER3 and HER4), and or combinations of dimers 
between these receptors, are selectively used by GPCRs.  As already mentioned in Chapter 
4.0, the classical view that EGFR monomers form activated dimers following EGF ligand 
binding has been replaced by more sophisticated models suggesting that dimerisation can 
occur in the absence of ligand (Fortian & Sorkin, 2014; Kozer, Barua, Henderson et al., 2014; 
Kozer, Barua, Orchard et al., 2013; Pinilla-Macua, Watkins & Sorkin, 2016).    The use of a 
BRET-based assays that can report on effector-specific RTK activity offers the opportunity to 
not only catalogue GPCR multifaceted processes but also provides information to examine the 
relative contribution of HER receptor homologs in the transactivation process. 
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Figure 7.01: The recruitment of adaptor molecules to major EGFR tyrosine 
phosphorylation sites. 
 (A) The EGFR exists as monomers at the plasma membrane.  Ligand binding to the extracellular 
region results in (B) ligand-induced receptor dimerisation (C) and the phosphorylation of distinct 
tyrosine as well as serine/threonine resides, acting as docking sites for a number of effector proteins. 
T: threonine residue, S: serine residue, white coloured P: phosphorylation sites, red coloured P: 
phosphorylation sites that bind Grb2.  Figure adapted from Huang and Chang (Huang & Chang, 2011). 
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With these unique tools on offer, it is important to identify novel candidates that can precisely 
discriminate between individual signalling pathways.  Of course, this reasoning lead to the 
development of the functional siRNA screen that identified three novel genes: BMX, CHKA 
and TRIO (George, Purdue, Gould et al., 2013).  Accordingly, the first major undertaking of 
my project was to investigate the potential involvement of these novel proteins in controlling 
AngII-mediated EGFR transactivation.  Given the anti-tumour effects of CHKA inhibitors 
(Challapalli, Trousil, Hazell et al., 2015; Granata, Nicoletti, Tinaglia et al., 2014; Lacal & 
Campos, 2015), and its reported association with the EGFR (Lin, Hu, Gu et al., 2017; Miyake 
& Parsons, 2012), my first priority was better understating CHKAs involvement in EGFR 
transactivation.  Disappointingly, preliminary studies indicated that the addition of the BRET 
tags renders CHKA inactive and I was unable to use BRET to detect an association with the 
EGFR.  
 
BMX, however, was shown to interact with the EGFR following EGF-stimulation, with this 
association further enhanced in cells co-expressing AT1R.  This association was partially 
dependent upon Gq coupling as well as AT1R phosphorylation and arrestin recruitment.  
Interestingly, upon AngII-treatment, EGFR-BMX de-associated, with a similar observation 
observed when testing AT1R-BMX interaction, It will be imperative to examine the 
contribution of BMX in additional relevant models of AT1R-EGFR transactivation, 
predominantly in cardiac and vasculature systems.  Although further experiments are required 
to better understand BMX function, it certainly supports the idea that BMX is a genuine 
mediator of transactivation (George, Purdue, Gould et al., 2013).  
 
 
Despite the technical limitations associated with CHKA, this study offers new biology into the 
process of AT1R-EGFR transactivation, and may provide new therapeutic strategies to combat 
cardiovascular hypertrophy and dysfunction.  Indeed, new molecules that target various 
components of the RAS have been described recently (ACE2 activators (Ferreira, Shenoy, Qi 
et al., 2011; Prada, Ferreira, Katovich et al., 2008), Ang1-7 peptide and non-peptide analogs 
(Cunha, Lima, Silva et al., 2013; Savergnini, Beiman, Lautner et al., 2010)).  The next 
generation of RAS modifying agents will provide increased fidelity and efficacy by targeting 
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specific molecules (i.e., BMX, CHKA or TRIO) in contrast to blocking the RAS or AT1R 
completely.   
 
A major observation of my thesis was that AT1R-EGFR transactivation, as measured by Grb2 
recruitment, was independent of Gq/11 and -arrestins, which was not expected (especially 
given our previous work (Smith, Chan, Qian et al., 2011; Thomas, Brandenburger, Autelitano 
et al., 2002). To date, most studies of EGFR transactivation have used various inhibitors 
and/or antagonists to better understand the signalling pathways that underlie AT1R-EGFR 
transactivation. The rapid development of genome editing, based largely on CRISPR/Cas9 
technology, provides a powerful platform to eliminate the expression of protein(s) and explore 
downstream signalling consequences.  During my canditure, Grundmann et al., 2018 used 
CRISPR/Cas9 technology to systematically dissect G protein- from arrestin-driven ERK1/2 
phosphorylation for a broad set of GPCRs (Grundmann, Merten, Malfacini et al., 2018).  In 
concert with our studies, they show that arrestins do not initiate AT1R-mediated ERK1/2 
signalling, instead emphasising the vital role of G proteins as genuine drivers of GPCR-
mediated signal transduction.  Although this paper may seem to contradict my conclusion (by 
clearly illustrating the importance of G protein signalling), an obvious discrepancy is the 
readout used to measure GPCR signal transduction.  Through the use of pharmacological 
inhibitors, mutant forms of the AT1R and CRISPR HEK293 cells depleted of Gq/11 and -
arrestins, I clearly demonstrate that AT1R-EGFR transactivation as measured by Grb2 
recruitment, is not Gq/11 mediated.  In support of this observation, other groups have shown 
that GPCR-induced ectodomain shedding is predominantly a G12/13 or Gq mediated event, 
raising the possibility that other G family member and/or G subunits may be involved 
(Inoue, Ishiguro, Kitamura et al., 2012).     
 
A final factor in considering AT1R-EGFR transactivation was the existence of AT1R-EGFR 
heterodimers.  The use of BiFC and Receptor-HIT assays provided evidence that the AT1R 
and EGFR exist as constitutive preformed complexes that are responsive to agonist 
stimulation.  The development of RET-based assays has been especially popular methods to 
demonstrate the existence of receptor oligomers.  Criticism has been raised regarding the use 
of these approaches, suggesting that random proximity can generate easily detectable RET 
signals between proteins that are restricted to the cellular membrane (Bouvier & Hébert, 2014; 
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Felce, Latty, Knox et al., 2017; Lambert & Javitch, 2014).  I would argue that AT1R-EGFR 
heteromers are unlikely to merely reflect chance co-localisation at the membrane and/or 
endosome because the association of the EGFR with a membrane marker, K-ras, was 
decreased following EGF-stimulation, but not with AngII-stimulation. Modulation of EGFR 
trafficking differed depending on whether it was modulated by activation of the AT1R or 
direct activation of the EGFR, emphasising that the BRET signal (whether it be Receptor-HIT 
or direct tagging of the AT1R or EGFR) was not due to chance localisation.   
 
As already mentioned in Chapter 4.0, the existence of AT1R-EGFR heteromers is consistent 
with previous data (Olivares-Reyes, Shah, Hernandez-Aranda et al., 2005), with a number of 
GPCRs shown to complex with the EGFR (Jensen, Godfrey, Niklas et al., 2013; Maudsley, 
Pierce, Zamah et al., 2000; Tilley, Kim, Patel et al., 2009; Zajac, Law, Cvetkovic et al., 
2011).  Although we show that modulation of AT1R-EGFR heteromerisation differed 
depending on whether the complex was modulated by activation of the AT1R or the EGFR, it 
is still unknown how this interaction effects downstream signalling of each receptor, or the 
mechanisms/binding domains that facilitate their interaction.  To understand the functional 
significance of AT1R-EGFR heterodimers requires the identification of heterodimer selective 
ligands or the development of molecular strategies that selectively disrupt AT1R-EGFR 
complexes.  Early studies have shown that peptides corresponding to GPCR transmembrane 
domains target protein-protein interaction interfaces and interfere with GPCR dimerisation 
(Hebert, Moffett, Morello et al., 1996; Jastrzebska, Chen, Orban et al., 2015), meanwhile 
antibodies have been described that sterically block EGFR domain rearrangement and 
receptor dimerisation (Li, Schmitz, Jeffrey et al., 2005; Schmiedel, Blaukat, Li et al., 2008; 
Yang, Yang, Pike et al., 2010), however neither approaches have been explored in the context 
of preventing GPCR-RTK dimers. 
 
The spatial distribution of receptors following their activation is a critical determinant of 
downstream signal propagation. The development of single-molecular microscopy methods 
has allowed for the direct visualisation of individual membrane proteins and has provided the 
means to investigate the spatiotemporal organisation of receptors. Single molecule 
measurements have shown that receptor activation leads to the compartmentalisation of 
receptors with cytosolic effector and adaptor molecules, leading to higher-order signalling 
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clusters (Wu, 2013; Yu, 2016). Indeed, studies have revealed that GPCRs and G proteins 
transiently interact with each other and form dynamic signalling nanodomains or ‘hot spots’ at 
the plasma membrane (Sungkaworn, Jobin, Burnecki et al., 2017).  In the case of RTKs, EGF 
stimulation significantly reduces EGFR mobility in a kinase-dependent manner, consistent 
with the formation of signalling clusters (Chung, Akita, Vandlen et al., 2010; Low-Nam, 
Lidke, Cutler et al., 2011).  In concordance with earlier studies (Didion, 2016; Olivares-
Reyes, Shah, Hernandez-Aranda et al., 2005), a common theme that has emerged from single-
molecule studies is that the structural components of the plasma membrane play an important 
role in regulating receptor interaction.   
 
Live-cell, single-molecule studies have also challenged the classical view that GPCR 
signalling occurs exclusively at the cellular membrane (or the endosomal membrane in the 
case of -arrestin-dependent activation of MAPK), having demonstrated that GPCRs can 
signal at Golgi/trans-Golgi network (Calebiro, Nikolaev, Gagliani et al., 2009; Ferrandon, 
Feinstein, Castro et al., 2009; Irannejad, Tomshine, Tomshine et al., 2013).  Internalised 
thyroid stimulating hormone receptor (TSHR) trafficks retrogradely to the trans-Golgi 
network, where it activates endogenous Gs-protein, leading to late phase cAMP/PKA 
activation and gene transcription (Godbole, Lyga, Lohse et al., 2017). This newly discovered 
modality of intracellular GPCR signalling might be particularly relevant for AT1R-EGFR 
transactivation.  Future studies are required to not only further investigate the nature, size and 
composition of AT1R-EGFR complexes but whether these complexes also form at 
intracellular sites.   
 
While most of this thesis focused on information flowing from the AT1R to the EGFR, a 
control experiment revealed an unanticipated observation, whereby EGF-mediated Ca2+ 
signalling was dependent on a component emanating from the AT1R and its capacity to 
couple to G proteins, representing the first overt example of what we describe as ‘reverse 
transactivation’.  Using a BRET-based approach, I demonstrate that EGF-stimulation 
activates pathways downstream of the AT1R, whereby EGFR activation can mediate -
arrestin recruitment to the activated and phosphorylated AT1R. Using AT1R conformation-
sensitive biosensors, I observed that EGF-stimulation promoted conformational changes that 
were distinct from those produced by AngII. This difference was also reflected in the fact that 
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in contrast to AngII, which causes a rapid internalisation of the AT1R from the cell surface to 
endosomes, EGF-stimulation lead to a retention of the AT1R at the plasma membrane. A 
recent study that examined AT1R heterologous phosphorylation and arrestin recruitment, also 
provided evidence that EGF stimulation promotes -arrestin2 binding to the AT1R in a PKC-
dependent manner (Tóth, Prokop, Gyombolai et al., 2018). Although this study did not 
directly focus on this observation, they suggest a mechanism whereby arrestin recruitment 
does not require the activate state of the receptor.  Given that the significant proportion of the 
EGF signalling is blocked by candesartan, we would argue the possibility exists that the 
EGFR can directly activate the AT1R.   
 
How this novel transactivation process occurs (a RTK can transactivate a GPCR) remains an 
open question.  As already mentioned in Chapter 5.0, some groups have suggested that RTK-
induced GPCR transactivation is mediated exclusively through intracellular signalling, while 
others have proposed that growth factor receptors trigger the release of GPCR ligands (El-
Shewy, Johnson, Lee et al., 2006; Hobson, Rosenfeldt, Barak et al., 2001; Mira, Lacalle, 
González et al., 2001).  Interestingly, the formation of GPCR-RTK complexes is also thought 
to mediate cross-communication between both receptor systems (Akekawatchai, Holland, 
Kochetkova et al., 2005). This alternative route in RTK signalling is still in its infancy, with 
further research required to determine the exact mechanisms that allow for EGFR to 
influence AT1R activity.   
 
This new concept of GPCR activation may have important implications for the development 
of future therapeutics. The EGFR is a validated therapeutic target for a number of different 
cancers; however there is emerging evidence that the RAS may also be involved in the 
ontogeny of selective cancers (Li, Zhang, Zhao et al., 2017; Wegman-Ostrosky, Soto-Reyes, 
Vidal-Millán et al., 2015; Wen, Dunne, O’Reilly et al., 2017; Xu, Fan, Wu et al., 2017).  In 
1998, a retrospective study conducted by Lever and colleagues, showed a decreased risk of 
lung and breast cancer in patients taking ARBs and ACE inhibitors (Lever, Hole, Gillis et al., 
1998).  This seminal study was the first to implicate the RAS as a potential component of 
cancer progression.  Subsequent retrospective studies have been performed, however the 
results have been varied (Chae, Valsecchi, Kim et al., 2011; Christian, Lapane, Hume et al., 
2008; Collaboration, 2011; Fryzek, Poulsen, Lipworth et al., 2006; Li, Malone, Weiss et al., 
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2003; Wang, Liu, Chao et al., 2013).  The most conclusive evidence to date is a large scale 
Cancer Outline Profile Analysis of gene expression-profiling datasets that comprised of 
nearly 3,200 microarray experiments (Rhodes, Ateeq, Cao et al., 2009). One of the most 
consistently amplified genes was AGTR1, which was overexpressed approximately 100-fold 
higher in 10-20% of breast tumours.  Interestingly, AGTR1 over-expression was mutually 
exclusive with HER2 over-expression.  More recently, in vitro studies have shown that 
perturbation of various RAS components reduce the growth of many tumour cells including 
breast cancer cells (Coulson, Liew, Connelly et al., 2017), non-small cell lung cancer cells 
(Aydiner, Ciftci & Sen, 2015), pancreatic cancer cells (Reddy, Baskaran & Molteni, 1995) 
and gynaecologic cancer cells (Ino, Shibata, Yamamoto et al., 2011).  
 
While the use of therapeutics that targets the activities of EGFR and HER family members 
are commonplace for many cancers, resistance to these treatments remain a problem. One 
potential explanation is that some of the actions of the EGFR may necessitate the 
concomitant activation of the AT1R and may provide an alternative avenue by which cancer 
cells can signal.  Interestingly, it has been shown that the use of RAS blockers, particularly 
ARBs, significantly improves the overall survival of patients with metastatic non-small cell 
lung cancer (Aydiner, Ciftci & Sen, 2015).  In fact, the survival benefit of ARBs was most 
beneficial when used concurrently with erlotinib treatment (an EGFR tyrosine kinase 
inhibitor).    While these studies demonstrate the association of AT1R activity with 
malignancy, there has been very little progress made in better understanding the molecular 
mechanisms underlying this.  In this regard, identifying how the EGFR may activate the 
AT1R remains part of ongoing studies.  We are currently in collaboration with Professor 
Gregory Monteith to determine if EGFR signalling and motility, in a breast cancer cell line, is 
regulated by AT1R signalling.    
 
7.1 Summary 
In summary, in this thesis I report an alterative approach to monitoring AT1R-EGFR 
transactivation in live cells, which provides a more direct and proximal view of this process.  
Data presented here suggests that a re-evaluation of this paradigm might be required, 
providing evidence that AT1R-EGFR transactivation may be independent of Gq/11 and -
arrestin activity.  Instead, I demonstrate that both AngII- and EGF-stimulation promotes 
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AT1R-EGFR heteromerisation.  At present, it is difficult to reconcile whether this complex 
formation subserves transactivation. The existence of complexes may facilitate the novel 
concept of ‘reverse transactivation.’  I was able to demonstrate that EGFR actions may be 
mediated in part by the coincidental activation of the AT1R, an observation that may have 
ramifications for our understanding of these receptors and drugs that target them, in 
cardiovascular disease and cancer. 
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9.0 Appendices 
Appendix A: Solutions & Buffers 
 
LB Media (1L) 
10g  Bactotyrptone 
5g  Yeast 
10g  NaCl 
pH to 7.2-7.4 
+/- 15g Agar 
 
10x ADS Buffer 
68g    Sodium Chloride  
47.6g   HEPES (C8H18N2O4S)  
1.2g Sodium dihydrogen Orthophosphate (NaH2PO4) (1.37g NaH2PO4.H2O) 
10g  Glucose  
4g  Potassium Chloride  
1g  Magnesium Sulfide (MgSO4) OR (1.97g MgSO4.7H2O) 
900ml  UHP Water (Autoclaved) 
pH media to 7.35 +/- 0.05 using 1M Sodium Hydroxide (NaOH) 
 
1x ADS Buffer 
100mL  10x ADS Buffer 
900mL  UHP Water (Autoclaved) 
 
PBS 
1 packet Dulbecco Phosphate Buffered Saline 
1L  UHP Water (Autoclaved) 
 
4xTris-HCl/SDS (pH 6.8) 
0.125M  Tris-HCl 
0.1%   SDS 
4xTris-HCl/SDS (pH 8.8) 
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0.375M  Tris-HCl 
0.1%   SDS 
 
DMEM + 10% FBS 
1 packet  Dulbecco’s modified Eagle Media (containing high glucose, L-glutamine and 
sodium bicardbonate) (Invitrogen, 12100-038) 
50mL  FBS (heat inactivated) 
 
Enzyme Digest Buffer (EDB) 
110-140U/mL Collagenase II (Worthington Biochemical Corporation, 4176) 
0.8mg/mL Pancreatin (Sigma, P-3292) 
Variable Enough 1x ADS buffer to make a total of 300uL EDB/Heart 
 
DMEM CCT SS2 (1L) 
1 packet  DMEM powder (Invitrogen, 12100-038) 
800ml  UHP Water (autoclaved)  
50mL   7.5% Sodium Bicarbonate (final concentration 4.4mM) 
20mL   50x Essential Amino Acids (Invitrogen, 11130-051) 
10mL   100x Non-Essential Amino Acids (Invitrogen, 11140-050) 
10mL   100x Antibiotic/Antimyotic (Invitrogen, 15240-062) 
10mL   100x Sodium pyruvate (Invitrogen, 11360-070) 
10mL   100x Vitamins (Invitrogen, 11120-052) 
400uL  4.9mg/mL Insulin (final concentration 2g/mL) 
30mG   BrDu 
1mL   10mg/mL Apo-transferrin 
25.64mL 2M Potassium Chloride 
pH to 7.2 using 1M HCl 
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MEM + 10% NBCS (1L) 
1packet   MEM powder to make 1L (Invitrogen, 11900-016) 
800ml  UHP Water (autoclaved)  
29ml        7.5% Sodium Bicarbonate solution  
20mL   50x Essential Amino Acids (Invitrogen, 11130-051) 
10mL   100x Non-Essential Amino Acids (Invitrogen, 11140-050) 
10mL   100x Antibiotic/Antimyotic (Invitrogen, 15240-062) 
10mL   100x Vitamins (Invitrogen, 11120-052) 
100ml  NBCS heat inactivated (Invitrogen, 16010-159) 
pH to 7.2 using 1M HCl 
 
Percoll Stock gradient 
900mL  Percoll (Sigma, P-1644) 
100mL  10x ADS Buffer 
 
0.1% Gelatin 
1g   Gelatin (Sigma, G1890) 
1L  UHP Water (Autoclaved) 
 
2M Potassium Chloride 
37.27g  Potassium Chloride 
200mL  UHP Water (autoclaved)  
 
BrDu (10.257mM, 100x) 
31.5mg BrDu (Sigma, B5002) 
10mL   MEM + 10% NBCS 
 
Insulin (4.9mg/mL) 
100mg  Insulin (Sigma, I6634) 
200mL  UHP Water (autoclaved)  
400uL   1M HCl Acid 
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Apo-Transferrin (10mg/mL) 
100mg  Apo-transferrin (Sigma, T1147) 
10mL  UHP Water (autoclaved) 
 
RIPA Buffer (with protease and phosphatase inhibitors) 
86.5mL  ddH2O 
2.5mL   2M Tris-HCl (pH7.5) 
2mL   5M NaCl 
0.4mL   0.5M EDTA pH 8.0  
5mL   1M NaF  
1mL   10% SDS 
2.5mL   20% Deoxycholic acid (sodium salt) 
 OR 
0.5g  Deoxycholic acid 
 
10x Running Buffer 
60.4g   Tris Base (Trizma base)  
288g  Glycine 
20g  SDS 
Make up to 1L with water 
 
10x Transfer Buffer 
72.5g  Tris 
36.6g  Glycine 
Make up to 1L with water 
 
1x Transfer Buffer 
100mL  10x Transfer buffer 
200mL  Methanol 
Make up to 1L with water 
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Blocking Buffer 
50%  Odyssey blocking buffer 
50%  1x PBS 
 
50x TAE Buffer (1L) 
242g   Tris base 
57.1mL Glacial acetic acid 
18.6g  EDTA 
Make up to 1L with water and pH 8.5 
 
Western Gels 
12% Resolving Gel # of Gels 
Item 1 2 3 4 5 
40% Acrylamide/bis acrylamide 
37:5:1 
4.5mL 9mL 13.5mL 18mL 22.5mL 
4x Tris-HCl/SDS pH 8.8 3.75mL 7.5mL 11.25mL 15mL 18.75mL 
ddH20 6.75mL 13.5mL 20.25mL 27mL 33.75mL 
APS 75uL 150uL 225uL 300uL 375uL 
TEMED 15uL 30uL 45uL 60uL 75uL 
 
10% Resolving Gel # of Gels 
Item 1 2 3 4 5 
40% Acrylamide/bis acrylamide 
37:5:1 
3.75mL 7.5mL 11.25mL 15mL 18.75mL 
4x Tris-HCl/SDS pH 8.8 3.75mL 7.5mL 11.25mL 15mL 18.75mL 
ddH20 7.5mL 15mL 22.5mL 30mL 37.5mL 
APS 75uL 150uL 225uL 300uL 375uL 
TEMED 15uL 30uL 45uL 60uL 75uL 
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8% Resolving Gel # of Gels 
Item 1 2 3 4 5 
40% Acrylamide/bis acrylamide 
37:5:1 
3mL 6mL 9mL 12mL 15mL 
4x Tris-HCl/SDS pH 8.8 3.75mL 7.5mL 11.25mL 15mL 18.75mL 
ddH20 8.25mL 16.5mL 24.75mL 33mL 41.25mL 
APS 75uL 150uL 225uL 300uL 375uL 
TEMED 15uL 30uL 45uL 60uL 75uL 
 
4% Stacking Gel # of Gels 
Item 3 6 
40% Acrylamide/bis acrylamide 37:5:1 975uL 1.95mL 
4x Tris-HCl/SDS pH 8.8 2.5mL 5mL 
ddH20 6.43mL 12.85mL 
APS 75uL 150uL 
TEMED 15uL 30uL 
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Appendix B: Animals Ethics & Approval Certificate 
 
 
